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Summary 
Viruses are obligatory intracellular pathogens; hence an essential step of their replication 
cycle is the entry into a host cell. Enveloped viruses like the human immunodeficiency virus type 
1 (HIV-1) and the hepatitis C virus (HCV) enter cells by fusion with cellular membranes. The 
current knowledge of this process relies mostly on bulk measurements, which often comprise the 
outcome of several distinct replication steps in a non-synchronized manner. The recent 
development of novel quantitative approaches has opened the door for deeper understanding of 
the process by analyses on a single cell and single particle level.  
Fluorescently labelled viruses allow studying single steps in the interaction of individual 
virions with the host cell. A strategy for labelling HIV-1 with organic dyes using the recently 
described SNAP-tag was established and evaluated in this thesis. Introduction of the SNAP-tag 
did not significantly interfere with virus entry and infectivity and allowed specific labelling of the 
Gag structural polyprotein in the context of virions and virus producing cells. Combining 
fluorescently labelled HIV-1 with the HCV pseudoparticle system (HCVpp) allowed the analysis 
of virion attachment and entry dependent on the envelope protein of HCV on a single particle 
level. In addition, the β-Lactamase virion fusion assay was adapted to and optimized for HCVpp, 
allowing the detection of virus-cell fusion. The dependency of virus particle binding, endocytic 
uptake and fusion on various stimulating and inhibiting agents was investigated. The virus 
binding assay developed for HCVpp was subsequently adapted to HIV-1 and revealed cell-type 
specific kinetics of virion attachment. Interestingly, the expression level of the cellular virion 
tethering factor CD317 was shown to have no effect on exogenous virus binding.  
The main part of this thesis aimed at the acquisition and analysis of quantitative multi-
parameter data of HIV-1 entry. Besides the receptor CD4, HIV-1 entry depends on the presence 
of either one of the two major co-receptors, CXCR4 or CCR5. The ability of a virus variant to use 
a co-receptor defines the tropism of the virus and is at least in part determined by the sequence of 
the third variable loop (V3-loop) of the viral envelope protein (Env). In summary, HIV entry 
efficiency is determined by a complex interplay between Env sequence, receptor and co-receptor 
densities. A deeper insight into the interdependencies of these critical parameters provides a basis 
for the understanding of the mechanism of action of HIV entry inhibitors as well as of pathways 
of resistance development against these compounds. Mathematical models describing the 
interdependencies will also aid in the refinement of algorithms for the genotypic prediction of co-
receptor tropism, which is essential for the use of co-receptor antagonists in antiretroviral therapy. 
Here, experimental systems were developed which allow acquisition of detailed quantitative data 
on the interdependencies between these parameters as a basis for a mathematical model of the 
HIV-1 entry process. This comprised the selection and characterization of suitable model cell 
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lines and experimental conditions, the generation and characterization of defined isogenic virus 
variants and the establishment and calibration of virological assay systems. Multivariant data sets 
were acquired under standard conditions and algorithms for multivariant data analysis which 
have been developed in collaboration with bioinformaticians were evaluated. A comprehensive 
data set was obtained by studying a subset of viruses carrying patient-derived Env variants which 
revealed quantitative differences in receptor and co-receptor dependency as well as sensitivity to 
prototype entry inhibitors beyond the overall results of common phenotyping/genotyping 
methods. 
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Zusammenfassung 
Viren sind obligatorische Zellparasiten; der Eintritt in die Wirtszelle stellt daher einen 
essentiellen Schritt im Replikationszyklus jedes Virus dar. Umhüllte Viren wie das humane 
Immundefizienzvirus Typ 1 (HIV-1) und das Hepatitis C Virus (HCV) treten durch Fusion der 
Virushülle mit einer zellulären Membran in die Wirtszelle ein. Bisherige Analysen des 
Viruseintritts beruhen überwiegend auf Ensemblemessungen, in denen oft mehrere 
aufeinanderfolgende Replikationsschritte in nicht synchronisierten Messungen zusammengefasst 
werden. Neuere Methoden erlauben jedoch die eingehende quantitative Analyse einzelner 
Replikationsschritte auf der Ebene einzelner Zellen und Partikel.  
Fluoreszenzmarkierte Viren ermöglichen es, die Interaktion einzelner Virionen mit der 
Wirtszelle zu visualisieren. In dieser Arbeit wurde eine Strategie zur Markierung von HIV mit 
synthetischen Fluoreszenzfarbstoffen durch Einführung des ‚SNAP-tags‘ entwickelt und 
evaluiert. Der SNAP-tag beeinträchtigte die virale Eintrittseffizienz und Infektiösität nur 
geringfügig und ermöglichte die spezifische Markierung von Viren und dem viralen 
Strukturprotein in virusproduzierenden Zellen. Durch Kombination fluoreszenzmarkierter HIV 
Partikel mit dem HCV Pseudopartikel-System (HCVpp) sowie durch Anpassung des β-
Lactamase Fusionsassays an HCVpp konnten einzelne Schritte des durch die HCV Hüllproteine 
vermittelten Eintrittsprozesses und deren Abhängigkeit von stimulierenden und inhibierenden 
Faktoren untersucht werden. Die Anwendung der zuvor mit HCVpp entwickelten Methode zur 
Untersuchung der Virusbindung auf HIV-1 zeigte zelltyp-spezifische Unterschiede in der Kinetik 
der Virusbindung. Weiterhin wurde gezeigt, dass die Menge des zellulären Virusbindungsfaktors 
CD317 an der Zelloberfläche keine Rolle bei der Bindung exogener Viren spielt.  
Der Hauptteil dieser Arbeit befasst sich mit der Aufnahme und Analyse multivarianter 
Daten zum Zelleintritt von HIV. Neben dem Rezeptor CD4 benötigt HIV einen der beiden 
Korezeptoren CCR5 oder CXCR4. Der Tropismus für einen oder beide dieser Korezeptoren wird 
weitgehend von der Aminosäuresequenz in der 3. variablen Schleife (V3-loop) des HIV 
Hüllproteins (Env) bestimmt. Die Eintrittseffizienz des Virus wird von einem komplexen 
Zusammenspiel zwischen Env-Sequenz, Rezeptor- und Korezeptordichte bestimmt. Eine 
genauere quantitative Analyse dieser Abhängigkeiten ist die Grundlage für ein besseres 
Verständnis der Wirkungsweise von Inhibitoren des HIV Eintritts sowie der Entwicklung von 
Resistenzen gegen diese Präparate. Ein mathematisches Modell des Eintrittsprozesses wird auch 
zur Verbesserung von Algorithmen zur Vorhersage des Korezeptor Tropismus beitragen, die für 
den therapeutischen Einsatz von Korezeptor-Antagonisten essentiell ist. In dieser Arbeit wurden 
experimentelle Systeme entwickelt, die die Erhebung detaillierter quantitativer Daten zur 
Abhängigkeit der Eintrittseffizienz und Inhibitorsensitivität von Rezeptor- und Korezeptordichte 
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erlauben. Dies umfasste die Auswahl und Charakterisierung geeigneter Modell-Zellinien, die 
Herstellung und Charakterisierung einer Auswahl isogener Virusvarianten, sowie die Etablierung 
und Kalibrierung virologischer Testsysteme. Diese Daten bilden die Grundlage zur Erstellung 
mathematischer Modelle des Eintrittsprozesses. Systematische multivariante Datensätze wurden 
aufgenommen und Algorithmen zur Datenanalyse wurden in Zusammenarbeit mit 
Bioinformatikern evaluiert. Die Analyse eines umfassenden Datensatzes zur Eintrittseffizienz 
von isogenen Viren mit aus Patientenisolaten gewonnenen viralen V3-loop Sequenzen ergab 
individuelle Eintrittsprofile der Virusvarianten, die durch bisher gebräuchliche Geno- und 
Phänotypisierungsmethoden nicht erfasst werden.  
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1 Introduction 
Viruses are minute pathogens that lack the machinery for replication and therefore are 
highly dependent on their host cells. The most basic viruses consist only of a genome (RNA or 
DNA) packed into a protein shell for protection from the outer environment. In order to replicate 
viruses need to deliver their genomes into the cytoplasm or even nucleus of a susceptible cell. In 
case of enveloped viruses this step is accomplished by fusion of the viral envelope with a cellular 
membrane. After replication of the virus genome and expression of viral proteins with the help of 
cellular enzymes, new virus particles assemble within the cell. The egress of the progeny virus can 
be accomplished by lysis of the host cell or by budding off cellular membranes and release into 
the surrounding medium. The new virus particles then infect further target cells so that the virus 
eventually spreads within the organism and beyond.  
The replication cycle of different viruses has been studied in great detail. Most of these 
studies however, relied on bulk measurements due to restrictions of the respective methods. 
These traditional virological methods often merged multiple steps of the replication cycle due to 
indirect readouts and limited temporal resolution. The recent development of various quantitative 
methods allows the investigation of individual steps in much greater detail. Introduction of 
single-virus techniques such as fluorescent labelling of viruses significantly enhances the 
temporal, spatial as well as quantitative resolution of results. Advances in microscopic techniques 
such as stimulated emission depletion (STED) or stochastic optical reconstruction microscopy 
(STORM) furthermore circumvent the diffraction limited resolution of fluorescence microscopy 
allowing even deeper analyses of single-virus data. With these new quantitative single-cell 
methods, the distinct steps of the viral replication cycle can be visualized (for review see [26]). To 
date, virus cell interactions have been studied on the single-particle level for several viruses, 
including non-enveloped viruses like simian virus 40 and poliovirus, as well as enveloped viruses 
like influenza, murine leukaemia virus, human immunodeficiency virus (HIV) and very recently 
also hepatitis C virus (HCV) [25, 41, 129, 147, 179, 203]. In addition to trafficking of viral 
proteins within host cells and the interactions of viral and cellular proteins, those methods have 
also been applied to study viral egress, for example for HIV [101, 109]. Theses methods provide 
quantitative data of cellular systems which represent a basis for mathematical modelling. The 
comprehension and simulation of complex cellular processes by mathematical models is a major 
goal of systems biology approaches. In this regard, the relative low complexity of a virus 
represents a benefit for the development of mathematical models of biological processes and the 
preciseness of their outcome.  
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This work focuses on two enveloped RNA viruses, the human immunodeficiency virus 
type 1 (HIV-1) and the hepatitis C virus (HCV), specifically on their entry into and egress out of 
host cells. The following chapter will therefore introduce these two viruses.  
1.1 Human Immunodeficiency Virus type 1 – HIV-1 
HIV is the major member of the virus genus of lentiviruses among the family of 
retroviruses. It is the causative agent for the acquired immunodeficiency syndrome (AIDS) [10, 
70] with app. 33.4 million people infected worldwide and 2 million deaths due to AIDS in 2008 
alone [229]. There are two types of HIV, HIV-1 and HIV-2, with HIV-1 accounting for the 
majority of infections. Therefore, this chapter will focus only on HIV-1.  
Fig. 1.1: HIV-1 genome and particle structure. (A) Schematic drawing of the HIV-1 genome. Vertical 
positions denote each of the three different reading frames that encode viral proteins. An RNA structural 
element, the Rev-responsive element (RRE) is depicted with a bold horizontal line. Two long terminal 
repeats (LTR, dark grey) are flanking the open reading frames (ORF) of the three major genes, gag (group 
specific antigen), pol (polymerase) and env (envelope) and six accessory genes coding for Vif (virion 
infectivity factor), Vpr (viral protein R), Tat (transactivator), Rev (regulator of virion), Vpu (viral protein U) 
and Nef (negative factor). Abbreviations of fully processed gene products are depicted in regular type 
within the gene region coding for them; compare text for details. The two exons of tat and rev genes (shades 
of grey) are connected with dotted lines, respectively. Viral protease cleavage sites are indicated with 
vertical lines within the three major ORFs, the cleavage site of the cellular protease in env is indicated with 
a bold vertical line. Dotted vertical line in pol indicates RNAse H domain of reverse transcriptase (RT) gene 
product. This figure is modified from [130]. (B) Schematic drawing of HIV-1 particles in immature (left) 
and mature (right) conformation. Accessory proteins packaged into the virion are ommited. This figure is 
modified from[103].  
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HIV-1 is an enveloped virus forming particles with an average diameter of app. 145 nm 
[28]. It carries two copies of a single-stranded 9.7 kb RNA genome in plus orientation. In 
addition to the three major genes group specific antigen (gag), polymerase (pol) and envelope (env), 
which are shared by all retroviruses, lentiviruses code for accessory proteins that have regulatory 
functions in gene expression, replication capacity and pathogenicity. The HIV-1 genes are 
partially overlapping, arranged in all three reading frames and harbour splice signals so that 
multiple splice variants of the HIV-1 RNA can be processed. The open reading frames (ORF) of 
retroviruses are flanked by two long terminal repeats (LTR), which harbour enhancer elements 
and the promoter and are necessary for reverse transcription of the genome. The structure of the 
viral genome is depicted in Fig. 1.1 A. As depicted in Fig. 1.1 B, HIV-1 virions are surrounded by 
a lipid membrane. Inside this membrane the structural proteins, encoded by the gag gene, form 
the viral core, which encloses the viral RNA. The pol gene codes for the viral enzymes, which are 
packaged into the virion as well. The last major ORF carries the env gene, which encodes for the 
envelope proteins which are incorporated into the viral lipid membrane.  
The Gag precursor protein, which in immature particles radially lines the inside of the 
viral membrane, is subsequently processed into matrix (MA), capsid (CA), spacer peptide 1 (sp1), 
nucleocapsid (NC), spacer peptide 2 (sp2) and protein of 6 kDa (p6). CA and NC build up the 
inner structure of the mature virion and protect the viral genome. The Gag-Pol precursor protein 
is also processed further, yielding the enzymes needed for replication, reverse transcriptase (RT) 
and integrase (IN) as well as the viral protease (PR). PR fulfils all the sequential enzymatic 
cleavages of the precursor proteins starting with an autocatalytic activation event [221]. The Env 
precursor is processed by cellular subtilisin proteases into gp41, the membrane anchor, and 
gp120, the surface domain of Env [81, 83]. The accessory proteins Vpr (viral protein R), Vif 
(virion infectivity factor), Vpu (viral protein unique) and Nef (negative factor) account for 
pathogenicity, whereas Tat (transactivator) and Rev (regulator of virion) regulate viral gene 
expression. 
The HIV-1 virion occurs in two distinct forms (Fig. 1.1 B,): the immature virus 
incorporating the uncleaved Gag and Gag-Pol precursor proteins is non-infectious and is only 
rendered infectious upon full processing by the viral PR into its mature form. In the mature 
virion, MA forms a thin protein layer underneath the viral membrane, whereas CA is organized 
into the characteristically cone-shaped structure surrounding the viral RNA. NC lines the two 
RNA copies and protects it from nuclease digestion, while the viral enzymes RT and IN are also 
closely associated with the nucleoprotein complex. HIV-1 virions also incorporate the accessory 
proteins Vpr, Nef and Vif.  
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1.1.1 HIV-1 replication cycle  
The HIV-1 replication cycle is schematically depicted in Fig. 1.2 and begins with the entry 
of the virus into the host cell. This process will be discussed in detail below, due to its importance 
to this study. In brief, the viral protein gp120 binds to its cellular receptor CD4 and one of two 
major co-receptors, the chemokine receptors CXCR4 or CCR5, respectively. Binding triggers the 
fusion of viral and cellular membranes and the release of the viral core into the cytoplasm of the 
target cell. After disassembly of the core, the so-called reverse transcription complex (RTC) is 
formed, in which reverse transcription of the viral RNA by RT takes place. Subsequently, the 
double-stranded viral cDNA is transported towards the nucleus, incorporated into the so-called 
preintegration complex (PIC), which contains at least IN and Vpr, but potentially several other 
viral and cellular proteins [30]. 
Fig. 1.2: Replication cycle of HIV-1. Schematic drawing of the major steps during HIV-1 replication. See 
text for details. RTC = reverse transcription complex; PIC = preintegration complex.  
After nuclear import, the viral DNA is integrated into the cellular genome with the help 
of the viral IN. This integrated provirus can persist quiescently in cells for prolonged time periods 
– up to many years – and will, upon activation of the cell, be transcribed by the cellular RNA 
polymerase II. Early gene products comprise Tat, Rev and Nef, which are translated from fully 
spliced mRNA species. Efficient gene expression can take place only upon binding of Tat to the 
LTR. Tat-independent transcription is driven by cellular transcription factors, which also 
recognize the LTR, but to a lesser extent. Partially spliced or unspliced viral mRNAs have to be 
actively exported from the nucleus with the help of Rev, which binds to the RRE (rev-responsive 
element), an RNA stem loop structure located in the env gene (Fig. 1.1 A). Those intron-
containing mRNAs serve as templates for the late gene products, Vpr, Vif, Vpu and Env, whereas 
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Gag and the Gag-Pol precursor are translated from fully unspliced mRNA that also serves as 
viral genome for progeny virus. All viral proteins are translated on free ribosomes in the 
cytoplasm, except the transmembrane protein Env, which is translated at the rough endoplasmic 
reticulum (ER). From there, it will be transported via the secretory pathway to the plasma 
membrane, where assembly of new progeny virus takes place. All other viral proteins which will 
be incorporated into the virion also travel to the plasma membrane, as described in greater detail 
below. Gag alone is necessary and sufficient to form virus like particles [72], although it engages 
cellular factors of the endosomal sorting complex required for transport (ESCRT) machinery, 
which helps to pinch off the curved budding structure in an ATP-dependent membrane fission 
event [233]. Concomitant with or shortly after release, PR starts to process the viral precursor 
proteins into their final functional units. After this so-called maturation step, which includes also 
the rearrangement of the inner viral structure, the mature virus is ready for the next round of 
infection.  
1.1.1.1 HIV-1 Gag trafficking 
The HIV-1 Gag precursor protein is translated in the cytosol of infected cells on 
polysomes. It is then thought to oligomerize, maybe with the help of cellular proteins [256]. 
However, significant multimerization only takes place when Gag is bound to membranes [74]. 
Gag membrane binding is mediated by several factors. The N-terminal myristate and the basic 
cluster within the first 31 amino acids (aa) of MA, forming an amphipathic β-sheet, confer 
membrane binding [192]. MA alone nevertheless shows reduced membrane binding affinities 
compared to full length Gag, which can be explained by the myristyl-swich model [193, 218]: the 
myristic acid covalently attached to the N-terminus of MA is hidden in a hydrophobic groove in 
the monomeric protein. Upon Gag oligomerization the myristate is exposed which increases 
membrane affinity dramatically without changing the overall conformation of MA. Gag 
multimerization is mainly driven by intermolecular interactions between the CA, NC, sp1 and 
MA basic cluster region of neighbouring Gag molecules [32] as well as the interaction with RNA. 
In addition, it also seems to be stimulated by membrane binding, thus leading to a cumulative 
mechanism of multimerization and membrane binding of Gag [192].  
As mentioned above, budding of HIV-1 particles takes place at the plasma membrane of 
infected cells. Also, the majority of Gag is found at the plasma membrane in steady-state [92], 
hence requiring a plasma membrane targeted trafficking of Gag. The specificity of targeting to the 
plasma membrane is achieved by interaction with phosphatidyl-4,5-bisphosphate (PI(4,5)P2) 
which predominantly resides within the plasma membrane [174]. Interactions with the adaptor 
protein AP-3 have also been suggested to play a role [52]. The exact pathway in which Gag 
travels towards the plasma membrane is however still under debate. It was suggested that after 
diffuse cytoplasmic distribution Gag forms perinuclear accumulations from which it will travel on 
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through the multivesicular body (MVB) [182]. The involvement of the endocytic pathway was 
favoured for a long time as budding seemed to take place at MVB membranes in certain cell 
types, e.g. primary macrophages [178]. The “Trojan exosome hypothesis” [78] also favours the 
model of MVB as an intermediate trafficking location. In this theory, however, Gag is not 
transported to the plasma membrane via endosomes, but complete viral particles bud into the 
MVB and are released from the cell via exocytosis [166]. However, Welsch and colleagues [241] 
could show that the plasma membrane is the primary site for HIV-1 budding also in 
macrophages. This does not exclude that trafficking through the endosomal pathway could still 
be an intermediate step on the way towards the budding site.  
1.1.2 HIV-1 entry mechanism 
The first step in the replication cycle of every virus is the entry into its host cell. Viruses 
achieve the crossing of the plasma membrane by several distinct mechanisms (reviewed in [145]). 
Clathrin-dependent and -independent endocytic processes are used by non-enveloped viruses as 
well as several enveloped viruses. Some viruses rely on acidification of early endosomes to 
activate their fusion protein. Other viruses have been described to directly fuse with the cellular 
plasma membrane.  
The mechanism of HIV-1 entry is overall well understood, but is still a topic of ongoing 
research. As HIV-1 entry into target cells is pH-independent, it has long been thought to occur at 
the plasma membrane. However, evidence for involvement of clathrin-dependent endocytosis in 
productive entry was reported some years ago [45, 80], and has recently been suggested to be the 
exclusive route of entry [152]. Independent of the location of the fusion event, the mechanism 
proposed remains the same and will be described in the following paragraph.  
1.1.2.1 The HIV-1 Env protein 
The HIV-1 Env protein is a type I fusion protein displaying predominantly α-helical 
secondary structure. It is translated from the singly spliced mRNA at the rough endoplasmic 
reticulum (ER) as the precursor protein, gp160, which is cotranslationally edited by N-
glycosylation. During gp160 transport to the plasmamembrane, it is cleaved into its functional 
parts, gp41 and gp120, by cellular proteases within the Golgi complex. Here, further addition of 
highly complex glycosylation also takes place. The two separated protein parts stay 
noncovalently attached to each other, though this interaction is fairly weak, resulting in frequent 
Env-shedding – the loss of gp120 from its membrane anchor, gp41. The functional unit of Env is 
a trimer [251, 252], which will eventually be incorporated into the budding virion at the plasma 
membrane. Within this trimer, gp120 conveys virus binding to the cellular receptor and co-
receptor, whereas gp41 serves as a membrane anchor for Env and provides the machinery for 
membrane fusion.  
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The surface unit of Env, gp120, is a highly variable protein among different HIV-1 
isolates, which hampers the development of an active immunization strategy against the virus. As 
depicted in Fig. 1.3 A, it consists of five variable (V1 to V5) and five conserved (C1 to C5) 
interspersed regions and harbours 18 highly conserved cystein residues [219]. Four of the variable 
regions are linked to large loops by disulfide bonds each [133], with V1 and V2 forming one 
continuous loop. Gp120 is arranged into an inner, gp41-interacting, and an outer domain, which 
is exposed at the viral surface, bridged by a β-sheet [126, 250]. Elements of all three domains 
contribute to CD4-binding, which occurs over an area of ~800 Å2 [251]. Co-receptor binding on 
the other hand, is believed to mostly depend on interactions with the third variable loop (V3-
loop) [40], although other variable (V1/V2-loop, [176]) as well as conserved regions have been 
discussed to play a role in co-receptor binding [195]. Fig. 1.3 B depicts a structure-based model of 
the trimeric Env protein, including both gp41 (brown) and gp120 (blue). Interaction sites with the 
cellular receptor (grey) and a CD4-induced (CD4i) epitope (orange) as well as the V3-loop (cyan) 
which is protruding outwards from gp120, pointing away from the viral membrane, are shown.  
Fig. 1.3: The HIV-1 Env protein. (A) 
Domain structure of gp120 and gp41. 
The five conserved (C1-C5) and variable 
(V1-V5) domains in gp120 are separated 
by horizontal lines. Positions of 
conserved glycosylation sites are marked 
by branched structures. The V3-loop is 
highlighted in red. Arrow indicates 
cleavage site of a protease. In gp41, the 
fusion peptide (FP), two heptad repeat 
regions (HR1 and HR2) and the 
transmembrane domain (TM) are 
depicted. (B) Structure-based model of 
the extraviral part of HIV-1 Env protein 
in its trimeric state. The extraviral gp41 
is shown in brown, whereas the surface 
unit of Env (gp120) is depicted in blue. 
The outwards protruding third variable 
loop (V3 loop) is shown in cyan. The 
interaction site of Env with CD4 (CD4-
binding) is highlighted in grey and the 
CD4-induced epitope (CD4i) is shown in 
orange. Pictures were modified from 
[223] and [112].  
 
In contrast to the multiple interaction sites in gp120, the gp41 transmembrane unit of Env 
does not directly contribute to receptor or co-receptor binding, but rather provides an ectodomain 
that is mostly responsible for trimerisation [213], a membrane-spanning anchor domain (TM) and 
a long cytoplasmic tail (CT). The exact function of this among retroviruses unconventionally long 
CT is not known, yet. It may take part in Env internalization through an endocytosis signal [199] 
and Env incorporation into the newly formed virion through interactions with MA [163]. The N-
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terminus of gp41 harbours a glycine rich stretch, the so-called “fusion peptide” (FP) [36]. It is 
buried underneath gp120 in the fusion incompetent stage of Env and is only exposed upon gross 
conformational changes, thereby preventing early fusion. Gp41 also exhibits two amphipathic 
heptad repeat regions (HR), HR1 and HR2, which are able to form a coiled-coil structure with an 
interconnecting loop. They are arranged in an antiparallel packing, with HR1 in the centre and 
HR2 fitting in the hydrophobic grooves [33].  
1.1.2.2 The cellular receptor and co-receptors of HIV-1 
Cluster of differentiation 4 (CD4), a member of the immunoglobulin (Ig) superfamily has 
been identified as the primary receptor of HIV-1 shortly after the discovery of the virus itself 
[144]. CD4 is a 55 kDa transmembrane protein and physiologically functions as a co-receptor of 
the T-cell receptor by stabilizing the interaction with major histocompatibility complex type II 
(MHC-II) molecules on antigen-presenting cells [23]. However, the presence of CD4 alone is not 
sufficient to render cells susceptible to HIV-1, but a co-receptor is needed for successful infection. 
The two major co-receptors of HIV-1 are both members of the G protein-coupled receptor 
superfamily of seven-transmembrane proteins: the CXC-chemokine receptor 4 (CXCR4) [64] and 
the CC-chemokine receptor 5 (CCR5) [5, 48]. The natural ligands for CCR5 are the CC-
chemokines macrophage inflammatory protein 1 (MIP-1α and MIP-1β) and RANTES (regulated 
upon activation, normal T-cell expressed and secreted) [205], while CXCR4 is stimulated by the 
CXC-chemokines of the stromal cell-derived factor type 1 (SDF-1) family [171]. Other 
chemokine and orphan receptors can also be utilized by some HIV-1 strains, but do not play an 
essential role in vivo [16]. Therefore, this study focuses on the two major co-receptors, CCR5 and 
CXCR4.  
Although CCR5 and CXCR4share little sequence homology [51], they can be used as 
interchangeable co-receptors by some, but not all HIV strains (see 1.1.3). Whereas both co-
receptors are expressed on primary T-cells and macrophages, only CXCR4 is ubiquitously 
expressed on T-cell lines as well as a variety of other human cell lines. In vivo, CCR5 is 
exclusively expressed on memory T-cells and to a significantly higher degree on the subset of 
those cells residing in nonlymphoid tissue (e.g. the gastrointestinal tract) [54]. Only a small 
percentage of circulating CD4-positive (CD4+) T-cells are CCR5+, whereas CXCR4 is present on 
80-90 % of circulating naïve CD4+ T-cells [168].  
A 32 base pair (bp) deletion within CCR5, the so-called CCR5/∆32 mutation, confers 
resistance to HIV-1 infection of homozygous carriers of this allele [140] due to inefficient cell 
surface expression of the truncated co-receptor that cannot pursue its function anymore. 1 % of 
the total European Caucasian population is homozygous and 15 % are heterozygous for this 
specific mutation, which has no observable effect on the life expectancy or health of affected 
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persons [140].  
1.1.2.3 Membrane fusion 
HIV-1 fusion with the host cell membrane is a pH-independent step that has long been 
thought to solely occur at the plasmamembrane of cells. Over time, it has been shown that 
clathrin-mediated endocytosis can also play a role [45] and it has recently been proposed to be the 
major productive entry route [152].  
Fig. 1.4: Membrane fusion mechanism of HIV-1. Schematic representation of the consecutive steps of 
membrane fusion. Details see text. The picture was modified from [223].  
Independent of the location of fusion, the mechanism is similar to other retroviruses (e.g. 
MLV) and to Influenza virus fusion [239]. The first step in HIV-1 entry is unspecific attachment 
to the cell via heparan sulphate proteoglycans (HSPG) [154] or cellular proteins incorporated into 
the virus envelope [224]. To illustrate the fusion process in greater detail, the consecutive steps 
are depicted in Fig. 1.4: First, the specific interaction of gp120 with CD4 is established. The Env 
protein is thought to be in a metastable, fusion-incompetent conformation prior to CD4 binding. 
Binding to CD4 represents the trigger for conformational changes within gp120 that allow the 
exposition of co-receptor binding motifs [249]. Only the subsequent binding of the co-receptor 
activates gp41 to insert its N-terminal fusion peptide into the opposing host cell membrane [68]. 
The actual fusion mechanism is believed to appear in analogy to the so-called “spring-loaded 
model” of influenza virus membrane fusion [31]. This model describes the convergence of the 
two opposing membranes through the formation of a six-helix bundle of the two heptad repeat 
regions. Fusion then proceeds through a hemifusion state, in which only the outer membrane 
sheets of virus and cell have fused, to full fusion of the membranes with both N- and C-termini of 
gp41 residing in the same membrane, again.  
1.1.2.4 Inhibition of HIV-1 entry 
HIV-1 is the causative agent for the fatal disease AIDS. The lack of a protective vaccine 
stresses the need for specific antiviral treatment to suppress HIV-1 replication. Currently, several 
classes of inhibitors targeting different steps of the viral life cycle are used in highly active 
antiretroviral therapy (HAART): two classes of reverse transcriptase inhibitors, protease 
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inhibitors, integrase inhibitors and entry inhibitors.[246] For the latter, several possibilities of 
interference are illustrated in Fig. 1.5. Today, there are two different classes of entry inhibitors 
used in clinical practice: a fusion inhibitor and a co-receptor antagonist.  
Fig. 1.5: Possible interference points of different drugs with the entry process of HIV-1. Schematic 
representation of the consecutive steps of membrane fusion with possible interference points highlighted in 
red. Inhibition of CD4-binding, thus preventing the progression from the first to the second picture, has 
been attempted with soluble CD4 molecules (sCD4) and antibodies (depicted as a Y) directed against CD4. 
The next step, namely co-receptor binding, can successfully be inhibited by the usage of co-receptor 
antagonists (ovals), such as maraviroc (MVC). In addition, antibodies directed against the co-receptor 
(depicted as Y) are another strategy. The next interference point is the inhibition of six-helix bundle 
formation, which can be achieved by gp41-derived C-peptides (cylinders). Modified from [60].  
Early studies focussed on the usage of soluble CD4 molecules to compete with effective 
cell binding and in addition to promote premature gp120 shedding which renders the virion non-
infectious [155]. After the discovery of the two major co-receptors, their ligands were shown to 
efficiently block entry of the respective HIV-1 strains by downmodulation of the co-receptor from 
the cell surface (reviewed in [139]). Based on this, small molecule inhibitors have been developed, 
as discussed below. Another class of entry inhibitors that has been investigated are humanized 
monoclonal antibodies directed against CD4 or CCR5. Although it binds to CD4, Ibalizumab 
[50] (also known as TNX-355, TaiMed Biologics, Taipei, Taiwan) does not show 
immunosuppressive action, but still inhibits viral entry independent of co-receptor usage [102]. 
The phase II clinical trial is expected to be completed at the end of this year [169]. An antibody 
targeting CCR5, PRO 140 (Progenics Pharmaceuticals, Tarrytown, NY, USA), has completed 
phase II clinical trials and was approved for the “Fast Track” process by the FDA to accelerate 
medical availability [20].  
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The first entry inhibitor approved for clinical use, belonged to the class of fusion 
inhibitors. The small peptidomimetic drug T-20/Enfuvirtide (trade name Fuzeon, Roche 
Pharmaceuticals, Basel, Switzerland), is a 36 aa HR2-derived peptide, which inhibits fusion at the 
stage of 6-helix-bundle formation. Peptides derived from HR2 are called C-peptides, as HR2 is 
closer to the C-terminus of gp41 than HR1. Mimicking their origin, these C-peptides bind to HR1 
in the intermediate state of fusion. At this stage, gp41 is easily accessible to the peptides, as it is in 
its extended conformation with the C-terminus still anchored to the virus membrane while the N-
terminal fusion peptide is inserted into the host cell membrane. Due to the mechanism of action, 
resistance mutations are mostly found in HR1 of gp41 [194]. Other synthetic C-peptides were 
also shown to inhibit fusion at nanomolar concentrations [247], but have not been developed into 
antiretroviral drugs due to the disadvantages of peptidic drugs.  
The other class of approved entry inhibitors are, as mentioned above, co-receptor 
antagonists. Antagonists for CXCR4 have been developed and tested early after identification of 
this co-receptor, but did not get approval for clinical use in HIV-1 patients due to severe adverse 
effects. AMD-3100, a bicyclam which binds to CXCR4 and blocks HIV-1 entry in vitro at 
nanomolar concentrations, was the first co-receptor antagonist described [47]. The latest tested 
derivative, AMD11070 (Genzyme, Cambridge, MA, USA), showed promising results but a 
clinical trial phase II had to be discontinued due to liver toxicity of the compound [160].  
CCR5, on the other hand, has always been considered to be the easier target, since 
individuals homozygous for the CCR5/∆32 mutation show no signs of decreased life expectancy 
and remain healthy [140]. Several compounds shown to block CCR5 engagement of HIV-1 Env 
have entered clinical trials, although most of them are not approved for clinical use yet. A phase 
II trial with Aplaviroc [236] (GlaxoSmithKline, London, UK) was discontinued in 2006 due to 
high liver toxicity [44]. Vicriviroc (Schering-Plough, now Merck, Whitehouse Station, NJ, USA) 
showed promising results and low adverse effects, but trials were discontinued very recently 
[183]. Nevertheless, in late 2007 the first co-receptor antagonist was finally approved for clinical 
use. Maraviroc (MVC), sold under the trade name of Celsentri (Selzentry in the USA; ViiV 
Healthcare, Brentford, UK), is a small molecule that inhibits chemokine binding to CCR5 and 
ligand-induced signalling, but fails to induce signalling or downmodulation of the co-receptor 
itself. Therefore, it is termed an inverse agonist or functional antagonist of CCR5 [53]. This 
compound was shown to be active in the low nanomolar range against a broad spectrum of R5-
tropic HIV-1 strains in vitro and in vivo with no observable increase in adverse effects in 
comparison to the control group of patients with optimized treatment background only [62]. 
Resistance to MVC has been reported to occur in such a way that the adapted virus is able to use 
the drug-bound co-receptor [226, 243]. This resistance was obtained by several mutations within 
the V3-loop and elsewhere in gp120 and resulted in a reduced maximum inhibition rather than 
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increased 50 % inhibitory concentration (IC50) values. In contrast to what most people would 
expect, no tropism-switch from R5- to X4-tropic viruses could be observed in this in vitro study. 
This resistance mechanism of usage of drug-bound co-receptor has also been reported in vivo 
[158]. However, most patients failing MVC treatment showed a switch of co-receptor usage 
towards X4-tropic viruses, which cannot be inhibited by the drug. It was shown, though, that 
these patients possessed a reservoir of X4-tropic viruses already before the start of the treatment, 
which had only occurred at an undetectable level before the start of treatment [157, 242].  
1.1.3 Co-receptor tropism and its testing 
The range of host cells for HIV-1 is restricted due to the necessity of CD4 expression, 
although also CD4-independent viruses have been described [95]. Within the human organism, 
only T-helper cells, macrophages and some populations of dendritic cells are CD4+ and therefore 
susceptible to HIV-1 entry. Yet, due to the requirement of a suitable co-receptor, not all HIV-1 
strains behave similarly in regard to which target cells can be infected. Therefore, the viruses have 
been classified in different ways over the last two decades.  
In the early days of HIV-1 research, mitogen-activated human primary blood 
mononuclear cells (PBMCs) were used to propagate primary virus isolates. These cells possess 
both co-receptor molecules and therefore allow the replication of most HIV-1 strains. As soon as 
human T-cell lines were used to study virus replication, it was noticed that some strains did not 
replicate in those cells. Those viruses were, on the other hand, able to replicate in human 
monocyte-derived macrophages and were hence named M-tropic [42]. The remaining primary 
isolates, mostly from patients with progressed infections, were termed T-tropic in reference to 
their ability to infect T-cell lines. Another observation was made very early: the rapid replication 
of isolates from patients with progressed disease (termed RH for rapid/high) compared to the 
majority of primary isolates from newly infected patients (termed SL for slow/low) [65]. In 
addition to this, the formation of huge syncytia could be observed when the T-cell line MT-2 was 
cocultured with PBMCs producing T-tropic isolates. Syncitia are multinucleated cells resulting 
from membrane fusion of cells infected with HIV-1 and therefore expressing Env and 
neighbouring non-infected cells expressing CD4 and co-receptor. Those T-tropic isolates were 
therefore classified as SI – syncytium-inducing – in contrast to the M-tropic isolates that were 
mostly NSI – nonsyncytium-inducing [120, 198].  
All phenotypes described showed interdependencies, though exceptions from the rule 
could always be observed. Also, those schemes can be misleading in some instances [51], e.g. the 
term M-tropic implies that those strains cannot enter and replicate in primary T-cells, which is 
not the case. The designation SI/NSI on the other hand is also misleading, as it refers to the 
ability to form syncytia in one particular cell line which happens to be negative for CCR5 and 
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therefore renders CCR5-using viruses to be NSI. If cultured within CCR5+ cells, those viruses are 
nevertheless also able to form syncytia.  
Tab. 1.1: Different classifications of HIV-1. HIV-1 can be classified into X4-, R5- or dual-tropic strains 
[15]. The table correlates the tropism with co-receptor usage, the ability to replicate in PBMCs, 
macrophages or in T-cell lines. The speed of replication RH = rapid/high and SL = slow/low and the 
ability to form syncytia if infected PBMCs are cocultured with MT-2 cells is also depicted for the different 
tropic strains. SI = syncytium-inducing, NSI = nonsyncytium-inducing.  
To avoid confusion, Berger and colleagues [15] proposed a new classification scheme in 
1998. This classification will also be used throughout this thesis. It organizes all HIV isolates into 
three classes depending on the co-receptor they use for entry. Those viruses that use solely 
CXCR4 are called X4-tropic, whereas viruses utilizing exclusively CCR5 as a co-receptor are 
termed R5-tropic. Viruses that are able to use either of the two major co-receptors are classified as 
dual- or R5X4-tropic. Another term that is commonly used in concordance with this 
classification system is mixed-tropic, describing a virus population that consists of a mixture of 
R5-, X4- and possibly also dual-tropic viruses. If working with virus pools derived from patient’s 
samples, dual- or mixed-tropic viruses cannot be distinguished, hence the two latter phenotypes 
are often combined and referred to as dual/mixed (D/M). Tab. 1.1 summarizes the relation of 
this current classification to the different earlier used classification schemes.  
Fig. 1.6: Correlation of co-receptor-usage and 
CD4+ cell count over the typical course of HIV-
1 infection. Viral load in RNA copies per ml (left 
y-axis) in correlation to CD4+ cell count per µl 
blood (right y-axis) is schematically depicted with 
respect to time of infection in years. The acute 
phase of infection (0 – 0.3 years) is characterized 
by high viral loads, mostly of R5-tropic viruses 
(blue line). It coincides with a temporary drop in 
CD4+ cells (black dotted line). After several 
years, X4-tropic viruses (red line) begin to 
emerge, concomitant with a loss in CD4+ cells. 
At the same time, R5 viruses decrease in 
abundance, leading to the so-called co-receptor 
switch. The presence of low levels of X4-tropic 
virus in the acute phase of HIV-1 infection is 
depicted with a dotted red line. The figure was 
modified from [191].  
Co-receptor usage is closely associated with disease progression [119] and the efficacy of 
antiretroviral treatment. While R5-tropic viruses mostly account for acute and early HIV-1 
infections [16], X4-tropic variants occur later in infection in about 50 % of cases [220] and hint 
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towards a more rapid disease progression [143]. As depicted in Fig. 1.6, the occurrence of R5-
tropic virus declines with decreasing CD4+ cell count and increasing viral load, while X4- and 
D/M-tropic viruses can be found independent of those parameters. High natural killer (NK) cell 
counts on the other hand coincide with increased incidence of R5-tropic variants [161]. While 
80 % of patients in the early stage of infection directly after transmission only harbour R5-tropic 
viruses [29], pure X4-usage is very uncommon in antiretroviral-naïve (0.1 %) as well as 
experienced patients (3-4 %) [248]. On average, the majority of viruses within a patient stay R5-
tropic over the whole course of the infection (56 % in treatment-experienced patients).  
With the introduction of co-receptor antagonists into clinical treatment schemes 
determination of the tropism of the virus population within a patient has become of major 
interest. Co-receptor tropism testing is required before initializing therapy to ensure sensitivity of 
the patient’s virus population towards the drug. In addition, a drug induced selection of X4-tropic 
viruses is avoided to prevent increased disease progression. Nevertheless, whether the switch to 
X4-tropism precedes the more rapid progression towards AIDS or vice versa has not yet been 
understood [191].  
1.1.3.1 Phenotyping 
All “old” classification schemes of HIV-1 have been based on phenotypic analyses. Early 
phenotypic tropism testing has been conducted by cocultivation of patient’s PBMCs with other 
cell lines and deducing the viral tropism by judgement in regard to its obvious replicative 
characteristics like the ability to replicate in certain cell types, the speed of spread or its 
cytophathic effect (CPE) [135]. The discovery of the two major co-receptors led to a classification 
based on this molecular background. The phenotypic analysis of viral tropism is nevertheless still 
a major tool to classify viral strains of patient’s samples.  
Current phenotypic analysis is performed on cell lines expressing only CCR5 or CXCR4 
respectively and deducing the tropism based on the ability to enter one or the other cell type in 
the presence or absence of antagonists of either of the two major co-receptors. The first 
recombinant assay has been described by Trouplin and colleagues [227]. Viral env gene sequences 
comprising the gp120 regions between V1 and V3 were amplified by nested PCR. Those multiple 
sequences were then introduced into a replication competent reporter virus by homologous 
recombination. The resulting virus population was then tested for entry efficiency on indicator 
cells expressing only one of the two major co-receptors. Current assays no longer depend on the 
usage of replication competent HIV-1 derivatives, which is a marked increase in safety. The 
PhenoSense entry assay [161, 243] as well as the Trofile assay [244] both make use of 
pseudoparticles. To this end, the complete gp160 sequence is amplified from patient’s plasma 
samples and cloned into an Env expression vector. Non-replication competent pseudoparticles 
are produced by cotransfection of this Env expression vector with a non-replication competent 
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self-inactivating (SIN) vector encoding a luciferase reporter enzyme. Entry in dependence of 
different drug levels (PhenoSense) and cells with different expression patterns of co-receptors 
(Trofile) can hence be scored by measurement of luciferase activity through a fluorimetric read-
out.  
The administration of the CCR5-antagonist MVC is currently governmentally 
constrained to a preceding phenotypic tropism test, namely Trofile (Monogram Biosciences, Inc., 
South San Francisco, CA, USA).  
1.1.3.2 Genotyping 
The term genotypic analysis describes the assignment of the viral phenotype in silico based 
on the nucleotide sequence of the relevant viral gene. With regard to co-receptor analysis, this 
gene of interest is the viral env gene, mostly confined to the V3-loop as the major determinant for 
co-receptor tropism (compare 1.1.2.1).  
Early genotypic co-receptor analyses relied on the observation that different charges 
within the V3-loop hint at a different tropism. The so-called 11/25 rule predicts that the presence 
of a positively charged aa at position 11 and/or 25 within V3 is indicative for the SI phenotype 
[67]. Today, more advanced prediction methods based on complex statistical methods can be 
used. Among those are decision trees, support vector machines (SVM) and position-specific 
scoring matrices (PSSM). In decision trees, consecutive yes/no decisions in a tree like fashion 
lead to a final conclusion. SVM on the other hand is a machine learning technique to classify 
different samples into two distinct binary groups. PSSM weights the information used, in this 
case depending on the importance of different positions within the V3-loop, to classify the sample 
into different classes. Genotyping algorithms using combinations of the aforementioned methods 
have been described and are available as web-based tools. WetCat ([185], 
http://genomiac2.ucsd.edu:8080/wetcat/v3.html) makes use of the 11/25 rule, several decision 
trees and SVM. It is up to now only trained on a small set of data, making prediction less 
confident [214]. Furthermore, it demands translated aa sequences of the V3-loop exclusively and 
manual alignment to a reference strain, a time-consuming an error-prone step. WebPSSM ([104], 
http://indra.mullins.microbiol.washington.edu/webpssm/) uses, as the name implies, PSSM to 
predict co-receptor usage. It accepts aa sequences in FASTA format and performs automated 
sequence alignment. The program allows choosing the scoring matrix based on the virus subtype 
(only subtype B and C) and classification of the training data set (X4/R5 or SI/NSI). Our 
collaborators in the group of Thomas Lengauer (Department of Computational Biology and 
Applied Algorithmics, Max-Planck-Institute for Computer Sciences, Saarbrücken, Germany) also 
developed a web-based prediction program, geno2pheno[co-receptor] ([216], www.geno2pheno.org), 
which is based on SVM. Nucleotide as well as aa sequences are accepted as an input, either as 
FASTA file or pasted directly into a text field on the website. The newest version allows the 
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inclusion of clinical data such as viral load, CCR5-genotype of the patient, CD4 percentages, 
CD4+ cell counts and CD8+ cell counts.  
An advantage of genotyping over the more conventional technique of phenotyping clearly 
is the time needed for analysis. Whereas phenotyping takes several weeks, including the shipping 
of freshly frozen plasma samples, genotyping can be done within a few days. The only 
requirement is a viral load which allows for PCR amplification of the V3-loop region of env. In 
contrast to this, the Trofile assay can only be performed with viral loads over 1000 viral RNA 
copies/ml. In addition, the much lower cost of genotypic tropism tests renders this method more 
attractive in comparison to the very costly phenotypic tests.  
1.1.3.3 Viral quasispecies and the need for sensitivity in tropism testing 
In regard to viral tropism, it is nevertheless also crucial to keep in mind the existence of 
viral quasispecies. The term quasispecie is derived from the observance of a rather heterogenous 
viral population within a patient instead of one single viral clone [18, 59]. This results from the 
very high error rate of viral replication enzymes. In case of HIV-1, the viral RT has no 
proofreading function and thus has been shown to have an error rate of 1/1700 per nucleotide 
incorporated [196]. In addition, selective pressure in terms of the virus’ need to escape 
immunological control and the presence of different drugs play a role in the establishment of viral 
quasispecies.  
Hence, the detection of a pre-existing X4-tropic variant within a patient which could 
outgrow the prevalent R5-tropic virus population is strongly dependent on the sensitivity of the 
tropism test. The first established Trofile assay claimed a sensitivity of X4-minority detection of 
5-10 % [244]. A newer version of this assay is supposed to detect minorities of 0.3 % [225]. 
Genotypic assays display a low sensitivity of about 20 % based on bulk sequencing data [132]. 
The fact that a minority of 0.1 % pre-existing X4-tropic variants has been described to cause a 
viral rebound [134] implies that an enhanced sensitivity of assay methods is required.  
For genotypic analysis, this can be achieved by the so-called ultra-deep sequencing 
technique. This method is based on a pyrosequencing approach with massive parallel sequencing 
[197]. It allows the detection of minor differences within a population of sequences, for example 
within a viral quasispecies.  
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1.2 Hepatitis C Virus – HCV 
HCV is the sole member of the genus hepacivirus, belonging to the family of flaviviruses. 
There are 7 genotypes, the most common genotype being genotype 1b, and a wide variety of 
subtypes of HCV, with sequence variations of about 30 % between genotypes and 20 % between 
subtypes [77, 215]. The virus is the causative agent of Hepatitis C, a liver disease with an 
estimated 130 million chronically infected individuals worldwide, representing 2.2 % of the total 
population [6]. The currently available treatment is composed of unspecific antiviral agents like 
pegylated interferon-α in combination with ribavirin. More specific antiviral drugs are 
nevertheless in the pipe-line. Though the acute infection is often asymptomatic, the infection 
becomes chronic in about 80 % of all cases [6]. The symptoms of chronic Hepatitis C range from 
none to chronic inflammation of the liver, leading to fibrosis, liver cirrhosis and hepatocellular 
carcinoma.  
The virus that causes this disease is a small (app. 55-65 nm in diameter) enveloped virus 
carrying a single positive stranded RNA genome of app. 9.6 kb. It is a hepatotropic virus 
replicating in the cytoplasm of only human hepatocytes, although additional target cells have also 
been discussed [238, 255]. Replication of the viral genome takes place in a virus-induced, ER-
derived compartment close to the nucleus the so-called membranous web, which is rich in lipid 
droplets [76]. The assembly of viral particles in close proximity to lipid droplets and the coupling 
of viral secretion to the lipoprotein metabolizing pathway most likely explain the fact that HCV 
particles in patients have been found to be closely associated with several lipoproteins [222].  
1.2.1 HCV entry mechanism 
The two envelope glycoproteins, E1 and E2, mediate cell attachment and receptor 
binding and are indispensable for HCV entry. Both of them are type I integral membrane proteins 
with a C-terminal transmembrane domain and a large N-terminal extracellular domain. They are 
synthesized at the rough ER as part of the polyprotein precursor and are cotranslationally cleaved 
off by the cellular signal peptidase. E1 and E2 stay non-covalently linked to each other via 
interactions of their transmembrane domains and form a functional heterodimer [175] which is 
retained at the ER [57]. Within the ER, they become heavily glycosylated, a feature proposed to 
be needed for proper protein folding, the entry process itself and epitope shielding from the 
immune system [75].  
Fig. 1.7 schematically illustrates the early steps of HCV replication: virus attachment, 
receptor binding, internalization via endocytosis and fusion. The first step of this entry 
mechanism is unspecific attachment to the host cell. Several attachment factors have been 
described, including the low density lipoprotein receptor (LDLr) and glycosaminoglycans (GAG) 
like heparan sulphate (HS) [2, 13]. This cell attachment could serve as a way to retain the viral 
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particles at the cell surface long enough for receptor recruitment.  
Fig. 1.7: Entry process of HCV. 
Schematic drawing of the proposed entry 
mechanism of HCV. Attachment factors, 
i.e. low density lipoprotein receptor 
(LDLr) and glycosaminoglycanes 
(GAG), and four confirmed cellular 
receptor molecules, i.e. scavenger 
receptor class B type I (SR-BI), cluster of 
differentiation 81 (CD81), claudin-1 
(CLDN) and occludin (OCLN) are 
depicted. Uptake of the viral particle, 
associated to lipoproteins (LP) is thought 
to occur via clathrin-mediated 
endocytosis. Fusion with the membrane 
then occurs in a pH-dependent step after 
acidification of early endosomes. The 
picture was modified from [156].  
 
At least four specific receptors have been shown to play major roles in the entry process of 
HCV. Those comprise the scavenger receptor class B type I (SR-BI), the tetraspanin cluster of 
differentiation 81 (CD81) and the two tight junction molecules claudin-1 (CLDN1) and occludin 
(OCLN) [61, 184, 187, 207]. SR-BI is an 82 kDa glycoprotein which is highly expressed in liver 
hepatocytes. It harbours two transmembrane domains and is involved in the uptake of cholesterol 
esters through the interaction with high density lipoprotein (HDL) particles. CD81 was the first 
candidate receptor and is a typical tetraspanin protein with four transmembrane domains, a small 
and a large extracellular loop (SEL and LEL, respectively) and an intracellular loop. It is widely 
expressed on a variety of tissues and thus is not considered to be a determinant for the 
livertropism of HCV. The two tight junction proteins CLDN1 and OCLN both harbour four 
transmembrane domains with both termini facing to the cytosol, two extracellular loops and an 
intracellular loop. In addition to CLDN1, two other members of the claudin family, namely 
Claudin-6 and Claudin-9, have been shown to act as HCV entry receptors [253].  
The sequence of receptor engagement is not yet exactly known, however it is speculated 
that the process starts with interactions of E1/E2 with SR-BI. The virus will then subsequently 
encounter CD81, which has been proposed to be relocalized to tight junctions upon virus binding 
[27]. Here, the virus can then bind to the remaining two receptors and finally get internalized by 
clathrin-mediated endocytosis [21, 148]. The fusion of viral and cellular membrane finally has 
been shown to be a pH-dependent step, triggered by the low pH of early endosomes [228]. After 
this step, the viral capsid is released into the cytosol, where protein translation, replication and 
assembly of new virus progeny take place.  
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1.2.1.1 Possible ways to interfere with HCV entry 
Although no specific HCV entry inhibitors have been developed, yet, there are several 
ways to interfere with it in vitro. One strategy is to block the pH-dependent fusion step. To this 
end, acidification of endosomes can be inhibited by the addition of alkalizing reagents or specific 
inhibitors of the proton pumping ATPase (NH4Cl or Bafilomycin A, respecitively). One step 
before fusion, the endocytic uptake of viral particles can also be blocked by inhibition of clathrin-
mediated endocytosis. To target the four known receptors of HCV entry, RNA interference 
(RNAi) techniques or neutralizing antibodies can be utilized. Most likely due to the association 
of HCV particles with lipoproteins and the interaction of those with molecules implicated in entry 
of the virus (LDLr and SR-BI), it has been described that different lipoprotein complexes can also 
manipulate HCV entry efficiency. In this regard, HDL has been shown to enhance HCV entry 
efficiency [56], whereas oxidized low density lipoprotein (oxLDL) has been shown to decrease it 
[232]. As attachment of HCV to the target cell has been shown to rely on interactions with 
GAGs, the addition of Heparin can mimic those structures and thus prevent successful virus-cell 
interactions [122].  
1.3 Fluorescently labelled viruses as a tool 
To visualize various steps of the viral replication cycle, several methods have been used, 
including different techniques of electron and fluorescence microscopy. One of the most 
commonly used techniques is immunofluorescence, in which the protein of interest is detected by 
specific antibodies in fixed cells. A drawback of this technique is the need for fixation which is 
preventing live cell observation. In addition, epitopes may be masked due to fixation artefacts or 
steric inaccessibility. Those points do not apply for fluorescent proteins (FP), which can be fused 
to the protein of interest and have thus extensively been used to study protein localisation and 
trafficking within living cells with a high spatial and temporal resolution [138]. The first FP 
characterized was the green fluorescent protein (GFP), cloned from the jellyfish Aqueorea victoria 
[188]. Like other FPs developed from GFP, it harbours a chromophor build up by aminoacid side 
chains of a tripeptide inside its beta barrel structure. Optimisation of FPs in regard to quantum 
yield, spectral properties, stability and folding kinetics has been pursued by site-directed and 
random mutagenesis. Also, FPs from other species, e.g. corals, have been isolated and found to 
exhibit desirable properties (reviewed in [46]). Today, enhanced versions of the original FPs, e.g. 
eGFP, are mostly being used and a broad range of spectral variants is available. More recently, 
FP variants permitting dynamic analyses have been developed.  
The major drawbacks of FPs, include slow maturation kinetics, high light sensitivity 
leading to fast bleaching, low quantum yield and restricted spectral properties. In contrast to this, 
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organic dyes have the advantage of higher stability, greater quantum yield and a nearly unlimited 
choice of excitation and emission wavelength. Those dyes therefore allow for applications with 
the need of strong fluorescence signals or a special excitation and emission wavelength. To make 
use of these benefits, the chemical dye has to be specifically attached to the protein of interest. 
The introduction of a tetracystein-tag into the protein of interest for example allows staining with 
the FlAsH/ReAsH technique (Invitrogen, San Diego, CA, USA). With this, several groups have 
been studying HIV-1 Gag trafficking [79, 182, 201] as well as tracking of cytoplasmic and nuclear 
HIV-1 complexes by labelling the IN [8]. This technique has nevertheless been reported to be 
accompanied by very high background signals [201].  
1.3.1 SNAP-tag as a substitute for fluorescent proteins 
Another way to deal with the challenge of specifically labelling a protein of interest with 
organic dyes within the living cell is the use of the so-called SNAP-tag (New England Biolabs, 
Ipswich, MA, USA). It is derived from the mammalian DNA repair protein O6-alkylguanin-
DNA-alkyltransferase (AGT) which removes alkyl chains from guanines by covalently adding 
them to a cystein residue within its active site [177]. Mutational evolution led to a version of this 
protein with enhanced activity, smaller size (app. 20 kDa), higher substrate specificity and higher 
activity [113]. SNAP-tag binds to its substrate, O6-Benzylguanine (BG), with high affinity, 
allowing the use of low non-toxic concentrations of substrate. It then transfers the benzyl-moiety 
irreversibly from the substrate to its active site. Thus, SNAP-tag performs a self-labelling reaction 
if fluorescently labelled derivatives of O6-Benzylguanine are offered as substrate [114].  
Fig. 1.8: Labelling mechanism of SNAP-tag. Covalent labelling of the SNAP-tag fusion protein with a 
substrate coupled to a fluorochrome (label). The picture was taken from [114].  
To use it as a labelling technique, SNAP-tag can easily be fused N- and C-terminally to 
the protein of interest. It then allows covalent labelling of the fusion protein by the addition of the 
substrate of choice [115].  
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1.3.2 Fluorescently labelled HIV-1 proteins 
To study different aspects of the HIV-1 replication cycle, many viral proteins have also 
been fused to several FPs. Those viral proteins include Vpr [147], Vpu [82, 164], Nef [84] as well 
as the Gag precursor protein [180], MA [162], IN [4, 49] and the viral membrane by 
incorporation of membrane anchored FPs [34]. In our department, labelling of HIV-1 derived 
particles to study attachment and entry has been achieved with the incorporation of Vpr.FP [127] 
and IN.FP [118] and the fluorescent label directly fused to MA [117, 118, 127, 162]. Viruses 
incorporating the fusion protein of MA.FP within the complete viral context have been shown to 
be reduced in infectivity and entry competence. An equimolar cotransfection of wt and the tagged 
version, however, leads to rescue of full single round infectivity [162]. The C-terminal fusion of a 
FP to MA allows the observation of its localisation and trafficking within the cell in the context 
of all other viral proteins that may play a role. In addition, the incorporation of the fluorescent 
tag within released viral particles allows using those fluorescently labelled viruses as a tool to 
study attachment and virus entry. Furthermore, the MA.FP fusion protein represents a clear 
advantage of over the immunofluorescence technique, as the HIV-1 CA protein has been shown 
to be recognised by antibodies to a much lesser degree within the protein precursor, Gag, than if 
already processed.  
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1.4 Aim of the work 
Recent advances in the development of quantitative analysis methods on a single cell 
level open up the possibility to study biological processes in much greater detail as had been 
possible with bulk assays. Data obtained with those methods can be used to computationally 
derive mathematical models describing and predicting the studied events. Viruses are ideal study 
objects because of their relative simplicity compared to the complexity of larger organisms. 
Viruses are obligatory intracellular pathogens and entry into host cells is the first step in their 
replication cycle. The aim of this thesis was to quantitatively study entry of two of the most 
important human pathogens, HIV and HCV, into host cells.  
Studying the details of the viral life cycle is facilitated by the visualisation of individual 
viral particles. Several systems to label viral particles have been implemented, most of which 
employ fusion of viral components with autofluorescent proteins. New high resolution imaging 
techniques requiring stronger illumination make the use of more stable organic dyes desirable. To 
this end, a new labelling technique which allows the covalent coupling of organic dyes to viral 
structures was applied to HIV-1 and its usefulness was evaluated. The lack of a suitable virus 
labelling method for HCV at the time implied the adaptation of an already existing approach to 
this virus, using HIV derivatives carrying the HCV envelope proteins (HCVpp). In addition, a 
virion fusion assay to study entry independent of later steps of the replication cycle was optimized 
for HCVpp. These different approaches were used to dissect the early steps of HCVpp entry. The 
imaging methods established were expanded to HIV-1, and virus binding to cells in dependence 
of different factors was investigated.  
The main focus of this thesis, however, was the quantitative assessment of HIV-1 entry in 
dependence of multiple cellular and viral parameters. Although the course of events during HIV-1 
entry is well-characterized, the major part of this knowledge is based on bulk data. In the light of 
the employment of co-receptor antagonists in the antiviral treatment of HIV-1 patients, the 
prediction of sensitivity of a given virus population towards these drugs is of major importance. 
The detailed investigation of the dependence of HIV entry on the presence of different levels of 
receptor and co-receptor on the target cell will lead to a greater understanding of this process and 
allow the development of improved prediction algorithms. Establishing methods that allow the 
acquisition of reliable quantitative data in relatively high throughput systems was a major goal of 
this thesis. A comprehensive dataset describing the detailed dependencies of virus entry on 
receptor and co-receptor levels on the target cell, V3-loop sequence of the viral Env protein and 
presence of different concentrations of entry inhibitors was generated using an initial subset of 
patient-derived virus samples.  
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2 Materials and Methods 
2.1 Materials and instruments 
Acrylamide Rotiphorese Gel, Roth, Karlsruhe, Germany 
Ampicillin Roth, Karlsruhe, Germany.  
Blasticidin S HCl Invitrogen, Karlsruhe, Germany 
Blotting paper 3 MM Chr, Whatman, Dassel, Germany 
BTP SNAP-block Covalys, Witterswill, Switzerland 
CCF2-AM Loading Kit Invitrogen, Karlsruhe, Germany 
CO2-independent medium Gibco/Invitrogen, Karlsruhe, Germany 
Collagen Collagen A, 1 mg/ml, Biochrom AG, Berlin, Germany 
Concanamycin A Sigma-Aldrich, Steinheim, Germany 
Confocal laser scanning  
microscope 
Nikon C1Si 
Nikon Imaging Center at University Heidelberg, Heidelberg,  
Germany;  
Nikon, Düsseldorf, Germany 
Confocal laser scanning  
microscope 
Leica SP2 
Leica Microsystems GmbH, Wetzlar, Germany 
DMEM high glucose Gibco/Invitrogen, Karlsruhe, Germany 
DNA gel extraction kit Nucleospin® Extraction II, Macherey-Nagel, Düren, 
Germany 
ECL substrate ECL Western blotting substrate, Pierce, Rockford, IL, 
USA 
ELISA plates Maxisorb, Nunc, Wiesbaden, Germany 
Epifluorescence microscope 
Zeiss Axiovert 200M 
Carl Zeiss Imaging Solutions GmbH, München, Germany 
Epifluorescence screening 
microscope 
Olympus ScanR  
Olympus Soft Imaging Solutions GmbH, Münster, Germany 
FACSAriaTM ZMBH, Heidelberg, Germany 
BD Biosciences, Heidelberg, Germany 
FACSCalibur BD Biosciences, Heidelberg, Germany 
FACSCantoTM II ZMBH, Heidelberg, Germany 
BD Biosciences, Heidelberg, Germany 
FCS Lot.Nr.: 0251L  
Biochrom AG / seromed, Berlin, Germany 
FCS, tetracycline-free Biochrom AG / seromed, Berlin, Germany 
Fibronectin Sigma-Aldrich, Steinheim, Germany 
Ficoll-Plaque Plus GE Healthcare Life Science, München, Germany 
FugeneHD Roche, Basel, Switzerland 
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G418 Calbiochem, Darmstadt, Germany 
HDL Lipoproteins, Low Density, Human Plasma,  
Calbiochem, Darmstadt, Germany 
Hygromycin B Calbiochem, Darmstadt, Germany 
IL-2 Biomol, Hamburg, Germany 
Infrared scanner Odyssey, LI-COR Inc., Lincoln, NE, USA  
Kanamycin Roth, Karlsruhe, Germany 
LDL Lipoproteins, Low Density, Human Plasma,  
Calbiochem, Darmstadt, Germany 
Mircoplate reader MR5000, Dynatech, Enbrach, Switzerland 
Nitrocellulose membrane Protran, Schleicher & Schüll/Whatman, Dassel, 
Germany 
PHA Sigma-Aldrich, Steinheim, Germany 
Plasmid purification kit NucleoBond MaxiPrep Kit, Macherey-Nagel, Düren, 
Germany 
Ponasterone A Invitrogen, Karlsruhe, Germany 
Puromycin dihydrochloride Invitrogen, Karlsruhe, Germany 
QuantiBRITE™ PE BD Biosciences, Heidelberg, Germany 
RPMI1640 Gibco/Invitrogen, Karlsruhe, Germany 
SDS-PAGE electrophoresis 
chamber 
Mighty small, Hoefer, Almstetten, Germany 
Semi-Dry Blotter Fastblot B32, Whatman Biometra, Göttingen 
cti GmbH, Idstein, Germany 
SNAP-cell TMR-Star Covalys, Witterswill, Switzerland 
Spectrophotometer DU 640, Beckman Coulter, Fullerton, CA, USA 
Tabletop ultracentrifuge TL-100, Beckman Coulter, Fullerton, CA, USA 
Tetracycline Invitrogen, Karlsruhe, Germany 
Trypsin 10x Trypsin/EDTA (0,5% / 0,2%), Biochrom AG,  
Berlin, Germany 
Ultracentrifuge Optima XL-70, Beckman Coulter, Fullerton, CA, USA 
X-ray films for ECL-WB CL-XPosure, Pierce, Rockford, IL, USA 
Zeocin Invitrogen, Karlsruhe, Germany 
2.1.1 Buffers and reagents 
Buffer name Concentrations Recipe 
10x DNA loading buffer 
(10 ml) 
50 % sucrose 
10 mM EDTA  
2 % bromphenol blue 
2 % orange G 
5 g sucrose 
200 µl 0.5 M EDTA 
0.2 g bromphenol blue 
0.2 g orange G 
10x PBS 
(1000 ml) 
1.37  M NaCl 
27 mM KCl 
80 mM Na2HPO4 
18 mM KH2PO4 
80 g NaCl 
2 g KCl 
14.4 g Na2HPO4‧2H2O 
2.4 g KH2PO4 
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Buffer name Concentrations Recipe 
10x PonceauS stain (100 ml) 30 % trichloric acetic 
 acid 
30 % sulfosalycylic acid 
2 % (w/v) PonceauS 
 
30 ml trichloric acetic 
 acid 
30 ml sulfosalycylic acid 
2 g Ponceau S 
40 ml H2O 
10x TBST (1000 ml) 200 mM 1M Tris 
150 mM NaCl 
0.5 % Triton-X100 
200 ml 1 M Tris pH 7.5 
87.66 g NaCl 
5 ml Triton-X100 
1x SDS-PAGE  
electrophoresis buffer 
(1000 ml) 
25 mM Tris 
19.2 M glycine 
0.1 % SDS 
3.03 g TRIS 
14.4 g Glycine 
1 g SDS 
200x NaN3 stock solution 10 % NaN3 in PBS 5 g NaN3 in 50 ml PBS 
2x CaCl2 transfection buffer 
(1000 ml) 
250 mM CaCl2 36.8 g CaCl2‧2H2O; 
filter sterilize through 0.45 µm pore  
size filters; store at 4°C 
2x HeBS transfection buffer 
(1000 ml) 
280 mM NaCl 
50 mM HEPES 
1.5 mM Na2HPO4 
pH 7.05-7.12 
 
16.4 g NaCl 
11.9 g HEPES 
0.267 g Na2HPO4‧H2O 
filter sterilize through 0.45 µm pore 
size filters; store at 4°C 
30% acrylamide (200:1) 0.15 % bisacrylamide 
30 % acrylamide 
1.5 g N,N’-Methylen-bis-acrylamid 
1000 ml 30% Rotiphorese Gel A  
3x protein sample buffer 125 mM Tris/HCl 
pH 6.8  
10 % glycerol 
0.02 % bromphenol blue 
2 % SDS 
0.5 % β-MeEtOH 
prepare for 100 ml, but add H2O only  
ad 95 ml  
before usage, add 0.5 ml β-MeEtOH 
to 9.5 ml of buffer,  
store at 4°C up to 4 weeks 
4x separating gel buffer 
(500 ml) 
1.5 M Tris-HCl pH 8.8 
0.4 % SDS 
90.8 g Tris  
0.2 g SDS 
4x stacking gel buffer 
(500 ml) 
0.5 M Tris-HCl pH 6.8 
0.4 % SDS 
30.3 g Tris 
0.2 g SDS 
50x TAE buffer 
(1000 ml) 
2 M Tris-acetate 
50 mM EDTA 
242 g Tris 
57 ml acetic acid 
100 ml 0.5 M EDTA pH 8.0 
 
acrylamide for stacking gels  
(30:0.8%) 
0.8 % bisacrylamide 
30 % acrylamide  
8 g N,N’-Methylen-bis-acrylamid 
1000 ml 30% Rotiphorese Gel A 
Fixative for cryo-EM 
(6 ml) 
4 % PFA 
0.1 % glutaraldehyde 
0.1 M PHEM 
1.2 ml 20 % PFA 
24 µl 25 % glutaraldehyde 
1.5 ml 0.4 M PHEM 
3.3 ml H2O 
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Buffer name Concentrations Recipe 
Fixative for epon-EM (6 ml) 2.5 % glutaraldehyde 
0.2 M NaCacodylate 
600 µl glutaraldehyde 
3 ml NaCacodylate 
2.4 ml H2O 
LB agar 13 % agar in LB  
medium 
1 l LB medium 
13 g agar 
LB medium 
(1000 ml) 
1 % peptone 
0.5 % yeast extract 
171 mM NaCl 
10 g tryptone 
5 g yeast extract 
5 g NaCl 
0.5 ml 10 N NaOH pH 7.0 
Mowiol embedding medium 8 mM Mowiol 4-88  
in PBS 
stir 10 g Mowiol in 40 ml PBS for  
24 h at RT; add 20 ml 100 %  
glycerol; stir for 24 h; control  
pH (6-7); 12.000 rpm 15 min; make  
1 ml aliquots; store at -20°C 
separating gel  
(2 minigels; 10 ml) 
17.5 % acrylamide 
375 mM Tris-HCl  
pH 8.8 
0.1 % SDS 
0.1 % APS 
0.0017 % TEMED 
5.8 ml acrylamide 200:1 
2.5 ml 4x separating gel buffer 
1.7 ml H2O 
 
for polymerisation add  
83 µl 10 % APS; 17 µl TEMED 
stacking gel  
(10 ml) 
2 % acrylamide 
125 mM Tris-HCl  
pH 6.8 
0.1 % SDS 
0.0025 % APS 
0.0025 % TEMED 
1.5 ml 30 % acrylamide 
2.5 ml 4x stacking gel buffer  
6.0 ml H2O 
this mixture can be stored at 4°C 
for polymerisation add per 2 ml 
50 µl 10 % APS; 5 µl TEMED 
Western blot blocking buffer 5 % milkpowder  in TBST 
Western blot buffer I 
(1000 ml) 
0.3 M Tris 
20 % MeOH 
36.34 g Tris 
200 ml MeOH 
Western blot buffer II 
(1000 ml) 
25 mM Tris 
20 % MeOH 
3.03 g Tris 
200 ml MeOH 
Western blot buffer III 
(1000 ml) 
25 mM Tris 
20 % MeOH 
40 mM DL-Norleucine 
3.03 g Tris 
200 ml MeOH 
5.25 g DL-Norleucine 
2.1.2 Primers 
Number Sequence (5’ -> 3’) See chapter 
5251 GGCGCATCGATCCGCCCAGCCCAGGCTTGCC 2.2.4.1 
5252 CAGGGATCGATAGGCGGCATGGACAAAGACTGCGAA 2.2.4.1 
3159 TGTACAAACGCGTATGGACAAAGACTGC 2.2.4.1 
3160 TTTTGGCTTCTAGAGCCCAGCCCAGGC 2.2.4.1 
251 CAGGGATCGATAGGCGGCATGGTGAGCAAGGGC 2.2.4.1 
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Number Sequence (5’ -> 3’) See chapter 
252 GGCGCATCGATCCGCCCTTGTACAGCTCGTC 2.2.4.1 
2539 TTGTAACATTTCTAGAGC 2.2.4.3 
2540 GCTCTAGAAATGTTACAATGTGC 2.2.4.3 
2541 TAGTACAGCTGAACACATCTGTAG 2.2.4.3 
2542 ACTTCTCCAATTGTCCCTCATATCG 2.2.4.3 
2747 TAGTACAATTGAACACATCTGTAGAAATTAATTGTAC 2.2.4.3 
2748 TAGTACAATTGAACACATCTGTAGAAATTAATTG 2.2.4.3 
2749 TAGTACAATTGAACACATCTGTAGAAATTAATTG 2.2.4.3 
2750 TAGTACAATTGAACACATCTGTAGAAATTAATTGTTTCAG 2.2.4.3 
2751 TTGCTCTAGAAATGTTACAGTATGC 2.2.4.3 
2.1.3 Plasmids 
Plasmid name Description Reference 
pNL4-3 subviral plasmid  [1] 
pNLC4-3 subviral plasmid  [127] 
pKHIV non-infectious subviral plasmid  [162] 
pCHIV non-infectious subviral plasmid  [127] 
pCHIV.Env(-) non-infectious subviral plasmid  
harbouring a frameshift in the env gene 
B. Müller 
pCHIV.eGFP non-infectious subviral plasmid  
harbouring the egfp gene within the gag ORF 
[127] 
pCHIV.mCherry non-infectious subviral plasmid  
harbouring the mCherry gene within the gag ORF 
this work 
pBSMAJ.ClaI intermediate construct [162] 
pVpr.eGFP expression plasmid for Vpr.eGFP fusion protein [147] 
pMM310 expression plasmid for Vpr.BlaM fusion protein [35] 
pCHIV.SNAP non-infectious subviral plasmid  
harbouring the snap-tag gene within the gag ORF 
this work 
pNLC.SNAP subviral plasmid  
harbouring the snap-tag gene within the gag ORF 
this work 
pNLCiSNAP subviral plasmid harbouring the snap-tag gene  
flanked by two PR cleavage sites within the gag ORF 
this work 
pHIViGFP subviral plasmid harbouring the snap-tag gene  
flanked by two PR cleavage sites within the gag ORF 
[98] 
pCAGGS-NL4-3 expression plasmid for HIV-1 NL4-3 Env protein R. Kaiser 
pCAGGS-NL4-3-R5 expression plasmid for HIV-1 NL4-3 Env protein,  
CCR5-tropic 
R. Kaiser 
pCAGGS-NL4-3XbaI expression plasmid for HIV-1 NL4-3 Env protein 
additional XbaI restriction site 
this work 
pCAGGS-220 expression plasmid for HIV-1 NL4-3 Env protein  
withV3-loop of patient number 220 
this work 
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Plasmid name Description Reference 
pCAGGS-286 expression plasmid for HIV-1 NL4-3 Env protein  
with V3-loop of patient number 286 
this work 
pCAGGS-409 expression plasmid for HIV-1 NL4-3 Env protein  
with V3-loop of patient number 409 
this work 
pCAGGS-651 expression plasmid for HIV-1 NL4-3 Env protein  
with V3-loop of patient number 220 
this work 
pCAGGS-685 expression plasmid for HIV-1 NL4-3 Env protein  
with V3-loop of patient number 685 
this work 
pCAGGS-838 expression plasmid for HIV-1 NL4-3 Env protein  
with V3-loop of patient number 838 
this work 
pCAGGS-924 expression plasmid for HIV-1 NL4-3 Env protein  
with V3-loop of patient number 924 
this work 
pCAGGS∆Env empty expression plasmid N. Herold 
pcDNA3∆CE1E2 expression plasmid for HCV Con1 Env protein [208] 
pVpu.GFP expression plasmid for fusion protein of HIV-1  
Vpu and GFP 
[82] 
pSS26m cloning vector coding for SNAP-tag Covalys 
pC1-Cherry expression vector for mCherry Invitrogen 
pCMV∆R8.9 CMV-driven HIV-1 packaging construct  [257] 
pSEW SIN-vector carrying a CMV-driven gfp reporter gene [257] 
2.1.4 Cell lines 
Name Origin / features Reference 
293T human embryonic kidney fibroblast,  
transduced with SV40 large T antigen 
[211] 
HeLa human cervix carcinoma [209] 
HeLaP4 HeLa stably expressing CD4 [37] 
JC53 HeLa stably expressing high levels of CD4 [186] 
Lunet/CD81 human hepatoma, Huh7-derived, cured from replicon,  
stably expressing CD81 
[121] 
Lunet/V human hepatoma, Huh7-derived, cured from replicon, 
sorted for low CD81 expression 
[121] 
Affinofile human embryonic kidney fibroblast, 293-derived,  
inducible for CD4 and CCR5 expression 
[105] 
SupT1/CCR5 human Non-Hodgkin's T-cell lymphoma, stably expressing CCR5 R. Doms 
C8166/CCR5 human umbrical blood lymphocytes, infected with defect HTLV-I,  
stably expressing CCR5 
M. Malim 
C8166 human umbrical blood lymphocytes, infected with defect HTLV-I  [204] 
MT-4 human T-cells isolated from a patient with adult T-cell leukemia,  
HTLV-I transformed 
[153] 
TZM-bl HeLa-derived, harbouring a Tat-inducible β-galactosidase  
and luciferase reporter 
[237] 
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2.1.5 Antibodies 
Antibody name Source Application Dilution 
mouse anti HIV gp41 
Chessie-8 
NIH AIDS Research and 
Reference Reagent Program 
WB 1:1000 
mouse anti-heparan sulphate 
clone F58-10E4 
Seikagaku Inc.  FACS 1:20 
mouse anti-HIVp24 mAb  
183-H12-5C 
NIH AIDS Research and 
Reference Reagent Program 
WB 1:50 
mouse anti-human CCR5 
clone 2D7 
BD Pharmingen™ IF 1:100 
mouse anti-human CCR5 
clone 2D7 
BD Pharmingen™ FACS 1:10 
mouse anti-human CD317 Chugai Pharmaceuticals FACS  
mouse anti-human CD4 
clone RPA-T4 
AbDserotec IF 1:100 
mouse anti-human CD4 
clone RPA-T4 
BD Pharmingen™ FACS 1:20 
mouse anti-human CD81 
clone JS-81 
BD Pharmingen™ neutralization  
mouse anti-human CXCR4 
clone 12G5 
BD Pharmingen™ FACS 1:20 
mouse anti-human IgG Invitrogen IF 1:2000 
goat anti-rabbit IgG Invitrogen IF 1:2000 
rabbit anti HIV CA Kräusslich lab WB 1:5000 
rabbit anti HIV MA Kräusslich lab WB 1:5000 
rabbit anti-HCV E2 
clone H52 
Th. Pietschmann WB 1:500 
rabbit anti-HIV RT Kräusslich lab WB 1:1000 
rabbit anti-HIV Vpr Kräusslich lab WB 1:2000 
rabbit anti-human Bst-2 Klaus Strebel IF  
sheep anti-HIV CA Kräusslich lab WB 1:5000 
2.2 Molecular Biological Methods 
2.2.1 Transformation of bacteria and DNA amplification 
Chemically competent bacteria were transformed with plasmid DNA (app. 100-500 ng) 
according to the heat-shock method. Briefly, bacteria were thawed on ice, DNA was added and 
incubated on ice for at least 10 min and then a heat-shock was performed at 42°C for 45 sec. 
Then, 450 µl of LB was added and bacteria incubated at 37°C for app. 1 h before plating on LB-
Agar plates with the respective selection antibiotic. After over night incubation at 37°C, single 
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bacterial colonies were picked, inoculated in 1.5 ml (Mini) or 200 ml (Maxi) LB with the 
respective antibiotic for selection and agitated over night at 37°C. Plasmid DNA was isolated 
with the alkaline lysis method using the NucleoBond® maxiprep kit (Macherey-Nagel, Düren, 
Germany). Purified plasmid DNA was dissolved in TE buffer and concentration and purity were 
determined by measuring the absorption at 260 nm and 280 nm respectively in a UV 
spectrophotometer (Beckmann Coulter). For Mini preparations, the same buffer set (Macherey-
Nagel, Düren, Germany) was used to perform the alkaline lysis and DNA was precipitated using 
isopropanol. After a washing step with 70 % ethanol, DNA was dissolved in H2O and subjected 
to restriction analysis.  
2.2.2 DNA digestion and ligation 
1 µg of purified plasmid DNA (5 µg for vector preparations) or 30 µl of purified PCR 
product was incubated with 10 U of the desired restriction enzyme in the appropriate buffer at the 
temperature recommended by the manufacturer for 0.5-2 h.  
Restriction products were checked using gel electrophoresis. To this end, 0.5-2 % agarose 
(standard 1 %) in TAE buffer was heated until melted, ethidium bromide was added and the cast 
gel was cooled until solidification. Gel electrophoresis was performed at 90 V for app. 30 min and 
DNA bands visualized under UV irradiation and compared to a molecular mass standard loaded 
as a control (1 kb ladder, Invitrogen Ltd., Paisley, UK). DNA fragments for cloning were cut out 
of the gel and purified using the NucleoSpin kit (Macherey-Nagel, Düren, Germany) according 
to manufacturer’s protocol using 30 µl Millipore H2O for elution.  
In case of a single cut within the plasmid, the vector was dephosphorylated by treatment 
with 10 U calf intestine alkaline phosphatase for 30 min at 37°C directly after enzyme digestion. 
Purified digestion products were ligated using 1 µl vector and 3 µl insert DNA (in case this 
standard did not yield a result, 3 molar excess of insert was used) by the addition of T4-DNA 
ligase in 15 µl 1X ligase buffer for 2 h at room temperature (or over night at 16°C). The complete 
ligase reaction was then transformed into 50 µl of chemically competent bacteria (see above).  
All enzymes were from Fermentas (Fermentas GmbH, St. Leon-Rot, Germany) or NEB 
(New England Biolabs GmbH, Frankfurt, Germany).  
2.2.3 DNA amplification by polymerase chain reaction (PCR) 
Typically 40 ng of purified plasmid DNA was used as a template for amplification using 
40 pmol of both forward and reverse primers. The reaction was performed in 20-50 µl total 
volume in the presence of 250 µM desoxy nucleotide triphospates (dNTPs). In most cases, a 
proofreading polymerase, e.g. Pfu was used in the recommended buffer. Initial denaturation was 
performed at 94°C for 5 min, followed by 20-30 circles of a short denaturation at 94°C, followed 
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by an annealing step for 45 sec at typically 48°C and a synthesizing step at 72°C for 1 min per 
1 kb of template length. A final step at 72°C was performed in addition to allow the completion 
of unfinished products. PCR products were controlled by agarose gel electrophoresis in 
comparison to mass standards and purified by gel extraction with the NucleoSpin® Kit 
(Macherey-Nagel, Düren, Germany).  
If no or unspecific PCR products were observed, the conditions were optimized regarding 
annealing temperature of the primers, template input, MgCl2 concentration in the buffer or 
addition of more efficient polymerase enzyme Taq. Cloning of different V3-loop sequences into 
pCAGGS-derived vectors (2.2.4.3) was performed using the Phusion high-fidelity DNA 
polymerase (Finnzymes, Espoo, Finland) with an accelerated protocol according to 
manufacturer’s instructions.  
2.2.4 Cloning procedures 
All plasmid obtained by cloning including a PCR step were verified by sequencing of the 
respective inserted fragments. Sequencing was performed by the company GATC Biotech 
(Konstanz, Germany).  
2.2.4.1 Construction of proviral plasmids including the fluorescent protein mCherry 
In order to insert the mcherry gene into the subviral clone pCHIV at the 3’ end of the MA 
coding sequence, the mcherry sequence was amplified by PCR from pC1-Cherry (Invitrogen) with 
primers 252 and 252, which introduced ClaI restriction sites at both ends of the mcherry gene. The 
resulting fragment was inserted into pBSMAJ.ClaI harbouring a unique ClaI restriction site at 
position 1171 of the NL4-3 sequence [162] to obtain pBSMAJ.mCherry as an intermediate clone. 
Then, the BssHII-SphI fragment comprising the modified MA sequence was subcloned into 
pKHIV to obtain pKHIV.SNAP. The AgeI-XbaI fragment from pKHIV.mCherry was further 
subloned into pCHIV to obtain pCHIV.mCherry, which expresses higher levels of all HIV-1 
proteins to obtain a better particle yield.  
2.2.4.2 Construction of proviral plasmids including the SNAP-tag 
In order to insert the snap-tag gene into the subviral clone pCHIV at the 3’ end of the MA 
coding sequence, the snap-tag sequence was amplified by PCR from pSS26m (Covalys) with 
primers 5252 and 5251, which introduced ClaI restriction sites at both ends of the snap-tag gene. 
The resulting fragment was inserted into pBSMAJ.ClaI harbouring a unique ClaI restriction site at 
position 1171 of the NL4-3 sequence [162] to obtain pBSMAJ.SNAP as an intermediate clone. 
Then, the BssHII-SphI fragment comprising the modified MA sequence was subcloned into 
pKHIV and pNLC4-3 to obtain pKHIV.SNAP and pNLC.SNAP, respectively. The AgeI-XbaI 
fragment from pKHIV.SNAP was further subloned into pCHIV to obtain pCHIV.SNAP, which 
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expresses higher levels of all HIV-1 proteins to obtain a better particle yield.  
For construction of the subviral clone carrying the SNAP-tag with two flanking PR 
cleavage sites (pNLCiSNAP), the snap-tag sequence was amplified by PCR using primers 3159 
and 3160. The forward primer introduced a MluI and the reverse primer an XbaI restriction site. 
The resulting fragment was inserted into pNLCiGFP to obtain pNLCiSNAP.  
2.2.4.3 Construction of Env expression plasmids harbouring different V3-loop sequences 
Different patient derived V3-loop sequences were inserted into pCAGGS-NL4-3, a 
mammalian expression vector for the complete HIV-1 Env protein. To this end, an additional 
restriction site had to be inserted into the env sequence first. XbaI was chosen as it was absent 
from the vector backbone as well as the complete env sequence and could be introduced by the 
introduction of two silent mutations 7 and 8 bp downstream of the 3’ end of the V3-loop coding 
sequence. Two PCRs with overlapping primers introducing the A-T and G-C mutations were 
performed followed by a fusion PCR of both fragments with the outer primers. The first forward 
primer, 2541, was overlapping with a unique PvuII restriction site and was used in combination 
with primer 2540, spanning the complete V3-loop sequence. The second fragment was flanked by 
the mutated primer 2539 and the reverse primer 2542, overlapping a unique MfeI site. After 
successful amplification of both fragments, they were purified and used in different dilutions for 
the fusion PCR step with the outer flanking primers 2541 and 2542. This fragment was then 
subjected to PvuII/MfeI restriction and inserted in the pCAGGS-NL4-3 vector.  
Sequencing of this construct revealed a mutation in the NL4-3 sequence which was found 
in several clones resulting from this cloning procedure and finally also located in the parental 
clone. Since this G378V mutation was not found in any HIV-1 Env sequences as confirmed by a 
BLAST search, and was also absent from the pCAGGS-NL4-3 derivative pCAGGS-NL4-3-R5, 
the mutation was reversed by a fusion PCR approach. To this end, a primer pair was designed 
changing the single nucleotide from T to G: 2583 and 2584. Primary PCRs were performed with 
the pairs 2541 and 2584, as well as 2583 and 2542, products purified and used in the fusion PCR 
with the flanking primer pair 2541 and 2542, cut by PvuII/MfeI and inserted into the above 
constructed clone harbouring the additional XbaI site. The final construct pCAGGS-NL4-3XbaI 
was confirmed by sequencing and used for further cloning.  
V3-loop sequences from patient’s samples were amplified by PCR directly on the RT-
PCR product amplified from the original sample (for patients 651, 685, 822, 838 and 924) or on 
mini preparations of inserted patient’s sequences into pCAGGS (for patients 220, 286 and 409; 
performed by E. Heger, group of R. Kaiser, Department of Virology, University of Cologne, 
Köln, Germany). PCR on patient’s samples 286, 409, 685, 838 yielded amplification products 
that led to positive clones by the partially mismatching original primer pair 2540 and 2541, 
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whereas new forward primers with perfectly matching sequences had to be used for samples 220 
(primer 2747), 651 (primer 2748), 822 (primer 2749) and both forward and reverse primers for 
924 (2750 and 2751). PCR products were cleaved with PvuII/XbaI yielding small fragments of 
~140 bp which were purified via agarose gel electrophoresis and gel extraction and ligated into 
the vector pCAGGS-NL4-3XbaI.  
2.3 Biochemical Methods 
2.3.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blot 
Protein samples were suspended in 1x SDS-sample buffer containing β-mercaptoethanol 
and boiled at 95°C for 5-10 min. Low crosslinking-gels of 17.5 % acrylamide containing 0.0875 % 
bis-acrylamide were used for protein separation at 25 mA per gel for app. 1 h. The gels were then 
blotted onto a nitrocellulose membrane using a semi-dry blotting machine (Fastblot B32, 
Whatman Biometra, Göttingen, Germany or one from cti GmbH, Idstein, Germany). To this 
end, 4 Whatman filter papers were soaked in buffer I, 2 in buffer II, the nitrocellulose and gel 
were briefly rinsed with buffer II and the gel was finally covered by 5 sheets of Whatman paper 
soaked in buffer III. Blotting was performed at 0.8 mA/cm2 for 1 h.  
If no prestained protein marker was used, the membrane was briefly stained with 
ponceauS for 5 min to visualize the marker bands and mark them with a pencil. Otherwise, 
blocking of the membrane was directly performed in 10 % milkpowder or 2 % BSA in TBST for 
app. 30 min at RT. Primary antibodies were incubated with the membrane o/n at 4°C in TBST 
containing 5 % milkpowder or 1-2 % BSA. After washing of the membrane with TBST, 
secondary antibodies raised against IgGs of the appropriate species directly coupled to 
horseradish peroxidase were incubated in TBST containing 5 % milkpowder for 1 h at room 
temperature.  
Detection of immunoreactive bands was performed using enhanced chemiluminescence 
(ECL) with a luminol-based substrate from Pierce (Thermo Fisher Scientific, Bonn, Germany) 
and the signal recorded by exposure of X-ray films for different time points which were then 
developed in an automatic film processor.  
2.3.2 Quantitative Western Blot 
SDS-PAGE separation of protein samples, western blotting, blocking and primary 
antibody incubation were performed as described in 2.3.1. A prestained protein marker was used 
that could be visualized on the infrared-imager and ponceauS staining was omitted to prevent 
background signals. Species specific secondary antibodies were coupled to fluorescent probes 
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with 700 nm or 800 nm excitation maximum, respectively. Incubation was performed in LiCor 
blocking buffer diluted 1:3 in PBS for 1 h at room temperature in the dark. The membrane was 
then washed and immunoreactive bands detected on the infrared imaging system Odyssey® (LI-
COR Biosciences GmbH, Bad Homburg, Germany).  
Quantitation of p24 amounts in virus samples was performed in comparison to a standard 
of purified CA-protein (sometimes mixed with purified MA-protein) applied on the gel in 
parallel.  
2.3.3 Dot Blot 
The Dot Blot device (Minifold® I, Whatman GmbH, Dassel, Germany) was assembled 
according to manufacturer’s instructions including one Watman filter below the nitrocellulose 
membrane briefly rinsed in PBS. Protein samples heated in SDS-sample buffer or crude 
supernatant inactivated with 0.5 % triton-X-100 for 90 min were loaded and applied to the 
membrane by vacuum. Membrane was dried, blocked for 15 min in 2 % BSA in TBST and 
incubated with primary and secondary antibodies as described for quantitative western blot 
membranes (see above).  
2.3.4 Enzyme-Linked Immunosorbent Assay (p24-ELISA)  
The in-house p24-ELISA for detection of HIV-1 CA-protein in samples was used to 
determine virus concentrations in p24 equivalents.  
Maxisorb 96-well plates (Nunc, Wiesbaden, Germany) were coated with a monoclonal 
mouse-antibody raised against p24(CA) (183-H12-5C) o/n at room temperature in a moist 
chamber and then blocked with 10 % FCS/PBST for 2 h at 37°C. Virus dilutions in PBST were 
added to the single wells and a titration of purified CA-protein was applied as a standard. 
Samples were incubated o/n at RT in a moist chamber. After washing with PBST, the plate was 
incubated with a rabbit-antiserum raised against CA protein, followed by another washing step 
and the incubation with horsereddish peroxidase-coupled secondary antibody raised in goat 
against rabbit IgG for 1 h at 37°C, each. After washing with PBST and H2O, the amount of 
bound antibody was visualized by addition of the chromogenic substrate tetramethyl benzidine 
(TMB) for 5 min. The labelling reaction was stopped by the addition of 0.5 M sulphuric acid and 
the absorbance of the coloured reaction product quantitated in a spectrofluorimetric plate-reader 
at 405 nm wavelength.  
2.3.5 Production of oxidized low density lipoproteins (oxLDL) 
LDL was diluted to 100 µg/ml in PBS and 1 ml of this solution was oxidized in presence 
of 10 µM CuSO4 for 18 h at 37°C. The oxidizing reaction was stopped by the addition of 2 µl 
Materials and Methods 
35 
0.5 M EDTA, resulting in a final EDTA concentration of 1 mM. All buffers were kept sterile so 
that the final oxLDL could be stored at 4°C and later on used in the BlaM assay.  
2.4 Cell Biological Methods 
2.4.1 Cell culture 
Adherent cell lines were kept in DMEM high glucose, supplemented with 10 % FCS, 
100 U/ml penicillin, 100 µg/ml streptomycin and 20 mM Hepes buffer and incubated at 37°C at 
5 % CO2 in 95 % humidity. The double-inducible 293-derived cell line Affinofile [105] was kept 
in DMEM, supplemented with 10 % FCS without tetracycline, with penicillin/streptomycin and 
20 mM Hepes buffer and the selection antibiotics Hygromycin, Blasticidin, Neomycin and 
Geneticin were added after each passage of the cells. Suspension cells were kept in RPMI 1640, 
supplemented with 10 % FCS, Pen/Strep and 20 mM Hepes buffer. SupT1-R5 and C8166-R5 
cells, subclones of the SupT1 and C8166 cell lines which stably express CCR5, were kept under 
permanent selection pressure with 0.3 µg/ml and 0.2 µg/ml Puromycin, respectively. Freshly 
isolated primary blood mononuclear cells (PBMC) were kept in RPMI 1640.  
Cells were passaged every 3-4 days. For that purpose, adherent cells were briefly washed 
with PBS, detached with 0.05 % Trypsin/EDTA in PBS for 5 min and resuspended in media. 
Suspension cells were separated and then passaged in the appropriate concentration.  
For maintenance, aliquots of cells were cyro-conservated in FCS (w/o Tetracycline for 
Affinofile cells) supplemented with 10 % DMSO. Then, they were slowly cooled to -80°C and 
then transferred to liquid nitrogen for long-term storage.  
2.4.2 Transfection of cells 
Cells were seeded app. 24 h before transfection with one of the different methods.  
2.4.2.1 PEI-method 
Polyethyleneimmine is a cationic polymer that forms positively charged complexes with 
DNA that can then enter cells. For this method, DNA was diluted in DMEM without any 
supplements and 3 times the µg amount of DNA was added in volume of polyethylenimine 
(1mg/ml in H2O), mixed well and incubated for at least 30 min at room temperature. The 
mixture was the added dropwise to the cells.  
2.4.2.2 Calcium phosphate precipitation method 
DNA was diluted in H2O and mixed with 1/10 2.5 M CaCl2. This mixture was then 
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slowly pipetted to the same volume of 2x HeBS buffer while vortexing, incubated for 30 min at 
RT and then slowly added to the cells. Medium change was performed app. 6 h post transfection.  
2.4.2.3 FuGene-method 
Two times the µg amount of DNA to be transfected of FuGene6 reagent was added in 
volume to OptiMEM and incubated for 5 min at room temperature. Then, DNA was added and 
incubated for further 15 min before adding the mixture to the cells.  
2.4.3 SNAP-labelling of cells 
Hela cells seeded on coverslips 24 h prior to the experiment were transfected with 
FuGene method and incubated at 37°C for 24 h. SNAP-labelling was conducted as 
recommended by the manufacturer. Briefly, cells were incubated with 1 µM TMR-Star in DMEM 
for 15 min at 37°C, washed three times and then incubated in fresh DMEM for 45 min at 37°C to 
allow diffusion of access substrate. For pulse-chase experiments, cells were first incubated with 
10 µM BTP for 5 min at 37°C, washed three times, incubated with fresh DMEM for the indicated 
chase period and then stained with TMR-Star as described above. Cells were then fixed with 3 % 
PFA for 30 min and counterstained with Hoechst 33258 for 30 min at room temperature, washed 
with PBS, rinsed with H2O and embedded in Mowiol.  
HIVSNAP infected C8166 cells were subjected to a modified protocol in solution using the 
same conditions as above. To wash cells, they were centrifuged at 4’000 rpm for 4 min. Fixation 
was carried out with 3 % PFA for 90 min and cells were then subjected to immunofluorescence 
staining (see 2.4.7). For imaging, suspension cells were adhered on fibronectin-coated coverslips 
and then embedded in Mowiol.  
2.4.4 Electron microscopic analysis of cell samples 
293T cells were transfected using FuGENE HD (Roche Diagnostics GmbH, Mannheim, 
Germany) with pNLC4-3 or pNLC.SNAP, respectively. At 24 h post transfection the cells were 
fixed and processed for resin-embedding as described [240]. Briefly, cells were fixed with 4 % 
paraformaldehyde, 0.1 % glutaraldehyde in 0.1 M PHEM for at 90 min at RT then washed with 
50 mM glycine in 0.1 M PHEM followed by 100 mM sodium-cacodylate, pH 7.4. Cells were 
scraped in 1 % BSA in 100 mM cacodylate, pelleted, washed with 100 mM cacodylate and post-
fixed with 2.5 % GA for 1 h. Pellets were washed in 100 mM cacodylate, post-fixed with reduced 
Osmium (1 % OsO4, 1.5 % potassiumhexacyanoferrat in 100 mM cacodylate) and stained for 
16 h with 1 % aequous uranyl acetate.  
Cells were gradually embedded in epoxy-resin after dehydration with a series of 
increasing concentrations of acetone. Ultra-thin sections were post-stained with lead-citrate. All 
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sections were examined with a Zeiss EM10 TEM and images taken using a Gatan MultiScan™ 
camera and Digital Micrograph™ software and further processed using Adobe Photoshop CS2. 
2.4.5 Flow cytometry of cells (FACS) 
Adherent cells were detached with 5 mM EDTA in PBS for 5 min and washed with 10 % 
FCS/PBS. For pelletation of cells between different staining or washing steps, centrifugation was 
either performed in 1.5 ml reaction tubes at 4000 rpm for 5 min at 4°C or in 96-well plates at 
1200 rpm for 5 min. If indicated, cells were fixed with 3 % PFA/PBS for 30 min and stained with 
antibodies against surface proteins in PBS at the given dilutions for 30 min at room temperature 
or on ice if unfixed samples were used. If primary antibodies were not available as directly 
coupled variants, species specific secondary antibodies coupled to the indicated fluorophore were 
used for staining for 30 min in PBS. Samples were briefly washed in PBS, resuspended 
thoroughly in PBS and then subjected to flow cytometry on a FACSCalibur, FACSAria, 
FACSCanto II or BD LSR II machine (BD Biosciences, Heidelberg, Germany). For some 
applications, dead cells were stained with propidium iodide or 7-aminoactinomycin D (7-AAD) 
which was added to the sample directly before measurement at a dilution of 1:1000.  
2.4.6 Quantitative FACS measurements with QuantiBRITE  
Affinofile cells were seeded at 3x105 in 24-well plates and induced 18 h prior to the 
experiment. Cells were detached with 5 mM EDTA, transferred to test tubes, washed with PBS 
and surface staining of CD4, CCR5 and CXCR4 was performed as described above with 
monoclonal mouse antibodies directly coupled to PE. Flow cytometric analysis was performed 
with a FACSCalibur and a vial of QuantiBRITE PE (BD Biosciences, Heidelberg, Germany) was 
measured with the same instrument settings, only adjusting forward (FSC) and sideward scatter 
(SSC). This sample was gated on bead singlets and geometric mean values of PE fluorescence 
intensity were measured for the four bead-populations as described in the manufacturer’s 
protocol. A standard curve was calculated from the Log10 of geometric mean values and lot-
specific number of PE molecules per bead as given by the manual. Log10 of geometric mean 
values of individual cell measurements of FSC-SSC-gated Affinofile cell populations were then 
transformed to antibody molecules bound per cell (ABC) based on slope and intercept of the 
standard curve.  
2.4.7 Immunofluorescence staining of cells 
For intracellular p24 staining, C8166 cells infected with HIV-1 derivatives and control 
mock infected cells were fixed with 3 % PFA for 90 min and washed with PBS. 1x106 cells were 
adhered to fibronectin coated cover slips and permeabilized by incubation with 0.1% TritonX-
100/PBS for 3 min at room temperature and blocked with 3 % bovine serum albumin (BSA) in 
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PBS for 10 min. Intracellular p24 was detected by incubation with a rabbit antibody raised 
against HIV-1 CA for 30 min at room temperature. After washing with PBS, 30 min incubation 
at room temperature with a secondary goat anti-rabbit antibody coupled to Alexa 488 
(Invitrogen, Karlsruhe, Germany) was utilized for visualization. Counterstaining of nuclei was 
performed using 1:500 Hoechst 33258 in the secondary antibody solution. Cells were washed 
again with PBS, rinsed with H2O and embedded in Mowiol.  
For surface detection of cellular proteins, cells were fixed and blocked directly without 
preceding permeabilization. Antibody staining was performed in PBS for 30 min each at room 
temperature. If coupled antibodies were applied, cells were subsequently kept in the dark. 
Affinofile cells were stained against CCR5 in a first step, using a mouse-antibody raised against 
CCR5, secondary goat anti-mouse antibodies coupled to Alexa 568 and cells were subsequently 
stained with an Alexa 647-coupled mouse-anti CD4 antibody. During the last two steps, 
Hoechst 33258 was present for nuclei counterstaining. Staining in 96-well plates was performed 
in 30 µl/well to minimize the amount of reagents needed. To ensure proper distribution of 
staining solution over the complete well, plates were gently agitated during the incubation 
periods. To prevent cell detachment, supernatants were decanted rather than aspirated.  
For imaging on coverslips, adherent cells were grown on coverslips briefly rinsed in EtOH 
and flamed for sterilization. After fixation and blocking, cells were stained in 60 µl solution 
applied as a drop on top of the coverslip. Subsequently, cover slips were rinsed in H2O and 
embedded in Mowiol.  
2.4.8 Automated fluorescence microscopy 
Affinofile cells transduced with equivalent amounts of isogenic viral vectors as described 
in 2.5.8, fixed and stained for cell surface molecules and nuclei as described in 2.4.7 were imaged 
in a fully automated inverted epifluorescence screening microscope equipped with the ScanR 
acquisition software (Olympus ScanR IX81 'inverted' microscope setup, Olympus Soft Imaging 
Solutions GmbH, Münster, Germany). 16 images per well were recorded in 4 channels using a 
10x objective. The appropriate excitation and emission filters were used to acquire images in the 
channels DAPI for the detection of Hoechst staining of nuclei, GFP for reporter gene expression, 
TexasRed for CCR5 stained with Alexa 568 and Cy5 for CD4 staining with Alexa 647. Exposure 
times were adjusted for each experiment empirically but kept constant over the course of one 
experiment including all proper controls. The times were in the range of 2-5 ms for DAPI, 50-
100 ms for GFP and 500-1000 ms for the two remaining channels.  
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2.5 Virological Methods 
2.5.1 Particle preparation 
293T cells were seeded at 3x106 in 10 cm-dishes 24 h prior to transfection with the PEI-
method. 15 µg pcHIV or a 1:1 mixture of pcHIV and a fluorescently labelled variant thereof were 
transfected per dish. Supernatants were harvested app. 40-48 h post transfection and cleared by 
brief centrifugation at 1500 rpm for 5 min at 4°C and subsequently filtered through 0.45 µm 
filters. App. 28 ml of supernatant were layered upon a 8 ml sucrose cushion (20 % sucrose (w/v) 
in PBS) and pelleted in the ultracentrifuge at 24’000 rpm for 2 h at 4°C. The pellet was the 
resuspended in 75 µl of PBS 20 mM Hepes and 10 % FCS. Aliquots of the virus preparation were 
shock-frozen in liquid nitrogen and then stored at -80°C. For smaller preparations, 293T cells 
were seeded in 6-well plates at 3x105 or 8x104 in 12-well plates and pelletation performed in a 
table-top ultracentrifuge at 44’000 rpm for 45 min-1 h.  
HCV pseudoparticles were produced by transfection of 293T cells with the PEI method 
using 15 µg of proviral pcHIV.Env(-) or a mixture with the fluorescently labelled variant and 
2.5 µg of pcDNA3∆CE1E2. Harvesting and purification of particles was performed as described 
above.  
Isogenic gfp reporter gene carrying vectors only varying in the Env protein incorporated 
were produced by transfection of 293T cells with the PEI method. To this end, 3x106 293T cells 
were seeded in 10 cm dishes and 24 h later transfected with a mixture of 11.29 µg pSEW, 6.72 µg 
pCMV∆R8.9 and 2.5 µg of the respective Env expression plasmid. Harvesting and purification of 
particles was performed as described above.  
2.5.2 Virus Binding Assay 
Adherent cells were seeded 24 h prior to the experiment at 1x104 cells/well in 8-well 
chambered cover glasses (LabTek, Nunc, Wiesbaden, Germany) precoated with Collagen A for 
Lunet cells or 1x105 HeLaP4 cells in 12-well plates with coverslips rinsed in EtOH and briefly 
heated over a flame. Suspension cells were directly used at a density of 1x106 cells/100 µl. Cells 
were transferred to CO2-independent medium, chilled on ice for 10 min and the indicated p24 
equivalent of fluorescently labelled virus was added. Virus binding was allowed for 1 h on ice, 
excess virus was washed off with cold PBS and cells were then fixed with 3 % PFA on ice for 
30 min. Suspension cells were then adhered to Fibronectin coated coverslips and embedded in 
Mowiol, whereas cells in LabTeks were overlayed with PBS and imaged directly.  
Microscopy was performed using an inverted epifluorescence microscope (Zeiss Axiovert 
200M, Carl Zeiss Imaging Solutions GmbH, München, Germany) equipped with the appropriate 
filter sets. To cover the complete cell volume, z-stacks were recorded. In case of the virus binding 
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assay to determine dependence on CD317 expression levels, single images at one z-position were 
acquired in the GFP and Alexa 647 channel in addition.  
2.5.3 Virus Uptake Assay 
Lunet cells were seeded 24 h prior to the experiment at 1x104 cells/well in 8-well 
chambered cover glasses (LabTek, Nunc, Wiesbaden, Germany) precoated with Collagen A or at 
3x105 in 6-well plates with coverslips rinsed in EtOH and briefly heated over a flame. Cells were 
transferred to CO2-independent medium, chilled on ice for 10 min and the indicated p24 
equivalent of fluorescently labelled virus was added. Virus binding was allowed for 1 h on ice, 
medium was changed to warm DMEM thereby washing excess virus off and cells were incubated 
for the indicated time period at 37°C. Subsequently, cells were washed and fixed with 3 % PFA. 
To monitor cellular endocytosis, samples were incubated with virus in the presence of 50 µg/ml 
fluorescently coupled transferrin (Invitrogen, Karlsruhe, Germany).  
Microscopy was performed using a confocal laser scanning microscope (Nikon C1Si, 
Nikon Imaging Center at University Heidelberg, Heidelberg, Germany; Nikon, Düsseldorf, 
Germany) equipped with the appropriate filter sets.  
2.5.4 β-Lactamase Virion Fusion Assay 
The β-Lactamase virion fusion assay was based on the method developed by Cavrois and 
colleagues [35]. Briefly, viral particles containing a fusion protein of Vpr and the bacterial protein 
β-Lactamase were produced from 293T cells as described in 2.5.1 by co-transfection of 1 µg of the 
plasmid pMM310 per 10 cm dish. Virus concentration was determined by p24-ELISA or 
quantitative Western Blot as described in 2.3.4 and 2.3.1, respectively.  
Cells were seeded in 96-well plates at a density of 1-2x104 for adherent cells app. 24 h 
before virus addition or 1x106 suspension cells directly before virus addition, respectively. Virus 
dilutions of a given amount of p24 were added to the cells and incubated for 6 h at 37°C if not 
stated differently. Cells were then briefly washed with CO2-independent media and 60 µl CCF2-
AM, a fluorescent substrate for β-Lactamase (GeneBLAZER, Invitrogen Ltd., Paisley, UK), 
added according to the manufacturer’s protocol. After o/n incubation at RT in the dark, cells 
were washed with PBS, fixed with 3 % PFA/PBS for at least 30 min and then subjected to further 
antibody staining if indicated.  
Read-out was performed either microscopical, in a plate fluorimeter (Tecan Safire, Tecan 
Deutschland GmbH, Crailsheim, Germany) or with flow-cytometry in a FACSAriaTM or 
FACSCantoTM II (BD Biosciences, Heidelberg, Germany) with the appropriate filters (Ex 
409 nm, Em 447 nm and 520 nm). The entry efficiency was calculated in relation to a control 
where no virus was added.  
Materials and Methods 
41 
2.5.5 Infectivity assay 
TZM-bl cells were seeded in 96-well plates at 8x103 cells/well in 100 µl. After 24 h cells 
were infected with 100 µl supernatant form transfected 293T cells (HIV, HIVSNAP and HIViSNAP 
were produced by transfection with the plasmids pNLC, pNLC.SNAP and pNLCiSNAP, 
respectively) and serial 1:2 dilutions were performed in DMEM. Cells were incubated for 48 h at 
37°C and supernatant was discarded. Cells were lysed with 50µl of Steady-Glo® reagent in 100µl 
DMEM (Steady-Glo® Luciferase Assay System, Promega, Mannheim, Germany) for 5 min at 
room temperature. 80 µl of cell lysate was transferred to a white 96-well plate and luminescence 
was measured in a plate luminometer.  
2.5.6 Replication kinetics of HIV-1 derivatives 
HIV, HIVSNAP and HIViSNAP were produced by transfection of 293T cells with the plasmids 
pNLC, pNLC.SNAP and pNLCiSNAP, respectively. The amount of p24 in the supernatant was 
determined using qWB as described in 2.3.2 and 0.5 ng of p24 of each virus derivative were used 
to infect 1 x 105 MT4 cells in 200 µl per 96-well (V-bottom). 95 µl of supernatant were collected 
every 2 to 3 days and inactivated with 5 µl of 5 % Triton X-100, leading to a final concentration 
of 0.25 % of Triton X-100.  
2.5.7 SNAP-labelling of HIVSNAP  
Non-infectious HIVSNAP and HIV as a control were produced by transfection of 293T cells 
as described above. Viruses were purified by ultracentrifugation through a 20 % sucrose cushion 
and resuspended in PBS with 20 mM Hepes and 10 % FCS. 300 ng p24 equivalent were 
incubated with 1 µM TMR-Star and 5 mM DTT in PBS at 4°C over night. Virus was re-purified 
by ultracentrifugation in a tabletop centrifuge through 200 µl 20 % sucrose cushion, resuspended 
in PBS with 20 mM Hepes and 10 % FCS and imaged in a wide-field epifluorescence microscope.  
2.5.8 Transduction of cells 
Isogenic gfp reporter gene carrying vectors only varying in the Env protein incorporated 
were produced as described in 2.5.1. For a typical Affinofile transduction experiment, cells were 
seeded in 96-well plates at 8x103 and induced for 18 h with the indicated concentration of 
inducing agents. Then, 5 ng p24 equivalent as determined by qWB (2.3.2) were added to the cells 
and incubated for 48 h at 37°C. Subsequently, cells were fixed with 3 % PFA for 30 min and 
immunofluorescence staining was performed if needed.  
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2.6 Computational Methods 
2.6.1 Semi-automated Particle Counting and Colocalisation Analysis 
A plug-in for the image analysis program ImageJ was complied which performed several 
subsequent analysis steps automatically. A batch read-in of pictures with the same base-name and 
incremented file numbering could be achieved. Then, depending on the file format, changes in bit 
depth and channel composition were performed to obtain 8-bit single channel images. The 
images were then filtered with a bandpass FFT (fast Fourier transformation) and a threshold was 
defined based on the mean background fluorescence signal or a fixed value which was 
determined empirically. A particle recognition program was applied on signals above this 
threshold and the intensity of the fluorescence signals in the different channels measured at the 
respective spots. To determine colocalization of spots in different channels, the thresholded 
images of both channels were divided by 255 and 127.5, respectively. The resulting images were 
added to each other, obtaining a new image with intensity values of 0, 1, 2 or 3, depending on the 
signal in the two original images with no signal in both channels resulting in 0, a signal in the first 
picture resulting in 1, in the other picture resulting in 2 and an overlapping signal in both original 
pictures resulting in 3. This resulting image was then analysed at the beforehand recognized 
spots.  
2.6.2 Automated cell-segmentation and single cell read-out of microscopic data 
Cell segmentation was performed in a two-step process, starting with the identification of 
each cell according to the nucleus signal in the DAPI channel. To this end, DAPI images were 
binarized, filtered and local maxima assigned to individual cell nuclei. The algorithm was 
performed as described in [22]. As the second step, cell bodies were segmented on a maximum 
projection of the two cellular surface molecule images in the Cy5 and TexasRed channel. A 
maximum projection was chosen to provide the strongest possible signal if one of the channels 
showed only weak signals. Perfect matching of both channels was beforehand controlled 
manually and a relocalization could be implemented if necessary. The seeded watershed 
segmentation method was used, where segmentation was started from the centre of the nuclei 
assigned before. In this method, the grey value intensities of the image are viewed as in a 
landscape, with low intensities building valleys and high intensities building hills. The algorithm 
simulates a rising level of water, starting from the assigned nuclei valleys. As soon as two 
neighbouring “basins” are about to merge, a barrier is built which reflects the line at which two 
cell bodies hit. In 2D, the line can be imagined growing from the centre (nucleus) until it hits a 
sharp intensity border or the border of a growing neighbouring cell. To prevent too big cells, a 
maximum area threshold was applied.  
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3 Results 
This chapter is divided into two main parts. In the first part, the use of fluorescently 
labelled viruses as a tool to study the interactions of cells and viruses is described. While an 
emphasis is made on viral entry in this thesis, the establishment of a new internal labelling 
strategy also allows investigating virus egress. The second part (see page 69) describes a detailed 
analysis of virus entry into their host cells depending on different critical viral and cellular 
parameters. In order to find a better understanding of this process, the influence of the presence of 
different amounts of interfering drugs has also been investigated.  
3.1 Fluorescently labelled viruses to study virus cell interactions 
To study the kinetics and dynamics of the viral replication cycle, fluorescently labelled 
HIV-1 derivatives have widely been used in the past [117, 127, 147, 162]. In those studies, 
fluorescent proteins have been fused to various proteins of HIV-1, such as MA, Vpr or IN 
(compare chapter 1.3.1 for further details). For HCV, no such systems to directly label viral 
particles have been established, yet.  
The first part of this chapter will describe the combination of the well-established virus 
tagging, fusion of the viral MA protein, with a new labelling technique, the SNAP-tag, which 
allows the usage of organic dyes as fluorochromes. The second part focuses on the establishment 
of a system to study and dissect the early steps of HCV entry, mainly with the help of 
fluorescently labelled particles but also with other methods. Finally, in the last part of this chapter 
the newly established methods to quantify virus binding to cells are applied to study also HIV-1 
binding to cells.  
3.1.1 SNAP-tag as a tool to study virus release 
Major drawbacks of virus labelling by fluorescent proteins are the slow maturation 
kinetics, low quantum yield and fast photobleaching of those FPs. The recently described SNAP-
tag [114] on the other hand provides a much more versatile tool to label viral structures since 
much more stable chemical fluorescent probes can be linked to it. These dyes are superior to 
fluorescent proteins as to stability, quantum yield, bleaching properties and the range of 
observation wavelengths. SNAP-tag allows covalent labelling if fused to a protein of interest by 
transfer of the fluorescently labelled moiety of O6-Benzylguanine derivatives to its active site in a 
self-labelling reaction.  
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To make use of this labelling tool, I constructed a fusion of SNAP-tag to the main 
structural protein Gag in the proviral context to study virus formation and egress. The virus 
derivatives were characterized with respect to their protein composition, labelling properties and 
functional capacities. Preliminary data on the kinetics of Gag-trafficking were obtained using this 
tool.  
3.1.1.1 Construction and characterization of an HIV-1 derivative carrying the SNAP-tag 
In analogy to the previously described fluorescently labelled HIV-1 derivatives which can 
be used to study virus entry, the SNAP-tag was C-terminally fused to the viral protein MA. To 
achieve this, the snap-tag gene was amplified from the plasmid pSS26m by PCR and inserted in 
frame into the gag ORF shortly prior to the cleavage site of the HIV-1 protease between MA and 
CA (Fig. 3.1 A). A short fragment of the C-terminal end of MA was kept as a linker sequence and 
the protease cleavage site was fully retained. This results in a fully mature Gag protein that will 
be processed into its natural cleavage products CA, NC and p6. In addition, the virus will possess 
the fusion protein MA.SNAP which can be labelled by the addition of a fluorescently labelled 
SNAP-substrate (Fig. 3.1 B). To promote proper folding of the fusion protein, a short glycine rich 
linker sequence was introduced between the two protein coding sequences (Fig. 3.1 A).  
Fig. 3.1: Location of the SNAP-tag. (A) Schematic drawing of the HIV-1 gag ORF showing the snap-tag 
gene (brown) inserted between MA (blue) and CA (dark grey) coding regions. The expanded regions show 
the derived amino acid sequence at the domain borders, with HIV sequences displayed in boldface type 
and SNAP-tag sequences shown in black type on a brown background. An arrowhead indicates the PR 
cleavage site between MA and CA. (B) Schematic drawing the HIV-1 Gag protein with the approximate 
site of SNAP-tag insertion indicated by the green arrow. HIV-1 protease cleavage sites are indicated by grey 
arrows. Colour coding of protein domains according to the respective genes in (A).  
To characterize the constructed plasmid pcHIV.SNAP, 293T cells were transfected with 
the plasmid and compared to pcHIV as well as a 1:1 mixture of pcHIV and pcHIV.SNAP. The 
particles produced from this transfection were purified by sucrose pelletation (2.5.1) and analyzed 
by western blotting (2.3.1) in regard to incorporation of viral proteins and processing of Gag 
protein. The modified Gag-protein was incorporated into particles and processed by the viral 
protease to comparable levels as wild-type Gag (Fig. 3.2 A). As expected, mixed particles 
harbouring both tagged and untagged Gag-proteins were released into the supernatant after co-
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transfection of pcHIV and pcHIV.SNAP. To test if other viral proteins outside the gag ORF were 
affected by the insertion of the snap-tag gene, the particles were representatively analyzed for RT-
incorporation. To this end, equal amounts of p24 as determined by ELISA were loaded for each 
sample. No difference in the intensity of both RT bands could be observed between wild-type and 
SNAP-tagged viruses (Fig. 3.2 B) which suggests a normal composition of HIVSNAP.  
Fig. 3.2: Western Blot analysis of HIV-1 derived 
particles. HIV-1 derivatives were generated by 
transfection of 293T cells with pcHIV, pcHIV.SNAP or 
a mixture of both, particles were purified from the 
supernatant as described in 2.5.1 and subjected to 
Western Blot analysis. Membranes were probed against 
the viral proteins MA (A) or RT (B). Position of 
molecular mass standards is shown with numbers in 
kDa at the left and protein bands are labelled on the 
right.  
 
To analyze the new construct to a greater depth, the ultrastructure of HIVSNAP particles 
was investigated by electron microscopy (EM). 293T cells were transfected with pNLC4-3 or the 
SNAP-tagged variant thereof (pNLC.SNAP) and prepared for EM analysis as described in 2.4.4. 
Briefly, cells were fixed 24 h post transfection with PFA and GA, then transferred to a cacodylate 
buffer and scraped off the tissue culture dish. Pelleted cells were post-fixed with GA and Osmium 
and then stained with uranyl acetate. Cells were then embedded in an epoxy-resin, dehydrated 
and ultra-thin sections were post-stained with lead citrate. The samples were then examined with 
a Zeiss EM10 transmission electron microscope (TEM).  
Fig. 3.3: Electron microscopic images of HIV and HIVSNAP. 293T cells were transfected with pNLC4-3 
(A) or pNLC.SNAP (B), respectively. After 24 h, cells were fixed and embedded in epoxy-resin for EM 
analysis as described in 2.4.4. Samples were analyzed in a TEM and pictures of viral structures taken at 
different magnifications. Images of free virus particles are displayed for HIV and HIVSNAP. The bars 
represent 50 nm; bp = budding profile, arrowheads point at virus membranes. Sample embedding, 
processing and EM analysis performed by Anja Habermann.  
Fig. 3.3 shows representative electron micrographs of HIV (A) and HIVSNAP (B) produced 
from 293T cells. The cone-shaped core with dark dense material inside is characteristic for 
mature viral particles. The lipid bilayer surrounding the viral particles can be appreciated in both 
pictures (arrowheads). No obvious ultrastructural differences could be observed by comparison of 
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wt and HIVSNAP particles. While a comparable number of budding profiles (bp), immature and 
mature viral particles were found in both samples, the electron dense material underlaying the 
viral membrane appeared to be marginally thicker in HIVSNAP samples. To appreciate this, 
compare the thickness of the viral membrane at the arrowheads in Fig. 3.3 A and B, respectively. 
The difference seemed to be minor, though.  
Next, the new constructs were tested for their release efficiency and entry competence of 
the released viral particles. 293T cells were transfected with FuGene6 to prevent unspecific 
release of vesicles containing p24 which can occur after the transfection of cells with PEI, 
Lipofectamine or other comparable transfection reagents (B. Müller, personal communication). 
The amount of p24 released into the supernatant was quantified by quantitative Western Blot or 
Dot Blot using rabbit antisera raised against HIV-1 CA protein.  
Fig. 3.4: Release and entry efficiency of HIVSNAP. 293T cells were transfected with pcHIV, pcHIV.SNAP 
or a 1:1 mixture of both with FuGene6- (A) or PEI-method (B). (A) Amount of p24 released into the 
supernatant was quantified by quantitative Western Blot or Dot Blot and normalized to the release 
efficiency of HIV particles released from cells transfected with pcHIV. Error bars represent standard 
deviation of three independent experiments, each done in triplicate. (B) Entry efficiency of particles 
produced from 293T cells was tested on HeLaP4 cells as described in 2.5.4. Mean values of triplicates 
relative to entry efficiency of wild-type (HIV) are displayed. Error bars represent standard deviation.  
Release of viral particles from transfected 293T cells was only moderately reduced for 
HIVSNAP and could completely be restored by co-transfection of wt pcHIV in a ratio of 1:1 (Fig. 
3.4 A). In addition, the relative entry efficiency on HeLaP4 cells compared to wild-type was not 
reduced for the SNAP-tagged virus or for the mixed particles (Fig. 3.4 B). Those data further 
emphasized the assumption that the particles containing the SNAP-tag within Gag are 
comparable in their features to wild-type HIV-1.  
To further test this hypothesis, the SNAP-tagged HIV-derivative was subcloned into the 
infectious context of pNLC4-3 to test the infectivity and replication capacity of the constructed 
variants.  
3.1.1.2 Infectivity and replication capacity of HIVSNAP  
First, the infectious derivative HIVSNAP was tested for its infectivity on the reporter cell 
line TZMbl by titration of viruses produced from transfection of 293T and measurement of 
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luciferase activity of the reporter cells 48 h post infection.  
Fig. 3.5 displays the relative infectivity of HIVSNAP, which was reduced 4-fold in 
comparison to HIV wild-type. Mixed particles, produced from equimolar cotransfection of 293T 
cells with pNLC4-3 and pNLC.SNAP (HIVSNAP+HIV) regained full infectivity.  
 
Fig. 3.5 Infectivity of HIVSNAP on TZMbl cells. Infectious 
HIV-1 particles were generated by transfection of 293T cells 
with pNLC4-3, pNLC.SNAP or an equimolar mixture of 
both.  
 
 
During the course of this work, Hübner and colleagues published a GFP labelled HIV-
derivative with only moderately reduced replication capacity compared to wt [98]. In this study, 
they inserted the GFP label into the gag ORF at exactly the same position as the SNAP-tag in the 
above described pNLC.SNAP, but a second PR cleavage site was inserted N-terminally of the tag 
to allow for full Gag processing including free MA.  
Fig. 3.6: Location of the SNAP-tag in 
pNLCiSNAP. (A) Schematic drawing of the HIV-
1 gag ORF showing the snap-tag gene (brown) 
inserted between MA (blue) and CA (dark grey) 
coding regions. The expanded regions show the 
derived amino acid sequence at the domain 
borders, with HIV sequences displayed in boldface 
type and SNAP-tag sequences shown in black type 
on a brown background. Arrowheads indicate the 
PR cleavage site. The additional inserted PR 
cleavage site before the SNAP-tag sequence is 
highlighted in light blue.  
To test if the full processing of Gag has an impact on the replication capacity of the 
SNAP-tagged HIV-1 derivatives, a comparable subviral plasmid was constructed. To this end, the 
snap-tag sequence was amplified by PCR from pSS26m with primers introducing the coding 
sequence for a second PR cleavage site. The fragment was then inserted into pNLCiGFP to 
obtain pNLCiSNAP. Analogously to the HIViGFP clone described by Hübner and colleagues, 
no special flanking sequence of the inserted label was chosen (Fig. 3.6).  
To test the spread of HIVSNAP and HIViSNAP in cell culture, a replication kinetic was 
performed on MT4 cells. For this, viral particles produced from 293T cells were added to MT4 
cells at a defined concentration (0.5 ng p24 per well) and supernatants were monitored for p24 
release every other day for a period of 17 days. 
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Fig. 3.7: Replication kinetics of HIVSNAP and stability of SNAP-tag insertion over time. HIV, HIVSNAP 
and HIViSNAP were produced from transfection of 293T cells with the plasmids pNLC, pNLC.SNAP and 
pNLCiSNAP, respectively. The amount of p24 in the supernatant was determined using qWB as described 
in 2.3.2 and 0.5 ng of p24 of each virus derivative were used to infect MT4 cells. A replication kinetic was 
performed as described in 2.5.6. Briefly, supernatants were collected every two to three days and the 
amount of p24 was determined utilizing the Dot Blot procedure (2.3.3) in comparison to CA standard. (A) 
The graph displays p24 amounts in ng/ml released into the supernatant over time for HIV (grey line), 
HIVSNAP (black line) and HIViSNAP (dotted black line). Average of triplicate values and standard deviation of 
those are plotted. (B – D) show Western Blot analyses of input virus (B) and viral supernatants at day 14 of 
the replication kinetic (C + D). 293T (B) or MT4 (C + D) cell supernatants were analysed using antisera 
raised against the viral MA protein (B + C) or SNAP-tag protein (D). Approximate size of bands is shown 
with numbers in kDa at the left edge and protein bands are labelled on the right. Asterisk in (B) indicates 
background signal from αCA antibody staining which was performed in parallel. Arrowhead in (C) and 
(D) indicates cleavage product of MASNAP.  
In Fig. 3.7 A, the amount of virus released into the supernatant is plotted over time for wt 
(HIV – grey line), HIVSNAP (black line) and HIViSNAP (dotted line). Wt HIV reached a plateau of 
around 1µg/ml p24 after 5 days which only declined one log after 18 days. Both SNAP-tagged 
viruses showed a decreased spreading speed reaching the plateau of 1µg/ml p24 only after 14 
days. Before this time, there was only a minor difference in replication capacity detectable 
between the two SNAP-tag variants with HIVSNAP being slightly delayed compared to HIViSNAP. 
Comparable results could be obtained on C8166 cells (data not shown).  
To test for stability of the inserted SNAP-tag over time, Western Blot analyses of the 
input virus in comparison to supernatant from late time points of the replication kinetic were 
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performed. Fig. 3.7 B shows the Western Blot analysis of the input viruses HIV, HIVSNAP and 
HIViSNAP probed against the viral MA protein. While HIVSNAP showed a band slightly below 
37 kDa, corresponding to the fusion protein of MA and SNAP-tag (MASNAP), HIViSNAP harboured 
the fully processed MA band at 17 kDa at the same height as wild type HIV. The weak band that 
is marked with an asterisk in between the 20 and 25 kDa marker band represents a signal from an 
antibody contamination of αCA, proven by the simultaneous staining against CA (data not 
shown) and can therefore be neglected in further interpretations. After several rounds of 
replication in MT4 cells, the pattern of bands in the Western Blot remained the same for the three 
viruses tested (Fig. 3.7 C). Here, the supernatants of MT4 cells were analyzed 14 days post 
infection. The presence of a clear MASNAP band in the HIVSNAP lane confirms the stability of the 
snap-tag gene within the HIV-1 genome and the persistence of the fusion protein within viral 
particles. As expected, HIViSNAP shows one single band at the expected height for MA only. To 
confirm that this virus still harboured the cleavable SNAP-tag protein, an additional Western Blot 
analysis was performed where the membrane was probed against SNAP-tag itself (Fig. 3.7 D). 
This Western Blot confirmed the presence of free SNAP-tag protein at the expected height of 
20 kDa. It also confirmed that the MASNAP band in HIVSNAP corresponded to a fusion protein of 
MA and SNAP-tag. In addition, the band labelled with the arrowhead in Fig. 3.7 C was also 
stained with antibody against SNAP-tag, hinting at the existence of a cleavage product of MASNAP 
which still harboured the recognition epitopes of both MA and SNAP-tag antibodies.  
Taken together, these data suggested that the SNAP-tag introduced into HIV-1 had only 
minor effects on infectivity and replication in comparison to wt and was stable over prolonged 
replication within a standard T-cell line. Therefore, the constructed variants could be used to 
study intracellular Gag localization and trafficking.  
3.1.1.3 Intracellular detection and localization of SNAP-tagged Gag protein 
As the characterization of the SNAP-tag insertion into HIV-1 showed that those clones 
retained the characteristics of wild type HIV-1, they could now be used for the visualization of 
Gag proteins within cells. For this purpose, HeLa cells were transfected with pCHIV.SNAP in an 
equimolar mixture with the comparable eGFP-labelled variant pCHIV.eGFP. This strategy easily 
allowed identifying transfected cells and comparing the localization of the newly inserted tag with 
an already established viral label. At 24 h post transfection, cells were labelled with a SNAP-tag 
substrate coupled to TMR-Star (O6-Benzylguanine-TMR-Star, referred to below as TMR-Star), 
cell nuclei were counterstained with Hoechst 33258 and cells were analyzed by confocal 
microscopy. 
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Fig. 3.8: Intracellular detection and localization of SNAP-tagged Gag protein. HeLa cells were 
transfected with an equimolar mixture of pCHIV.eGFP and pCHIV.SNAP. At 24 h post transfection, cells 
were labelled with TMR-Star for 15 min according to the manufactor’s protocol and cell nuclei were 
stained with Hoechst 33258. Intracellular fluorescence was analyzed by confocal microscopy in a Leica 
SP2 setup with 60x oil immersion objective. (A) Microscopic images of a median section through a 
representative cell in the green GFP channel (i), red TMR-Star channel (ii) and a merged picture 
additionally showing the DAPI channel in blue (iii). (B) The histogram shows the intensities of GFP 
(green), TMR-Star (red) and DAPI (blue) fluorescence along the purple line in (A-iii). a.u. = arbitrary units.  
Fig. 3.8 A shows a representative cell which was co-transfected with both non-infectious 
HIV derivatives, a GFP-labelled and a SNAP-tagged variant, respectively. Fig. 3.8 A-i displays 
the GFP channel in green with a characteristic punctuated pattern of Gag.eGFP all over the cell. 
A weak staining of the cytosol is also visible in this picture. Visualization of the SNAP-tag by 
labelling with TMR-Star reveals a comparable localization of Gag.SNAP with a similar dotted 
appearance (Fig. 3.8 A-ii). The diffuse staining in the cytosol is less visible here, though. The 
overlay of both channels (Fig. 3.8 A-iii) shows a high degree of overlap of the two Gag labels. 
This colocalization is confirmed by the line scan shown as a histogram in Fig. 3.8 B. Here, the 
fluorescence intensity of all three channels is plotted along a line of 20 µm drawn through the cell 
body as indicated in Fig. 3.8 A-iii (purple line). Fluorescence intensities of Gag.eGFP (green line) 
and Gag.SNAP (red line) peak at the same location, indicating a colocalization of both markers. 
The blue line indicates the fluorescence intensity in the DAPI channel which is at background 
levels at the chosen intersection through the cell body far away from the nucleus. Controls for 
background staining were always analyzed in parallel. The non-transfected cell in the upper right 
corner of Fig. 3.8 A (single blue nucleus in Fig. 3.8 A-iii) showed no signal in the red channel. 
Unspecific binding of TMR-Star to cellular or viral proteins could therefore be ruled out as 
confirmed in TMR-star treated control cells only transfected with pCHIV.eGFP which did not 
show a signal in the red channel (data not shown).  
3.1.1.4 Labelling of cells infected with HIVSNAP  
To test if the SNAP-tag could also be stained after infection rather than transfection, 
C8166 cells were infected with the replication competent variant HIVSNAP produced from 
transfection of 293T cells with pNLC.SNAP and passaged over several weeks. 23 days post 
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infection, cells were stained with TMR-Star as described in 2.4.3, fixed with 3 % PFA for 90 min, 
adhered to coverslips and counterstained with antisera raised against p24 (see 2.4.7) and a 
secondary antibody coupled to Alexa 488 analyzed by confocal microscopy.  
Fig. 3.9: Intracellular detection and localization of SNAP-tagged Gag protein in infected C8166 cells. 
HIV or HIVSNAP were produced by transfection of 293T cells with pNLC4-3 and pNLC.SNAP, 
respectively. C8166 cells were infected with 100 ng of the respective virus and passaged for several weeks. 
23 days post infection, cells were stained with TMR-Star and immunofluorescence against HIV-1 p24 was 
performed as described in 2.5.7 and 2.4.7, respectively. Cells were counterstained with Hoechst 33258 and 
imaged by confocal microscopy in a Leica SP2 setup. (A) Pictures of middle sections of representative cells 
are shown for p24 immunofluorescence in the green channel (i, iv), TMR-star signal in the red channel (ii, 
v) and overlay of Alexa 488, TMR-star and DAPI signals (blue) in iii and vi. The upper row shows cells 
infected with HIVSNAP whereas the lower row shows a cell infected with HIV. The white asterisk indicates a 
non-infected cell. (B) The histogram shows the intensities of αp24 staining (Alexa 488, green), TMR-Star 
(red) and DAPI (blue) fluorescence along the purple line in (A iii). a.u. = arbitrary units. 
A clear correlation between p24 staining and SNAP-labelling with TMR-Star could be 
observed in this experiment. Only cells infected with HIVSNAP (Fig. 3.9 A i-iii) showed a signal in 
the TMR-Star channel, whereas cells infected with wt HIV (Fig. 3.9 A iv-vi) only stained positive 
for p24. An internal control for background staining was again present in the sample of HIVSNAP 
infected C8166 cells: cells that had not been infected (e.g. the cell marked with a white asterisk in 
Fig. 3.9 A) did not show any signal in the TMR-Star channel (Fig. 3.9 A-ii) whereas a very slight 
background signal could be detected with Alexa 488 (Fig. 3.9 A-i). The overall distribution of the 
SNAP-tag signal varied slightly from the more diffuse immunofluorescence staining of p24. 
Whereas the antibody staining led to a diffuse signal which was also present all over the cell, 
TMR-star stained the SNAP-tag predominantly at the plasma membrane and in close vicinity to 
it. The SNAP-tag staining was also much more punctuated than the p24 staining. This differing 
pattern can be appreciated in Fig. 3.9 B where a histogram of fluorescence intensities along the 
purple line drawn in Fig. 3.9 A iii is depicted. The TMR-Star signal of the SNAP-tag showed 
more single peaks at positions where the green signal from the immunofluorescence of p24 was 
more diffuse, although the overall trend of the distribution of peaks was comparable in both 
stainings.  
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Taken together, those results showed that the inserted SNAP-tag within full length 
infectious HIV-1 can specifically be stained by adequate fluorescently labelled substrates. This 
provides a versatile tool to study Gag trafficking within transfected and infected cells.  
3.1.1.5 Pulse chase experiments with Gag.SNAP 
A major advantage of SNAP-tag over conventional protein labelling techniques is the 
variety of substrate colours in combination with the possibility to perform the labelling reaction in 
living cells. This provides the opportunity to perform pulse chase experiments in which the 
existing protein fraction can be labelled in one colour and the newly synthesized protein can be 
labelled in another colour after a certain chase period. This allows the direct comparison of the 
localization of the same protein produced at different time points within one cell.  
To test this method and establish a suitable labelling protocol, HeLa cells were transfected 
with an equimolar mixture of pCHIV.eGFP and the SNAP-tagged variant pCHIV.SNAP. The 
GFP-tagged derivative was used in this setup to provide the reference point of Gag distribution 
within the cell over the whole course of the experiment. For those initial experiments, only one 
staining colour of SNAP-tag was chosen, TMR-Star as before. To only stain the portion of 
Gag.SNAP which was newly produced during the chase period, an approach was chosen where a 
non-labelled substrate (bromothenylpteridine, BTP, Covalys) was used in the beginning of the 
experiment to block all available SNAP-tag binding sites. BTP is a derivative of the SNAP-tag 
substrate O6-Benzylguanine that contains a non-fluorescent moiety which will covalently be 
transferred to the active centre of SNAP-tag to block further self-labelling reactions. With this 
strategy, different time points (chase periods) can be chosen after which the newly synthesized 
SNAP-tag fusion proteins can be labelled with TMR-Star.  
A representative proof of principle pulse chase experiment is depicted in Fig. 3.10. The 
figure shows single slice confocal microscopic images of HeLa cells expressing HIVeGFP and 
HIVSNAP which were stained with TMR-Star at the indicated time points after blocking with BTP. 
The first row (0 min) demonstrates that BTP blocked the SNAP-tag very efficiently as there was 
no detectable signal over background detectable in the red Gag.SNAP channel whereas the green 
eGFP signal was clearly visible and indicated that this particular cell had been transfected. In 
contrast to this, staining of cells after the shortest chase period tested in this experiment (30 min) 
yielded a detectable signal in the TMR-Star channel, which differed in intensity between 
individual cells. The overall signal intensity in the TMR-Star channel increased further at 60 min 
post blocking and reached an even higher level at the 2 h time point (120 min). Comparable 
results could be confirmed in several independent experiments (data not shown).  
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Fig. 3.10: Pulse chase labelling of Gag.SNAP. Pulse chase labelling of Gag.SNAP. HeLa cells were 
transfected with an equimolar mixture of pCHIV.eGFP and pCHIV.SNAP. At 24 h post transfection, cells 
were treated with BTP for 5 min at 37°C, washed 3 times with DMEM and incubated in DMEM at 37°C 
for the indicated chase periods of 0, 30, 60 or 120 min, respectively. Then, cells were stained with TMR-
Star and fixed directly after the staining procedure. Embedded coverslips were imaged in a confocal Leica 
SP2 setting. Single confocal slices of representative cells are shown in the green (Gag.eGFP) and red 
(TMR-Star) channel and a merged picture of both. 
No obvious difference in the distribution of both Gag-labels within the cell could be 
observed at any of the time points tested. Therefore, newly produced Gag protein did not seem to 
be transported to a single specific site but appeared to be quickly distributed relatively equal over 
the whole cell body. To narrow down the time that is needed to produce new SNAP-tagged Gag 
protein that can be labelled after the chase period, shorter time points were tested. Even the 5 min 
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chase yielded detectable TMR-Star signals (data not shown) which hints to a fast folding kinetic 
of the Gag.SNAP fusion protein.  
3.1.1.6 Labelling of HIVSNAP particles 
Another application of the SNAP-tag introduced within the Gag protein consists of the 
use of the labelled particles in live cell experiments comparable to published studies where virus 
entry was investigated in real time using XFP labelled derivatives (e.g. [117, 127]). To this end, 
the possibilities to label HIVSNAP particles in vitro was tested. Non-infectious HIVSNAP particles 
were produced from transfected 293T co-transfected with pCHIV or an equimolar mixture of 
pCHIV and pCHIV.SNAP in combination with a construct coding for a fusion protein of Vpr 
and GFP, namely pVpr.eGFP [147]. The green fluorescent viral label Vpr.eGPF was introduced 
as a reference. Vpr.eGFP has been shown to be incorporated into HIV-1 particles in a 
quantitative manner [147] and shows very low background in non-viral particles. It therefore 
represents a good control to measure the labelling efficiency of SNAP-tagged particles by the 
membrane permeable SNAP-tag substrate TMR-Star. After purification through a sucrose 
cushion as described in 2.5.1, the particles were stained as described in 2.5.7. Briefly, 300 ng of 
particles were incubated with 2µM TMR-Star in the presence of 5 mM DTT at 4°C o/n and re-
purified over a sucrose cushion. As a control, Vpr.eGFP labelled HIV particles not harbouring 
the SNAP-tag were treated in parallel to control for unspecific TMR-Star binding. In addition, 
HIVSNAP particles were incubated with a solvent control to rule out possible bleed through from 
the GFP channel.  
The labelled and purified particles were attached to fibronectin-coated coverslips and 
imaged in a wide-field fluorescence microscope. Particles were detected in the GFP channel and 
10 z-stacks of 21 pictures each were taken at random positions of the coverslip in the green (GFP) 
and red (TMR-Star) channel. The results of this experiment are depicted in Fig. 3.11. Qualitative 
inspection of the images reveals that after labelling with TMR-Star, HIVSNAP particle preparations 
showed strong punctuated particle signals in the red channel which colocalized to a great extent 
with the viral marker Vpr.eGFP in green (Fig. 3.11 A). In contrast to that, no signals in the TMR-
Star channel were detected in control preparations (no SNAP-tag (HIV) or solvent control, 
respectively). For quantitative analysis, fluorescence micrographs were analyzed with the help of 
a semi automated ImageJ plug-in as described in 2.6.1. Briefly, maximum projections of both 
channels were filtered and individual signal spots were identified and counted. A new image 
depicting all picked spots was created for each channel which could then be used for 
colocalization analysis. For this, an overlay of both results images was created harbouring 
different numerical values for a spot found in either of the original channel images or in both 
which allowed to count the number of double labelled spots as well.  
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Fig. 3.11: Labelling of HIVSNAP particles. Labelling of HIVSNAP particles. HIV and HIVSNAP particles 
incorporating Vpr.eGFP were produced from transfected 293T cells with pVpr.eGFP and pCHIV or an 
equimolar mixture of pCHIV and pCHIV.SNAP, respectively, and purified over a sucrose cushion. 
Particles were then labelled with TMR-Star (+ BG-TMR-Star) or treated with a solvent control and re-
purified as described in 2.5.7. Particles were seeded on coverslips and imaged in a wide-field fluorescence 
microscope with a 100x oil-immersion objective. Z-stacks of 21 pictures each were taken at 10 random 
positions for each condition. (A) Maximum projections of representative fluorescence microscopic images 
are shown in the red and green channel as well as an overlay of both. Green and red arrows point to single 
labelled particles in the respective channel. (B) Double labelling efficiency was assessed with the help of a 
semi-automated ImageJ plug-in as described in 2.6.1. The graph shows the percentages of particles which 
were double labelled (yellow) or showed a signal in one of the channels exclusively (red and green, 
respectively). Average of 10 view fields for HIVSNAP and HIV incubated in presence of substrate (+ BG-
TMR-Star) or a solvent control are shown.  
The percentage of double labelled particles (double) as well as particles only showing a 
signal in one of the two channels (red only and green only, respectively) are depicted in Fig. 
3.11 B for all three samples. For HIVSNAP, over 60 % of all spots were classified as double labelled. 
Only a minor fraction of signals (2.6 %) were found to be red only, indicating unspecific staining 
of non-viral structures within the sample. The remaining proportion of signals (36 %) was only 
detected in the green channel, indicating Vpr.eGFP labelled viral particles which were not 
successfully stained with TMR-Star. Only very low background staining was observed in the 
TMR-Star channel for particles not carrying the SNAP-tag (HIV, 2 %). A similar low number of 
double labelled particles (2.6 %) was observed in the solvent control sample of HIVSNAP. Those 
particles most likely represent background fluorescence which can be assumed to be present in all 
other samples. The very low background in both controls indicated a very specific staining, which 
is in agreement with results from the previously described experiments in cells. Therefore, the 
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proposed strategy to use SNAP-tagged HIV derivatives in live cell imaging experiments could be 
accomplished with the above characterized newly established HIVSNAP particles.  
In conclusion, the insertion of the SNAP-tag into the ORF of HIV-1 Gag was well-
tolerated by the virus. Particle release, morphology and entry into cells are not affected by the 
inserted tag. Infectivity was reduced, but could be restored in particles consisting of a 1:1 mixture 
of wt and tagged Gag proteins. Replication capacity was reduced but still detectable and the 
inserted tag proved to be stable over several replication cycles. The labelling of MA.SNAP was 
easily applicable for cells transfected with the constructs as well as viruses incorporating the 
tagged protein. Thus, the new labelling strategy for the HIV-1 MA protein presented here proves 
to be a versatile tool to study different aspects of the viral live cycle by microscopic techniques.  
 
3.1.2 Fluorescently labelled HCV pseudoparticles to dissect the steps of virus entry 
Although good progress towards an understanding of the early steps of the HCV 
replication cycle has been made since the establishment of tissue culture systems to study this 
virus, they are not yet understood completely. The use of fluorescently labelled HCV 
pseudoparticles (HCVpp) could help to dissect those early steps. Pseudoparticles are viral 
particles of a certain origin, in this case HIV-derived, which incorporate the envelope protein of a 
different virus, in this case HCV E1 and E2. This changes the tropism and mode of entry of the 
HCVpp accordingly [12]. HCVpp have previously been used by others to study the early steps of 
the HCV replication cycle [61, 148, 187] and results obtained with this system have been 
confirmed with the help of the infectious HCV cell culture system (HCVcc) [234].  
In this study, fluorescent labelling of virus particles was achieved based on the previously 
established labelling of the MA protein of HIV [162]. I used unmodified HCV envelope 
glycoproteins incorporated into envelope protein deficient HIV derivatives carrying a MA.XFP 
fusion protein. This approach provides the unique opportunity to visualize the dynamic events of 
individual viral particles interacting with host cells and allows resolving distinct steps of the entry 
process. In particular, I dissected the first steps of entry, particle binding (chapter 3.1.2.2), 
endocytosis (chapter 0) and fusion (chapter 3.1.2.4), depending on CD81 expression and the 
presence of different stimulating or inhibiting factors.  
3.1.2.1 Establishment of the system 
In order to produce HCVpp which mimic HCV entry into host cells, the particles had to 
be devoid of HIV-1 Env proteins. For this purpose, subviral plasmids with a insertional frame-
shift mutation in the beginning of the env gene were used. Cells transfected with pcHIV.Env(-) 
express all viral proteins except Nef and Env, since the plasmid harbours a deletion in the 3’ end 
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of nef and a translational frame-shift mutation in the 5’ of env. The plasmid does not contain LTR 
sequences and hence particles produced by transfection with this plasmid are non-infectious. The 
fluorescently labelled counterpart was constructed as described for the mCherry-tagged version in 
2.2.4.1.  
Fig. 3.12: Construction and characterization of a mCherry-tagged fluorescent HIV-1 derivative. (A) 
Schematic drawing of the 
HIV-1 gag ORF showing 
the mcherry gene (red) 
inserted between MA (blue) 
and CA (dark grey) coding 
regions. The expanded 
regions show the derived 
amino acid sequence at the 
domain borders, with HIV 
sequences displayed in 
boldface type and mCherry 
sequences shown in black 
type on a red background. An arrowhead indicates the PR cleavage site between MA and CA. (B) Western 
Blot analysis of HIV-1 derived particles. HIV-1 derivatives were generated by transfection of 293T cells 
with an equimolar mixture of pcHIV and pcHIV.mCherry, particles were purified from the supernatant and 
subjected to Western Blot analysis. The membrane was probed against the viral protein MA. Position of 
molecular mass standards is shown with numbers in kDa at the left and protein bands are labelled on the 
right. Asterisk indicates an unknown cleavage product of MAmCherry.  
The position of the mCherry label was chosen in exact analogy to the published 
pcHIV.eGFP derivative (Fig. 3.12 A; compare [162]). The modified Gag precursor was 
incorporated into particles produced from cotransfected 293T cells and showed protease 
processing comparable to wt Gag as shown by WB analysis. As represented in Fig. 3.12 B, an 
additional unidentified cleavage product of MA.mCherry could be detected (asterisk). 
Nevertheless, HIVmCherry particles were shown to be fusion competent and have successfully been 
used in a live-cell imaging study [117].  
To incorporate the HCV genotype 1b (Con1) envelope proteins E1 and E2 into the viral 
lipid membrane, virus producing 293T cells were cotransfected with an additional expression 
plasmid, pcDNA3∆CE1E2. WB analysis of particles purified from the supernatant by 
ultracentrifugation showed incorporation of the foreign Env protein, whereas no Env signal was 
detected in the control lacking an additional Env expression plasmid (Fig. 3.13 A). When 
incubated with target cells, for example the Huh-7 derived hepatocytic Lunet/CD81 cell line, the 
fluorescently labelled HCVpp (red dots) could readily be detected with a standard epifluorescence 
microscope (Fig. 3.13 B).  
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Fig. 3.13: Characterization of fluorescently labelled HCVpp. (A) Western blot analysis of virus particles 
purified by ultracentrifugation from 293T cells transfected with plasmids encoding for HIV.Env(-) and for 
the E1E2 of HCV (HCVpp) or the pCHIV.Env(-) alone (Env(-)). Membranes were probed against MA (left 
panel) and HCV E2 protein (right panel). Positions of molecular mass standards are shown with numbers 
in kDa at the left and protein bands are labelled on the right. (B) Overlay of bright field image and 
fluoerscence image of fluorescently labelled HCVpp (red) bound to Lunet/CD81 cells.  
3.1.2.2 HCVpp binding to cells 
Equipped with this useful tool, HCVpp binding to cells could be visualized and studied by 
microscopy. A virus binding assay based on fluorescently labelled HCVpp was established as 
illustrated in Fig. 3.14 and described in 2.5.2. Briefly, cells were seeded in 8-well chambered 
cover slides. After 24 h, cells were briefly pre-chilled on ice and fluorescently labelled virus was 
added and allowed to bind for 1 h on ice. This incubation in the cold was used to prevent particle 
endocytosis and other unspecific uptake into the cells. Subsequently, unbound virus was washed 
off with PBS and cells were fixed with cold PFA. Cell-bound virus particles were then imaged by 
wide-field fluorescence microscopy. In order to capture all virions bound, image stacks in z-
direction were recorded covering the entire cell body.  
Fig. 3.14: Schematic illustration of the workflow of the virus binding assay. Details see text.  
Image analysis was performed in a semi-automated system with the help of an ImageJ 
plug-in (based on a plug-in written by John Briggs). The workflow of this plug-in is depicted in 
Fig. 3.15. Maximum projections of fluorescence micrographs (Fig. 3.15 A) were transformed 
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with a bandpass filter to level out the background signal and to allow for single fluorescence spots 
of particles to be recognized more easily (Fig. 3.15 B). Then, an empirically set threshold was 
established to cut off the majority of background signals and to keep the signal intensity of 
individual viral particles (Fig. 3.15 C). Subsequently, an already implemented algorithm of 
ImageJ (“Analyze Particles…”) was used to identify spots of a certain size and circularity. The 
location of each spot in x and y was recorded and output in a table. These coordinates were used 
to create a new combined image depicting the picked spots as crosses on top of the maximum 
projection image of the particle imaging channel, and either a brightfield image of the cell bodies 
or an image of a channel that depicted the autofluorescence signal of the cells in blue (Fig. 
3.15 D). Either way, this overlaid picture was used to control for correct particle recognition and 
to manually count the approximate number of cells per image.  
Fig. 3.15: Workflow of the “particle picker” ImageJ plug-in. Image output of the different steps within 
the “particle picker” plug-in are shown of an exemplary cell. (A) Maximum projection of a z-stack of 
fluorescence signals detected in the respective channel detecting individual fluorescently labelled viral 
particles. (B) Image after the bandpass filter to level out the background noise including autofluorescence. 
(C) Image after execution of an intensity threshold. Signals above threshold are depicted in black, whereas 
areas with signals below the threshold remain white. (D) To control for accuracy of the plug-in, an output 
file is created overlaying an image of the autofluorescence (blue) with the original maximum projection 
from (A) (green). The picked spots are displayed as red crosses. The inset in the lower left corner magnifies 
the boxed area from the top of the image to allow easier observation of the colocalization of green signals 
and red crosses.  
As a proof of principle to test this new assay, I made use of the known fact that the 
addition of heparin decreases HCV binding to cells [122]. To this end, Lunet/CD81 cells were 
subjected to the virus binding assay in the presence of different concentrations of heparin. In 
addition, Heparinase I was used to enzymatically remove all heparin moieties from the cellular 
HSPGs, which should also abolish HCV binding to cells. For this purpose, Lunet/CD81 cells 
were incubated with 10 U of Heparinase I from Flavobacterium heparinum at 37°C for 30 min, 
washed with PBS and then subjected to the virus binding assay. Fig. 3.16 shows the 
representative results of two independent experiments. As expected, increasing amounts of 
heparin led to a decreased number of HCVpp bound to cells. The pre-treatment of cells with 
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Heparinase I also reduced particle binding to cells. Notably, Env(-) particles without any Env 
protein incorporated into their limiting membrane bound to the cells at comparable levels to 
HCVpp. This unspecific attachment of Env(-) viral particles could also be blocked by the addition 
of high amounts of heparin.  
Fig. 3.16: Interference of heparin and 
Heparinase-treatment of cells with HCVpp 
binding to cells. Lunet/CD81 cells were 
incubated with HCVpp (black squares) or 
Env(-) particles (grey circles) in the presence 
of the indicated amount of heparin. Cells 
were subjected to the virus binding assay and 
particle binding per cell in the absence of 
heparin was normalized to 100 %. Mean 
values of 30 view fields and standard 
deviations are depicted as representative 
results from two independent experiments. In 
addition, one set of cells was pre-incubated 
with 10 U Heparinase I for 30 min at 37°C 
and HCVpp added only after this treatment 
(Heparinase 10 U). Images of mock treated 
cells served as a control (no virus).  
After the successful proof of principle of this assay, the dependence of HCVpp binding to 
cells on the presence of HDL was tested, since a positive effect of those lipoprotein particles on 
HCVpp entry had been shown previously [56]. To this end, cells were subjected to the virus 
binding assay in the presence (HDL) or absence (no HDL) of 6 µg/ml HDL. Env(-) particles were 
always used as a control to monitor the contribution of unspecific attachment. As shown in Fig. 
3.17, no clear correlation of particle binding to the presence of HDL, or the presence of the HCV 
Env proteins E1E2 could be observed on Lunet cells. The variability of particle binding on the 
single cell level was very high and is reflected by large and overlapping error bars.  
Fig. 3.17: Dependence of HCVpp binding on the 
presence of HDL. Lunet/CD81 cells were subjected 
to the virus binding assay with 100 ng fluorescently 
labelled HCVpp or Env(-) control particles in the 
presence (black) or absence (grey) of 6 µg/ml HDL. 
Mean number of particles bound per cell from 30 
viewfields (corresponding to about 60 cells and a 
minimum of 500 particles per condition) and 
standard deviation is shown.  
 
In conclusion, the high number of unspecifically bound Env(-) particles was found to be a 
problem for this single cell based method and hampered a detailed study of specific HCVpp 
binding to target cells. The newly established microscopic virus binding assay could nevertheless 
be shown to reflect known binding properties of HCV particles in dependence on HSPGs. Hence, 
this assay represents as a valuable tool to study binding of viruses to cells in a different setting 
(compare 3.1.3).  
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3.1.2.3 HCVpp uptake 
The next step in HCV entry after the attachment to cells and receptor binding is the 
endocytic uptake of particles. In order to study this step in the viral replication cycle, an analogue 
assay to the virus binding assay described previously was established. After prebinding of virus 
particles and washing off excessive virus the cells were warmed up to 37°C and cellular uptake of 
particles was allowed for 1 h. In order to be able to monitor the efficiency of cellular endocytic 
uptake, cells were simultaneously incubated with transferrin coupled to Alexa 488 and mCherry 
labelled HCVpp. Transferrin has been shown to be taken up into cells by clathrin-mediated 
endocytosis, representing a reliable marker for endocytic uptake. As shown in Fig. 3.18, particles 
and transferrin only bound to the cell surface when cells were imaged after incubation with virus 
at 4°C, a temperature that precludes bulk endocytic uptake. When cells were warmed to 37°C, 
massive particle uptake could be observed. Also, endocytosed tranferrin could be observed in the 
green channel, whereas no obvious overall co-localization was detectable.  
Fig. 3.18: HCVpp binding to the cell surface and endocytosis. Lunet/CD81 cells were incubated with 
mCherry labelled HCVmCherrypp in the presence of transferrin-Alexa 488. Incubation was either conducted 
at 4°C for 30 min to monitor binding (A) or a subsequent warming of cells and incubation at 37°C was 
included to allow endocytosis (B). Cells were then fixed and z-stacks recorded with a confocal microscope. 
Representative fluorescence images of the red channel (HCVmCherrypp – HCV, upper panel) and an overlay 
with the Transferrin (Tf) signals in the green channel (HCV + Tf, lower panel) are shown.  
In line with the virus binding assay, no dependence of particle uptake on the presence of 
HCV Env could be observed on Lunet cells. Furthermore, the presence or absence of CD81 on 
the cell surface or blocking CD81 interaction with a neutralizing antibody did not influence the 
efficiency of HCVpp uptake (data not shown).  
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3.1.2.4 HCVpp fusion 
Although many systems have been used to study the early steps of HCV entry, no system 
has yet been established to exclusively investigate the step of virus-cell fusion. To this end, I made 
use of a virion fusion assay that is well-established for HIV, the β-Lactamase assay (BlaM assay) 
[35]. The activity of the enzyme β-Lactamase which is incorporated into virus particles and 
released upon fusion into the cytoplasm of the target cell can be measured by a shift in emission 
wavelength of a florescent substrate. In order to use this assay for HCVpp, I adapted and 
optimized several steps, as the simple inclusion of Vpr.BlaM into HCVpp and the use of standard 
assay conditions did not yield reliable results (Barbara Müller, personal communication).  
In a first step the amount of incorporated BlaM fusion protein was varied in HIV-derived 
particles pseudotyped with the glycoprotein of Vesicular Stomatitis Virus (VSV), below referred 
to as VSVpp. These pseudoparticles were chosen due to their very high entry efficiency so that 
virus input amounts could be kept minimal. Titration of these viral particles on HeLaP4 cells 
showed increasing BlaM activities with increasing amounts of cotransfected Vpr.BlaM expressing 
plasmid (pMM310), as seen in Fig. 3.19 A. In parallel, the particles were monitored for Gag 
processing in WB analysis with antibodies raised against the HIV-1 MA protein. Here, a strong 
increase in unprocessed Gag precursor protein could be detected with increasing amount of 
pMM310, which reached a plateau at 12.5 µg of cotransfected pMM310 (Fig. 3.19 B). Due to 
this, 10 µg pMM310 input per 10 cm dish of 293T cells during virus production was chosen as a 
compromise between increased entry efficiency (Fig. 3.19 A) and decreased Gag processing (Fig. 
3.19 B). The signal of HCVpp entry could further be enhanced by prolonged incubation times 
(Fig. 3.19 C) as well as by the addition of 6 µg/ml HDL during virus incubation (Fig. 3.19 D). 
Increasing amounts of HCV Env-expressing plasmid on the other hand did not improve the entry 
efficiency (Fig. 3.19 E). In contrast, a threefold increase of E1E2-expressing plasmid even led to a 
decrease in entry efficiency.  
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Fig. 3.19: Optimization of the β-Lactamase virion fusion assay for HCVpp. (A and B) Effect of amount 
of BlaM on entry efficiency. (A) VSVpp incorporating different amounts of Vpr.BlaM fusion protein were 
produced by cotransfection of the indicated amounts of pMM310 (BlaM plasmid). Purified viruses were 
titrated on Lunet/CD81 cells, the BlaM assay was performed as described and relative BlaM activity 
measured in a plate fluorimeter. (B) Viral particles from (A) were subjected to WB analysis with an 
antibody against HIV-1 MA protein to control for processing of Gag protein. Position of molecular mass 
standards is shown with numbers in kDa at the left and protein bands are labelled on the right. (C) Effect of 
incubation time on entry efficiency. Vpr.BlaM-containing HCVpp and VSVpp were produced as described 
and incubated with Lunet/CD81 cells for different time periods before addition of BlaM substrate and 
proceeding with the BlaM assay. Virus input: 100 ng p24 HCVpp, 1 ng p24 VSVpp. (D) Effect of HDL on 
particle entry. BlaM-containing HCVpp (black) and Env(-) control particles (grey) were titrated on 
Lunet/CD81 cells in the presence (solid lines) or absence (dotted lines) of 6 µg/ml HDL and BlaM assay 
was performed. Mean values of triplicate measurements and standard deviations are depicted. (E) Effect of 
E1E2 amount on entry efficiency. HCVpp incorporating different amounts of E1E2 were produced by 
cotransfection of the indicated amounts of pcDNA3∆CE1E2 (E1E2 plasmid), titrated on Lunet/CD81 cells 
and BlaM assay was performed.  
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To test the specificity of the modified BlaM assay, the entry efficiency of HCVpp on cells 
expressing high (Lunet/CD81) or very low (Lunet/V) amounts of CD81 [121] was compared. 
The importance of CD81 for HCV entry has been proven in different systems and therefore offers 
a good possibility to test the validity of the HCVpp-adapted BlaM assay. VSVpp, which can enter 
both cell lines equally well, served as a control.  
Fig. 3.20: Dependence of HCVpp entry on the presence of 
CD81. Entry efficiency of HCVpp (black) and VSVpp (grey) 
was tested with the BlaM assay on two different cell lines, 
Lunet/CD81 and Lunet/V, respectively. To obtain similar 
raw values of BlaM activity, different virus inputs had to be 
used (50 ng p24 equivalent for HCVpp and 0.25 ng p24 
equivalent for VSVpp). Normalized entry efficiency in 
comparison to VSVpp of triplicate measurements with 
standard deviation is depicted.  
 
Fig. 3.20 shows the entry efficiency of HCVpp in comparison to VSVpp. Note that due to 
much lower entry efficiencies of HCVpp, different concentrations of virus input were used to 
yield comparable BlaM acitivity (50 ng p24 HCVpp vs. 0.25 ng p24 VSVpp). Whereas HCVpp 
entered readily into CD81-expressing Lunet/CD81 cells, no BlaM activity could be detected after 
incubation with Lunet/V cells. In contrast to that, VSVpp entry was similar in both cell types. 
With this, the specificity of the BlaM assay adapted to HCVpp had been proven and several 
factors which had been shown to influence the early steps of replication of HCV could be tested 
regarding their influence on HCVpp fusion. To this end, the BlaM assay was performed in the 
presence of different agents that could potentially play a role in HCVpp fusion: HDL, oxidized 
high density lipoprotein (oxLDL), produced as described in 2.3.5, two different inhibitors of early 
endosome acidification, Concanamycin A (ConA) and Bafilomycin A (BafA), antibodies raised 
against CD81 (αCD81) and CD4 (αCD4) and two concentrations of Heparin.  
Fig. 3.21: Dependence of HCVpp and 
VSVpp fusion on different agents. Entry 
efficiency of HCVpp (black) and VSVpp 
(grey) was tested on Lunet/CD81 cells 
with the BlaM assay. Viruses were added 
in the presence of 6 µg/ml HDL, 
100 µg/ml oxLDL, 5 nM 
Concanamycin A (ConA), 25 nM 
Bafilomycin A (BafA), 1.5 µg/ml 
antibody raised against CD81 (αCD81) or 
CD4 (αCD4), 50 or 625 µg/ml Heparin or 
a combination of 625 µg/ml Heparin and 
CD81 antibody (Heparin high + αCD81). 
Entry efficiencies were normalized to the 
values in the absence of drug. Mean 
values of triplicate measurements and 
standard deviations are shown.  
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As a control, VSVpp were subjected to the same treatment. In the case of the endosome 
acidification inhibitors, cells were preincubated for 45 min at 37°C and the drugs were also 
present during the overnight incubation with BlaM substrate, while the other compounds were 
only present during the incubation with virus at 37°C.  
The relative entry efficiencies of both pseudoparticle types is shown in Fig. 3.21. Whereas 
HDL increased the entry efficiency of HCVpp, it did not have any effect on VSVpp. OxLDL had 
a negative effect on both types of pseudoparticles, although HCVpp were affected to a higher 
degree. Both inhibitors of endosome acidification strongly inhibited or completely blocked 
VSVpp and HCVpp entry. While both antibodies used did not reduce VSVpp entry, HCVpp entry 
efficiency was reduced more than threefold in the presence of αCD81, and HCVpp entry levels 
stayed stable in the presence of αCD4 antibodies. Treatment of cells with heparin blocked entry 
of HCVpp in a concentration dependent manner, while VSVpp was only reduced to about 50 % 
at both concentrations tested. The combination of the high heparin concentration with αCD81 
antibody could block HCVpp entry completely, whereas VSVpp entry levels were comparable to 
the heparin-only treated samples.  
In summary, the BlaM virion fusion assay was successfully adapted to HCVpp via several 
optimization steps. It provides a useful tool to study the early steps of HCV entry with fusion as 
an endpoint. The influence of several factors on those steps could be shown, confirming previous 
findings with systems looking at later time points in the replication cycle. In addition to the 
establishment of the virion fusion assay for HCV, microscopy-based assays were developed to 
investigate the steps preceding virus fusion with the target cell, namely virus uptake and cell 
binding as a first step. The validity of the binding assay was confirmed by showing the possibility 
to compete with cell binding of HCVpp by the addition of Heparin. Particle binding and 
endocytosis was nevertheless shown to be independent of the HCV Env proteins as well as the 
presence of CD81 on the cell surface. Both factors were in turn confirmed to be crucial for 
HCVpp cytosolic entry.  
3.1.3 Fluorescently labelled HIV-1 derivatives  
The microscopy-based virus binding assay established for HCVpp was also used to study 
cell binding of HIV-1. Binding efficiency to different cell lines as well as the dependence of virus 
binding on the newly identified virus restriction factor CD317/Tetherin was investigated.  
3.1.3.1 Binding to different cell lines 
Unspecific attachment of viral particles to heparan sulfate proteoglycans (HSPGs) on the 
cell surface can occur independent of the Env protein, as shown for HCVpp in comparison to 
Env(-) particles (see Fig. 3.16). In order to study the specific binding of HIV-1 particles to target 
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cells and eliminate background noise due to unspecific attachment, I sought to find the optimal 
conditions for HIV-1 cell binding. For this purpose, two different T-cell lines were compared in 
respect to efficiency of virus binding. SupT1 cells have been shown to possess a very low surface 
level of HSPGs (M. Lampe, personal communication).  
Fig. 3.22: HIV-1 binding to cells. HIVmCherry (black) and Env(-)mCherry (grey) were subjected to the virus 
binding assay and mean numbers of particles bound per cell determined. Standard deviations from app. 
300 cells per condition are depicted. (A) Particle binding to SupT1-R5 cells with two depicted virus input 
concentrations of p24 equivalent, in comparison to C8166 cells. (B) Time course of particle binding to 
SupT1-R5 cells (200 ng p24 input). A control of mock treated cells (no virus, light grey) is included.  
200 ng of fluorescently labelled HIV or Env(-) particles were incubated with 1x106 cells 
for 30 min on ice and subjected to the virus binding assay. As depicted in Fig. 3.22 A, HIV-1 
binding was shown to be dependent on the presence of Env on both cell lines. Those differences 
were statistically significant as determined by student’s T test (p<0.0001). The amount of bound 
particles was furthermore found to be dependent on the cell line, since on average 3.5 times more 
particles bound to C8166 than SupT1-R5 cells. This difference could be overcome by increasing 
the particle input (Fig. 3.22 A, 1.3µg p24), hinting at a concentration dependent mechanism. The 
time-dependence of Env-mediated cell binding could furthermore be shown in a time course 
experiment. While HIV binding to SupT1-R5 cells increased over time, unspecific Env(-) binding 
stayed at baseline over the course of 4 h (Fig. 3.22 B).  
3.1.3.2 Binding to cells in dependence on CD317/Tetherin 
The virus binding assay was furthermore applied in the context of a study on the 
distribution of the newly identified virion restriction factor CD317/Tetherin (also known as Bst-2 
or HM1.24). CD317 is an interferon-inducible cellular protein that is able to inhibit the release of 
a variety of enveloped viruses by the proposed mechanism of physically tethering already budded 
particles to the plasma membrane [19, 165]. The accessory HIV-1 protein Vpu has been shown to 
counteract this restriction mechanism by downmodulating overall cell surface expression of 
CD317. The ultrastructural distribution of CD317 on the cell surface of infected and uninfected 
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cells had so far not been investigated. Incorporation of endogenous CD317 into budding viruses 
had been proposed but not been finally verified to this point [151, 181].  
In a study utilizing mainly electron microscopy of cells endogenously expressing CD317, 
it was found to be downregulated from the plasma membrane in the presence of HIV-1 including 
Vpu (infection or transfection of cells). At the same time it was found to be enriched in budding 
structures of HIV-1 as well as in cell-bound and cell-free virions independent of the presence of 
Vpu [82]. In summary, these results indicated that CD317 function critically depends on the 
amount of CD317 at the plasma membrane as opposed to the virus membrane. This conclusion 
led to the hypothesis of differential binding of free CD317-containing HIV-1 particles depending 
on the surface expression levels of CD317 in a proposed CD317-dimer interaction model [181]. 
To test for this hypothesis, I produced fluorescently labelled HIVmCherry particles by transfection of 
HeLa P4 cells and used those in the virus binding assay. HeLa P4 cells were chosen for particle 
production in this experiment to mimic the situation of particles budding from producing cells 
and reattaching to the same cell in presence of CD4, to include the potential influence of CD4-
dependent virus binding. To mimic HIV-1 infection of the cells on which binding was 
investigated, HeLa P4 cells were transfected with plasmids coding for Vpu.GFP or GFP prior to 
their employment in the binding assay.  
Surface expression of CD317 was controlled for in microscopy- (Fig. 3.23 A) and flow 
cytometry-based experiments (Fig. 3.23 B). In a representative set of images, the 
downmodulation of CD317 (rαBst-2, blue in overlay) can clearly be seen in the two highly 
Vpu.GFP-positive cells (marked with asterisks) in Fig. 3.23 A. The two cells that show an 
intermediate Vpu.GFP signal (GFP, green in overlay) show an intermediate phenotype in CD317 
surface expression. HIVmCherry signals (HIVmCherry, red in overlay) can be detected distributed over 
the cell body independent of the other two channels. The second line of verification in regard to 
CD317 downregulation can be seen in Fig. 3.23 B. Cells harvested in parallel to the performance 
of the virus binding assay were stained against CD317 surface expression and monitored in a 
flow cytometer. CD317 expression (y-axis) is plotted against GFP expression (x-axis) for both 
transfection conditions. A clear decrease in CD317-Alexa 660 signal could be observed with 
medium to high expression of Vpu.GFP, whereas the expression of GFP alone did not correlate 
with the amount of CD317 surface expression. For clarity, mean fluorescence intensities (MFI) 
for the different expression levels of GFP are shown in the upper part of the plots. Quantification 
of the virus binding assay is depicted in Fig. 3.23 C with single dots and squares representing 
individual cells and the mean of virus bound per cell represented by horizontal lines. The 
difference between the number of particles bound to non-transfected versus Vpu.GFP expressing 
cells with a clear phenotype in CD317 downmodulation was shown to be very minor. On average 
46 particles were found to be bound to non-transfected cells and only 39 to Vpu.GFP expressing 
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cells, resulting in a difference of 7 ± 4 particles. Statistical analysis using the unpaired two-tailed 
student’s t-test showed a non-significant p-value of 0.1071.  
Fig. 3.23: HIV-1 binding to cells in dependence of CD317/Tetherin surface expression. (A) HeLa P4 
cells were transfected with pVpuGFP or peGFP-N1, treated at 48 h with 20 U/ml Heparinase I for 45 min 
at 37°C washed, and purified HIVmCherry produced from transfected HeLa P4 cells (200 ng p24) allowed to 
bind for 1 h at 16°C. Cells were labelled for CD317 surface expression with anti-Bst-2 and Atto647N-
conjugated antibodies and cell nuclei were counterstained with Hoechst33258. Fluorescence images of the 
three individual channels and an overlay (GFP, green; HIVmCherry, red; αBst-2, blue) is shown. Asterisks 
indicate cells that have been taken into account for quantification. (B) FACS analysis of CD317 surface 
expression of HeLa P4 cells transfected for 48 h with pVpuGFP or peGFP-N1 using a mouse anti-CD317 
and anti-mouse-Alexa660. Numbers represent the mean fluorescence intensity (MFI) for cell surface-
exposed CD317 on cells with medium to high GFP expression and of GFP-negative cells, respectively. (C) 
Quantitation of virions bound per cell by virus binding assay. Only cells with clear CD317-phenotype 
(medium to high surface staining for non-tranfected cells (n=42) or no surface staining for Vpu.GFP 
expressing cells (n=21), respectively) from triplicate transfections were taken into account. Single values 
(dots and squares), mean values (horizontal bars) and standard deviations are shown in a scatter plot. n.s. = 
not significant.  
In summary, no correlation of virus binding to cells on the surface expression level of 
CD317 could be shown. However, the utility of the newly established virus binding assay could 
be proven by this application.  
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3.2 Patient- and drug-specific models of HIV-1 entry 
HIV-1 entry is a multistep process, involving interactions between the viral Env protein 
and the cellular receptor CD4 and a CXCR4 or CCR5 co-receptor molecule. The viral co-
receptor tropism is at least in part determined by the third variable loop (V3) of Env. With the 
approval and use of co-receptor antagonists as a new class of antiviral drugs, a detailed 
understanding of co-receptor tropism and accurate prediction of co-receptor usage of virus from 
patient samples has become essential.  
The goal of this study was to develop a better understanding of the dependence of viral 
entry efficiency and sensitivity towards entry inhibitors on critical cellular and viral determinants. 
The interplay of viral Env sequence with receptor and co-receptor density on the cell surface, and 
prototype entry inhibitors from different classes (receptor blocker, co-receptor antagonist, fusion 
inhibitor) has been investigated. Computational models based on this comprehensive set of 
quantitative data should lead to a better understanding of the mechanisms and development of 
resistance against HIV entry inhibitors.  
3.2.1 Experimental systems to create multidimensional data 
This study was designed as a multidimensional analysis of HIV-1 entry. Therefore, 
several parameters had to be varied within a fixed system measuring HIV-1 entry efficiency. The 
variable parameters were chosen to be  
• surface concentration of CD4 receptor molecules on the target cell,  
• surface concentration of CCR5 co-receptor molecules on the target cell,  
• V3-loop sequence of HIV-1 Env protein and  
• presence of different concentrations of prototype entry inhibitors.  
In this chapter, the different experimental systems used to create this multidimensional 
setup will be described.  
3.2.1.1 Receptor and Co-Receptor expression on different cell lines 
To make use of different surface expression levels of the HIV-1 receptor CD4 and on of 
the co-receptors, CCR5, we took two different approaches. On the one hand, I made use of the 
293 derived Affinofile cell line, established by the Lee lab [105] which can be induced to express a 
wide variety of CD4 and CCR5 levels independent of each other. Those cells offered the 
possibility to examine the dependence of virus entry efficiency on the presence of different 
Results – Patient- and drug-specific models of HIV-1 entry 
70 
concentrations of those two receptors. On the other hand, T-cell lines which may mimic the 
natural target cells of HIV-1 infection more closely were utilized: the T-cell line pairs C8166 [204] 
and C8166/CCR5 [69] (below referred to as C8166-R5) as well as SupT1/CCR5 (below referred 
to as SupT1-R5). Both parental T-cell lines (C8166 and SupT1 [136]) express CD4 and CXCR4, 
but no CCR5, which was in both cases added by stable transfection, resulting in the cell lines 
C8166-R5 and SupT1-R5, respectively.  
To analyze the surface concentration of the three receptors on all cell lines used, 
quantitative flow cytometry was performed. With the help of the BD QuantiBRITE kit, the 
amuont of antibody molecules bound per cell (ABC) can easily be estimated. To this end, 
monoclonal antibodies directly coupled to Phycoerythrin (PE) recognizing the receptors of 
interest (CD4, CCR5 and CXCR4) were utilized to stain the respective cells. Beads with 4 distinct 
surface labelling densities of PE molecules were used to calibrate correlate the number of ABC 
with identical settings of the FACS machine. The resulting standard curve was then used to 
correlate the fluorescence intensity measured from an unknown sample to PE-molecules bound 
per cell, corresponding to the estimated amount of antibody molecules bound per cell.  
To analyze the surface expression of CD4 and CCR5 on the dually inducible Affinofile 
cell line, cells were seeded in 24-well plates in presence of different concentrations of the two 
inducing agents, Tetracycline (Tet) to induce CD4 expression and Ponasterone A (PonA) to 
induce CCR5 expression, respectively. 18 to 24 h after induction, cells were detached from the 
culture plate, stained with the different PE-coupled antibodies and subjected to quantitative 
FACS measurement as described in 2.4.6.  
Fig. 3.24: HIV-1 Co-receptor and receptor density on Affinofile cells upon differential induction of 
expression. Affinofile cells were seeded in multiwell plates and induced with increasing concentrations of 
Ponasterone A (A) or Tetracycline (B). 18 h post induction, cells were detached with 5 mM EDTA and 
stained with PE-coupled antibodies raised against CCR5 (A) or CD4 (B) for 45 min on ice. Samples were 
then subjected to flow cytometry analysis in comparison to QuantiBRITE-PE beads. Antibody molecules 
bound per cell were estimated from the standard curve. The graphs display mean values with standard 
deviations of triplicate measurements of CCR5-antibody molecules bound per cell (A) or CD4-antibody 
molecules bound per cell (B) and a four parameter dose-response curve fitted to the data. PonA = 
Ponasterone A, Tet = Tetracycline, ABC = antibody molecules bound per cell. R2 describes the correlation 
of data and fit.  
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Induction of CCR5 surface expression with PonA was concentration dependent (Fig. 
3.24 A). Increasing concentrations of 0.1 µM up to 2 µM PonA led to a steep increase in CCR5-
expression, followed by saturation at higher concentrations, with an calculated effective 
concentration inducing 50 % of response (EC50) of ~1 µM. In the presence of 1 µM PonA and 
concentrations above, the cells started to grow in islands and appeared less vital with increasing 
numbers of cells rounding up and detaching from the culture plate (data not shown). Thus, 1 µM 
was chosen as the upper limit of PonA concentration. In contrast to this, the expression of CD4 
could be induced up to saturating amounts on the cell surface without obvious damage to the 
cells. CD4 saturation was reached at a Tet concentration of 7.5 ng/ml to 10 ng/ml with app. 
35’000 CD4 ABC (Fig. 3.24 B). EC50 of 4.2 ng/ml was calculated and a working range between 
0.5 and 7.5 ng/ml Tet was chosen for further experiments. Of note, expression of residual 
amounts of CD4 (~1’200 ABC) could also be detected in the absence of inducing agent. This 
“leakage” of the inducible promoter could not be detected for CCR5 expression, where the 
background level of CCR5 molecules/cell was in the same range as background of cells without 
any antibody staining (no stain, ~500 ABC).  
Fig. 3.25: Amount of receptor molecules on the surface of different cell lines determined by 
QuantiBRITE flow cytometry analysis. (A) Affinofile cells were induced as depicted in the graph. 18-24 h 
later, cells were detached with EDTA, stained against the receptor molecules CD4, CXCR4 or CCR5, 
respectively. Mean values of triplicate measurements and standard deviations are shown (B) 1x106 SupT1-
R5 (dark grey), C8166 (grey) or C8166-R5 (light grey) cells were stained using antibodies raised against the 
receptor molecules CD4, CXCR4 or CCR5, respectively. The graphs show the estimated number of 
antibody molecules bound per cell (ABC). Background of unstained samples is shown as a reference (no 
stain). For comparison, the data set of dually induced Affinofile cells (Affinofile Tet/PonA, dark blue) is 
also depicted in (B).  
Fig. 3.25 shows a comparison of receptor expression on the surface of different cell lines. 
In panel (A), the amount of receptor and co-receptor molecules, CD4, CCR5 and CXCR4, 
respectively, is shown for different induction conditions of Affinofile cells. The maximum 
concentrations of both inducting agents, 10 ng/ml Tet and 1 µM PonA, were chosen for this 
analysis. As described above, the level of CCR5 remained at background without induction 
(white bars), whereas a low basal expression of CD4 could be detected. CD4 expression levels 
could be increased by more than one order of magnitude by the addition of 10 ng/ml Tet (black 
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bars), without affecting CCR5 levels. The addition of 1 µM PonA (blue bars) led to an increase of 
CCR5 expression by at least one order of magnitude with CD4 levels remaining at the same low 
basal expression level as without induction. Upon dual induction (dark blue bars), CD4 levels 
increased to comparable amounts as with single Tet induction, whereas the level of CCR5 
induction was app. twofold lower than with PonA induction alone. With respect to CXCR4, 
which should not be affected by Tet or PonA, the different induction conditions had a small but 
detectable impact. Affinofile cells that were induced with Tet, PonA or a combination of both 
showed an app. twofold increase in CXCR4 surface expression. To compare the range of receptor 
surface levels of Affinofile cells with more physiological target cells, the analysis was expanded to 
human T-cell lines. As shown in Fig. 3.25 B CXCR4 levels on Affinofile cells were more than 
one order of magnitude lower than on the T-cells (~1’500 ABC as compared to ~10’000-
20’000 ABC). CD4 was detected to comparable amounts of about 40’000 molecules per cell on 
dually induced Affinofile cells, SupT1-R5 and C8166-R5 cells, whereas C8166 cells showed 
increased CD4 surface levels of over 100’000 ABC. As expected, C8166 cells showed no 
expression of CCR5 on the cell surface. The CCR5-expressing T-cell lines on the other hand 
displayed about 2’000 CCR5 ABC, which in a similar range than the level on dually induced 
Affinofile cells. Overall, the surface expression levels of CD4 as well as CCR5 detected on the 
Affinofile cell line was found to be comparable to physiologically more relevant T-cell lines.  
In summary, the cell lines tested here represented a panel of model cells suitable for 
differential expression patterns of HIV-1 receptor and co-receptors. Thus, they represent a 
valuable tool to investigate different surface levels of CD4 and CCR5 without the necessity to 
utilize different cell lines.  
3.2.1.2 Selection of patient-derived V3-loop sequences 
In order to keep provide a system with reduced complexity for initial modelling 
approaches we decided to compare isogenic virus derivatives varying only in the V3-loop of Env. 
To this end, a pseudotyping system was used for the production of viral particles, with a subviral 
plasmid (pCHIV.Env(-)) harbouring a translational frame-shift in the beginning of the env ORF to 
provide all viral proteins except for Env, and expression plasmids encoding the NL4-3 Env 
carrying modified V3-loop sequences inserted as described in 2.2.4.3. Briefly, V3-loop sequences 
were amplified by PCR from patient’s samples and inserted into a pCAGGS-based expression 
vector encoding the complete NL4-3 Env protein.  
In order to obtain a comprehensive set of variants for initial experiments, 8 divergent 
patient derived V3-loop sequences were selected. To this end, we made use of a pool of patient 
samples from the Bonn haemophiliac cohort, collected in the 1980s [111]. Those samples, kindly 
provided by Rolf Kaiser (Department of Virology, University Hospital of Cologne, Cologne, 
Germany) provide a very valuable tool as by the time of sample collection, no anti-retroviral 
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drugs had been introduced into the market, yet, so that all patients were completely therapy-
naïve. In addition, naturally evolved broadly variable viral quasispecies pools without the 
selective pressure of drugs are present in those samples, which is in contrast to modern patient’s 
samples.  
Viruses from 94 patient samples had been propagated in PBMCs over a period up to 3 
months and characterized according to their CPE (cytopathic effect) phenotype. The samples 
were grouped according to SI (syncytium inducing) or NSI (non-syncytium inducing). Bulk 
sequencing of the virus populations was performed for a subset of the samples1. 60 different V3-
loop sequences of viruses isolated from 36 patient samples yielded evaluable sequences, which 
were then further characterized by our collaborators with the help of computational biology2. For 
this purpose, the sequences were subjected to several different analyses, including Splitstree 
analysis [99], analysis of their localization in sequence space, genotypic prediction outcome of 
three different methods (geno2pheno [216], WebPSSM [104], 11/25 rule [67]) and the overall 
clustering trend.  
Tab. 3.1: Comparison of selected V3-loop sequences with those of two standard clones NL4-3 and its 
R5-tropic variant, NL4-3 R5. The table shows CPE determined for original patient’s isolate, amino acid 
sequence of the V3-loop of the respective clone and overall outcome of bioinformatical analysis. Point 
mutations within the NL4-3 R5 V3-loop that led to the R5-tropism are highlighted in bold italic. Positions 
11 and 25 with respect to the consensus subtype B V3-loop sequence are highlighted in bold type. V3-loop 
sequences yielding a clear prediction for X4-tropism (clearly X4) are labelled in red, those yielding a clear 
prediction for R5-tropism (clearly R5) are labelled in blue and those receiving an ambiguous result 
(ambiguous) are labelled in black and have the geno2pheno tropism prediction assigned (X4 or R5). SI = 
syncytium inducing, NSI = non-syncytium inducing.  
Tab. 3.1 summarizes the characteristics of the V3-loop sequences selected for this study. 
                                                    
1Virus propagation, RNA isolation and sequencing performed by Saleta Sierra-Arragon and Rolf 
Kaiser, Department of Virology, University Hospital of Cologne, Cologne, Germany.  
2Computational biology analysis was always performed by Kasia Bozek, AG Lengauer, 
Department of Computational Biology and Applied Algorithmics, Max-Planck-Institute for Computer 
Sciences, Saarbrücken, Germany. 
Results – Patient- and drug-specific models of HIV-1 entry 
74 
NL4-3 represents the V3-loop sequence of the standard X4-tropic laboratory HIV-1 strain NL4-3 
[1]. To obtain a comparable R5-tropic standard clone, NL4-3 R5 was used, a clone harbouring 
several point mutations in the V3-loop conferring R5-tropism (changes highlighted in bold italic 
in Tab. 3.1). The patient # indicates the AIDS number of the patient carrying the virus species 
with the respective sequence, whereas the clone # is derived from the geno2pheno prediction 
outcome (X4 = X4-tropic, R5 = R5-tropic) in combination with internal numbering system of the 
sequences obtained. The character “C” within the clone # indicates that sequencing of the isolate 
yielded a single clonal sequence, whereas samples lacking the “C” had ambiguous nucleotide 
sequences that could be arranged in several variants of which only one sequence was cloned for 
our analyses. The vast majority (63 of 94) of all viruses expanded in culture were shown to have a 
SI-type CPE. This is in part reflected in the selection, as over 50 % of the clones (5 of 8) also 
showed this phenotype. All V3-loop sequences selected had a length of 33 to 36 aa, with different 
degrees of sequence overlap. For better visualisation of differences, amino acid sequences are 
aligned and gaps are filled with a dash (–) in Tab. 3.1. Prediction of the 11/25 rule (positively 
charged aa at position 11 and/or 25 indicates a SI phenotype [67]) corresponded to the actually 
determined CPE phenotype for all clones, except for X4_C15 and X4_25a. After computational 
analysis of all sequences, the clones were either labeled “clearly X4” (marked with red color in all 
following schemes), “clearly R5” (marked with blue color in all following schemes) or 
“ambiguous” (marked with black or purple color in all following schemes) if the bioinformatic 
analyses yielded conflicting outcomes. 
The location in sequence space of all selected variants is depicted exemplarily in a 
Splitstree analysis in Fig. 3.26. Splitstree analyses provide the basis to depict phylogenetic 
networks taking into account also conflicting relations. Here, every individual dot represents the 
location of one V3-loop sequence from a randomly selected sample of the Los Alamos Database 
(www.hiv.lanl.gov). Line distances between individual sequences in the graph represent the 
relative degree of relatedness between the respective V3-loop sequences, whereas the branches 
depict different possible connections between the sequences. R5 sequences (blue dots) tended to 
form more compact clusters with higher sequence similarity, whereas X4 sequences (red dots) 
varied to a higher degree (compare also [24]). The clones considered ambiguous (black labels) did 
not follow this overall trend or fell in between the clear boundaries of X4 and R5 clusters.  
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Fig. 3.26: Splitstree analysis 
of patient derived V3-loop 
sequences. V3-loop sequences 
selected for the study were 
subjected to Splitstree analysis 
together with random 
sequences from the Los 
Alamos Database 
(www.hiv.lanl.gov). Sequences 
that obtained a R5-tropic 
prediction outcome according 
to geno2pheno analysis (or 
phenotypic data from LA DB) 
are labelled in blue, whereas 
sequences predicted to be X4-
tropic are labelled in red. The 
sequences selected for the 
current study are labelled with 
the respective names. Black 
labels correspond to sequences 
that were judged to be 
“ambiguous” (see below for 
details).  
 
In combination with the usage of prototype drugs from of the class of entry inhibitors, 
these systems allowed the variation of the desired parameters, surface concentration of receptor 
and/or co-receptor molecules on the target cell, and V3-loop sequence of the Env protein on the 
virus independently of each other. Hence, a reliable system to monitor entry efficiency had to be 
chosen to study the dependencies of HIV-1 entry efficiency on all those factors.  
3.2.2 Two systems to measure entry efficiency of HIV-1 
The method of choice to investigate HIV-1 entry independent of any further steps of the 
viral replication cycle is the so-called β-Lactamase virion fusion assay (referred to below as BlaM 
Assay) as described by Cavrois and colleagues [35]. Briefly, viral particles are produced that, by a 
fusion to Vpr, incorporate the bacterial enzyme β-Lactamase which is delivered to the cytosol of 
the target cell upon fusion of viral and cellular membrane. The presence or absence of β-
Lactamase in the target cell can then be visualized by loading of cells with a cleavable fluorescent 
substrate (CCF2) that shows different emission wavelengths in its cleaved (blue) or un-cleaved 
(green) state. This method was used for the analysis of T-cell lines but could, due to high 
background signals, not be used in combination with the Affinofile cell line. Hence, I used an 
additional entry assay, namely GFP transduction of cells. To this end, viral particles 
incorporating a self inactivating (SIN) vector encoding for GFP [257], were produced and viral 
entry could be detected by the green fluorescence of target cells 48 h after transduction.  
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3.2.2.1 FACS-based read-out for BlaM assay 
The BlaM assay can be evaluated by flow cytometry using a 405 nm laser to excite the 
BlaM substrate CCF2. This method allowed the parallel determination of expression of the three 
relevant surface proteins CD4, CCR5 and CXCR4, respectively, could be monitored with the 
help of simultaneous immunostaining. Cells that had been incubated for 6 h with BlaM carrying 
virus at 37°C were subsequently loaded with BlaM substrate over night at room temperature, 
then fixed and stained against the three receptors with directly labelled primary antibodies. To 
control for the possibility of virus-induced receptor downregulation, the time point of staining 
was carefully evaluated. Staining of cells before incubation with the virus (green), before the 
overnight incubation (pink) or before fixation (light blue) yielded comparable results (Fig. 3.27), 
whereas overnight incubation (orange) with the antibody increased the overall staining due to 
increased incubation time and temperature (room temperature vs. 4°C for all other samples). As 
unspecific antibody-uptake during this prolonged incubation time at elevated temperature could 
not be excluded, this method was however considered inferior to the other three and staining 
after fixation was finally considered as the method of choice.  
Fig. 3.27: Comparison of different antibody staining time points. C8166 cells were subjected to BlaM 
assay in presence of no virus (A, C) or 10 ng BlaM-containing virus (HIV; B, D) and stained for receptor 
(A, B) and co-receptor (C, D) at different time points with APC-coupled antibodies. APC-fluorescence 
spectra (arbitrary units) of cell population are depicted as histograms. The different coloured lines represent 
the population at the individual staining time points: before infection (green), after infection (pink), 
overnight (orange) and after overnight incubation (light blue). The purple-shaded population represents the 
distribution of an unstained control.  
Overlapping fluorescence spectra of CCF2 and the chromophors used to detect the 
receptors (compare Fig. 3.28) demanded compensation controls during data recording. In the 
standard experiment, the following antibody labels were used: CD4-APC-H7, CCR5-PE and 
CXCR4-APC, with the need of proper compensation between PE and the green emission of 
CCF2 resulting from excitation of its FITC moiety (CCF2 – green) by the 488 nm laser and 
standard compensation between APC and APC-H7.  
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Fig. 3.28: Characteristics of 
fluorochromes used for FACS analysis. 
(A) Fluorescence excitation (dotted lines) 
and emission (filled curves) spectra for all 
fluorochromes used, including both 
spectra of cleaved (blue) and uncleaved 
(green) CCF2, PE (yellow), APC (red) and 
APC-H7 (dark purple). The three utilized 
laser lines (purple = 405 nm, turquoise = 
488 nm, orange = 635 nm) are depicted as 
vertical lines. (B) Table of excitation (Ex) 
and emission (Em) maxima (max) with 
additional local maxima indicated in 
brackets. The wavelength of the respective 
laser used for excitation is indicated in the 
column “laser”.  
To allow for analysis of single cell data, the data recorded by flow cytometry had to be 
extracted and converted to formats that could be used with the computational methods developed 
by our cooperation partners. In a first step, the standard binary fcs-files were converted to an 
ASCII text format using the program FCSExtract Utility [73] to access the data. To preserve the 
compensation corrected fluorescence intensity values throughout this extraction, original FACS-
data had to be stored in the FCS2.0 file format, as FCS3.0 files keep raw values for the data and 
only apply a compensation matrix within the flow cytometric analysis program. Data extracted 
like this could then be analysed using methods established for the computer software R [190] and 
other specialized software.  
This workflow allowed the simultaneous observation of entry efficiency and receptor 
expression of CD4, CCR5 and CXCR4 on the single cell level.  
3.2.2.2 Microscopy-based read-out for Affinofile cells 
For all T-cell lines utilized in this study, the above described FACS-based read-out 
represented the most convenient technique. For the adherent Affinofile cell line, on the other 
hand, this read-out was found to be very time-consuming and could only be operated in a very 
low-throughput scale. Therefore, a semi-automated medium-throughput microscopy based 
system was established instead3. To this end, cells were seeded in 96-well plates. As Affinofile 
cells are HEK293-derived and hence very lightly adherent, several different plates were tested in 
regard to cell adherence and performance in fluorescence microscopy: Corning #3603 black with 
clear bottom, Corning #3340 with CellBIND surface black with clear bottom, BD PureCoatTM 
                                                    
3In cooperation with Christoph Sommer, AG Hamprecht, Heidelberg Collaboratory for Image 
Processing (HCI), Interdisciplinary Center for Scientific Computing (IWR), University of Heidelberg, 
Heidelberg, Germany 
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black with clear bottom and BD BiocoatR clear plates. The latter were excluded due to 
fluoerescence spill from well to well. The specially treated CellBIND plate from Corning proved 
to be most suitable with regard to the amount of cells that could be kept on the plates after the 
multistep staining protocol. Cells were seeded in the presence of the desired concentration of Tet 
and PonA and transduced with 5 ng p24 equivalent of isogenic viruses harbouring the different 
Env proteins. After 48 h cells were fixed with 3 % PFA and briefly incubated with 2 % BSA in 
PBS to block unspecific antibody binding sites. Afterwards, a sequential immunostaining 
protocol against CCR5 and CD4 was applied. Monoclonal mouse antibodies raised against 
CCR5 (clone 2D7) were used in combination with a secondary antibody coupled to Alexa 568 
and a directly labelled monoclonal CD4-Alexa 647 mouse antibody (clone RPA-T4) was used to 
monitor CD4 surface expression. Nuclei were counterstained with Hoechst 33258 and cells were 
then subjected to automated fluorescence microscopy. For high-throughput image acquisition a 
fully automated epifluorescence ScanR screening microscope equipped with the ScanR acquisition 
software (Olympus Biosystems GmbH, Münster, Germany) was used. Images were acquired 
with a 10x objective at 16 positions per well in four channels with the respective filter sets: DAPI 
to detect Hoechst stained nuclei, GFP to detect transduced cells, TexasRed to detect CCR5 
stained with Alexa 568 and Cy5 to detect CD4 stained with Alexa 647. Segmentation of cell 
nuclei was performed as described in [22]. Then, a maximum projection of the TexasRed and 
Cy5 channel was created which was then used to segment the single cell bodies. For this purpose, 
the images of the two channels had to be corrected for a minor location shift to obtain completely 
overlapping frames. The segmentation of cell bodies was computed using the seeded watershed 
algorithm as described in 2.6.2. Briefly, the segmentation line was started at the previously 
identified nuclei boundaries and allowed to grow until they hit a sharp intensity cut in the 
segmentation channel or another growing border from an adjacent cell. In addition, the growing 
of segmentation borders was restricted to an empirically fixed size cutoff to avoid oversized cell 
bodies when no clear intensity cut was hit.  
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Fig. 3.29: Steps of a microscopy based single cell read-out. Affinofile cells were induced with 2.5 ng/ml 
Tet and 0.25 µM PonA and after 18 h transduced with 5 ng p24 equivalent of a GFP-coding HIV-1 
derivative. Cells were fixed with 3 % PFA 48 h p.t. and stained against CD4 and CCR5 expression. Cell 
nuclei were counterstained with Hoechst 33258 and cells imaged in an automated fluorescence microscope 
at a magnification of 10x. 16 images per well were taken in 4 channels (DAPI for nuclei, CCR5-Alexa 568, 
CD4-Alexa 647 and GFP), maximum projection of CCR5 and CD4 pictures calculated and cells were 
segmented based on DAPI and this maximum projection. Fluorescence intensities in CCR5, CD4 and 
GFP-channel were then read-out based on the single segmented cells. Fluorescence microscopic images of 
a representative experiment are shown for CCR5 staining (A) and CD4 staining (B). Overlay of DAPI 
(blue), maximum projection of CCR5 and CD4-channels (red) and GFP channel (green) is shown in (C). 
(D) graphically depicts the segmentation out-put with the picture from (C) overlaid with the segmentation 
of nuclei (blue lines) and cell bodies (yellow lines).  
In Fig. 3.29, the consecutive steps of the image analysis are shown. Fig. 3.29 A and Fig. 
3.29 B show microscopic images of CCR5 and CD4 surface expression immunofluorescence 
staining in the TexasRed and Cy5 channel, respectively. Here, the staining of the cellular plasma 
membrane could be observed, while also the whole cell body appeared to show some background 
signal. This background signal was higher in the CCR5 staining (Fig. 3.29 A), which exhibited 
overall higher fluorescence intensities than the CD4 staining. In both images, the presence of 
different fluorescence intensities of single cells was clearly visible. Comparison of both images 
showed stronger signal in either one of the channels for some single cells, representing the 
independent induction of CD4 and CCR5 in each single cell. With the chosen induction 
conditions, nevertheless most of the cells showed an intermediate fluorescence intensity. A 
segmentation of cell bodies based on one of the channels showed promising results, but could be 
Results – Patient- and drug-specific models of HIV-1 entry 
80 
improved by combining both channels in a maximum projection (data not shown). With this 
method, cells that only expressed one of the receptors induced for could more easily and reliably 
be subjected to segmentation as a signal in one of the channels was sufficient to guide the 
segmentation algorithm. Fig. 3.29 C shows an overlay of DAPI (blue) and GFP (green) channels 
with the maximum projection of TexasRed and Cy5 channels (red) is shown. To visualize the 
segmentation outcome of this set of images, Fig. 3.29 D displays an overlay of Fig. 3.29 C with 
segmented nuclei (red lines) and segmented cell bodies (yellow lines). For the majority of cells 
within one image, this segmentation yielded an exact representation of the cell body’s contour. 
Reliability of this segmentation was dependent on cell density. Also, a negligible fraction of cell 
bodies were depicted as merged or mal-shaped in the segmentation. Nonetheless, the developed 
algorithm reliably allowed segmentation of cells which could then be used to quantify the 
fluorescence intensities of every single cell in the three channels GFP, TexasRed and Cy5 to 
determine if the single cell had been transduced (GFP positive) and expressed CCR5 (TexasRed) 
and/or CD4 (Cy5) on the surface.  
The results of individual images were extracted as a table (csv format), which could be 
merged for further analysis. An average of 800 nuclei were counted per image, resulting in over 
10’000 cells included in the analysis per single well, compared to 10’000 to 300’000 cells per 
single condition in the FACS-based measurements.  
3.2.3 Establishment of single-cell analyses of entry efficiency4 
The data output from both the microscopic as well as the FACS-based read-outs were 
transferred to bioinformatics analysis in large tables via a SVN server. Data was merged if 
necessary and processed as follows: first, a binary classification of entry positive cells was 
established. For that purpose, the fluorescence intensities were scored in comparison to a mock-
infected control of cells.  
For GFP, a gamma distribution was fitted to the distribution of GFP fluorescence in the 
no virus control (Fig. 3.30 A, black line). With this method, the overestimation of single outlier 
cells within the uninfected control displaying high fluorescence intensity in the GFP channel due 
to autofluorescence or dust particles above the cell body could be avoided. Based on this gamma 
fitting, a threshold was established, which was set to a positive score of only 0.01 % of cells in the 
negative control (Fig. 3.30 A, red verical line). Cells displaying GFP fluorescence intensities 
                                                    
4In cooperation with Kasia Bozek, PhD student in the group of Thomas Lengauer, Department of 
Computational Biology and Applied Algorithmics, Max-Planck-Institute for Computer Sciences, 
Saarbrücken, Germany. 
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above the threshold were scored as GFP- and therefore entry-positive, whereas cells displaying 
lower GFP-fluorescence were scored as negative (Fig. 3.30 B).  
Fig. 3.30: Establishment of a threshold for binary classification. (A-B) GFP classifictation. (A) GFP-
distribution of mock infected cells (no virus, grey line), gamma fit to this curve (black line) and thereby 
established threshold (red vertical line) are shown for a representative data set. (B) GFP-distribution of cells 
infected with R5-tropic (blue), X4-tropic (red) or ambiguous (pink) virus variants are shown in comparison 
to the mock-infected control (no virus, grey). The cutoff established in (A) is shown as black vertical line. 
(C-E) BlaM classification. Distribution of the two emission wavelengths of CCF2, blue (x-axis) and green 
(y-axis) is shown in dot plots. (C) and (D) show densitiy heat maps ranging from yellow (few cells) to red 
(many cells). (C) A line is fitted through the mock infected controls and distances from the line established 
over the whole population (black bars perpendicular to diagonal). (D) A gate surrounding the negative 
control is established along the averaged distances from (C). (E) Example of data from a NL4-3 R5 infected 
cell population with cells within the negative gate depicted in green and cells within the positive gate in 
blue. Percentage of BlaM-positive cells is shown in the lower right corner. a.u. = arbitrary units.  
In the BlaM assay, entry-positive cells were defined with a scoring technique closely 
mimicking FACS-gating (Fig. 3.30 C-E). In standard FACS-gating, the user has to set gates 
according to control values, a method which can be biased at times. To provide an objective 
method and deal with the great amounts of data in reasonable time, we developed this gating 
method based exclusively on computational methods. To this end, fluorescence intensities of 
both uncleaved (green) and cleaved (blue) CCF2 β-Lactamase substrate were plotted in dotplots 
against each other for every individual cell in the control samples (mock treated cells merged with 
the unstained control). A linear function was fitted to the plotted points and the distance of the 
points from the fitted line was measured (Fig. 3.30 C, black diagonal and black lines 
perpendicular to this diagonal). The averaged distances of the most distant points from the fitted 
line were used to define the negative gate (Fig. 3.30 D). Data points lying below the fitted line 
and further away from it than the distances established using the control were scored to be BlaM- 
and therefore entry-positive (e.g. Fig. 3.30 E). After this binary classification of each individual 
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cell, the expression patterns of CD4, CCR5, and in FACS-measured samples also CXCR4, could 
be taken into account in the next step.  
To illustrate the interdependencies of receptor/co-receptor usage and entry efficiency, the 
data were represented as 3D plots. For this purpose, the extreme 0.5 % of data were rejected on 
both horizontal axes to avoid misleading effects of outliers, and the remaining 99 % of data were 
binned in a 30x30 grid. The ratio of entry positive cells per bin was quantified and depicted in 
dependence of two other parameters. To smoothen the appearance of the plots for better 
interpretability, values in neighboring bins were averaged as shown exemplarily in Fig. 3.31. 
Empty bins are colored in black, whereas those yielding unreliable results due to a low number of 
individual cells (less than 0.11 % of total cells) were labelled in grey.  
 
Fig. 3.31: 3D plot of single-cell data analysis. SupT1-R5 cells 
were incubated with BlaM carrying virus and subjected to BlaM 
entry assay and stained for surface expression of CD4, CCR5 and 
CXCR4. Single cell analysis was performed as described. Plot 
shows entry efficiency represented by the percentage of BlaM 
positive cells in dependence of CD4 and CCR5 for the virus 
harbouring Env proteins with NL4-3 R5 V3-loop.  
 
 
This method of data display allowed a comprehensive visualization of the multiparameter 
analysis. The 3D plots were used for an initial estimate of data quality and indicated potential 
technical or systematical problems which could impede with future mathematical models if the 
respective data set would be taken into account. Furthermore, analysis of the data plotted in this 
way allowed for an initial interpretation guiding subsequent steps in experimental design to 
generate further data sets for a good and valid mathematical model.  
3.2.4 Effect of the amount of virus-incorporated Env protein on entry efficiency  
Since the viruses used to investigate entry efficiency had to be produced as isogenic 
pseudoparticles (see 3.2.1.2), the amount of incorporated Env protein could in principle vary 
from particle preparation to particle preparation. To monitor for those possible changes, 
quantitative Western Blot (qWB) analyses were performed using antibodies against CA protein 
and gp41 – the transmembrane part of Env. The intensities of CA and gp41 bands were 
quantified for every sample and normalized to a wt control, consisting of a particle preparation of 
pCHIV transfected 293T cells, applied to each single qWB as a standard.  
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Fig. 3.32: Quantitation of Env incorporation into HIV-1 pseudoparticles. Isogenic viruses only differing 
in the Env protein incorporated were produced from 293T cells. Samples were diluted in SDS-sample 
buffer and subjected to quantitative Western Blot analysis probing against gp41 (A) and CA (B) at the same 
time. Lanes are labelled with the clone number of the Env protein used for pseudotyping. Env(-) = no 
envelope protein, wt = proviral plasmid encoding for the Env protein within the viral sequence (pCHIV). 
Position of molecular mass standards is shown with numbers in kDa at the left edge and protein bands are 
labelled on the right. (C) Single band intensities were quantitated using the LiCor Odyssey 2.1 software. 
The ratio of gp41 to CA was determined for every sample and normalized to wt. The graph shows the 
relative Env incorporation (ratio of gp41 per CA protein) for the different isogenic viruses of different 
particle preparations (ME75, ME76, ME82, respectively).  
Fig. 3.32 A and B show qWB images of a representative particle preparation. The 
Chessie-8 antibody (A) stained gp41-containing proteins, namely the precursor protein gp160, 
which was present in all pseudotyped samples (lanes 1-10), as well as gp41 itself. This band 
occurred somewhat blurry, which was due to differently glycosylated species of the protein. As 
expected, no gp41 bands could be detected in the Env(-) sample (lane 11). In contrast to that, the 
wt sample (lane 12) showed a stronger gp41 signal compared to the other viruses. The CA 
antibody (B) showed as expected free CA protein (24 kDa) as well as a weak pattern of Gag 
processing products, including Gag precursor and MACA cleavage intermediate at the expected 
heights of 55 and 43 kDa, respectively. In order to have a more comprehensive picture of the 
incorporation of Env protein into viral particles, the ratio of gp41 signal to CA signal was 
calculated for each sample. Those ratios were then normalized to wt and are displayed for 
different particle preparations in Fig. 3.32 C. Here, the varying incorporation between different 
Env protein variants as well as over different particle preparations (ME75, ME76 and ME82, 
respectively) can easily be appreciated.  
This result led to the question, if different amounts of Env protein incorporated per CA 
protein – and assuming a more or less constant amount of CA protein per virion also Env/virion 
– had an effect on entry efficiency of the respective viral particles. To investigate this, BlaM 
carrying pseudoparticles incorporating different amounts of Env protein were produced by co-
transfection of differing amounts of pCAGGS-NL4-3XbaI over a wide range corresponding to 
plasmid amounts of 0 to 5 µg per 10 cm dish (with 2.5 µg Env-plasmid as the standard 
procedure). Those viruses were characterized in respect to their gp41/CA ratio in comparison to 
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the wt control as described above and then subjected to BlaM assay measurements on C8166 
cells. The entry efficiency was quantified in a FACS read-out and percentage of BlaM positive 
cells plotted against the Env incorporation ratio (gp41/CA) in Fig. 3.33.  
Fig. 3.33: Dependency of entry efficiency on Env 
incorporation. Different amounts of NL4-3 Env 
expression plasmid were co-transfected with a proviral 
plasmid lacking the env gene (pCHIV.Env(-)) into 293T 
cells to obtain a panel of isogenic viruses differing in 
their Env incorporation levels. Env incorporation ratio 
of gp41/CA was determined as described in Fig. 3.34. 
Relative entry efficiencies were determined by BlaM 
assay on C8166 cells and plotted against the relative 
gp41/CA ratio compared to a wt preparation. Values of 
three independent triplicate experiments are plotted. 
Line represents Deming regression with the assumption 
of errors with standard deviation of 0.7 for x-values and 
standard deviation of 8 for y-values (as estimated from 
multiple measurements).  
An increase of entry efficiency could be observed in relation to the incorporation ratio of 
gp41 per virus. This dependency occurred to be roughly linear, as indicated by the fitting of the 
curve with a Deming regression (line in Fig. 3.33) which was significantly different from zero. 
While the standard linear regression method assumes that only the y measurements are 
associated with random errors, the Deming method takes errors for both measurements into 
account. Higher ratios of Env incorporation were also tested, but seemed to lead to a “saturation” 
of the function. The two triplicate values above the gp41/CA ratio of 2 seem to fall in this high 
Env classification already, but are taken into account in the regression. All particle preparations 
used in this study however showed gp41/CA ratios below the point where saturation was 
reached.  
In conclusion, the amount of Env protein incorporated into a viral particle plays a role in 
entry efficiency, at least in the lower range of gp41/CA which was relevant for the further 
experiments. Hence, all particle preparations were subjected to gp41/CA-quantification by 
quantitative western blot analysis and the linear correlation can be incorporated in future models.  
3.2.5 Dependency of entry efficiency on different receptor concentrations 
For an initial characterization of the selected virus variants, the quantitative dependence 
of entry efficiency on receptor concentrations was tested. Hence, the different model cell lines 
were challenged with the isogenic reporter vectors carrying various V3-loop sequences. Entry 
efficiency was monitored by flow cytometry of GFP expression 48 h post transduction. Fig. 3.35 
shows the distinct entry patterns of the selected vector variants into C8166 (orange), C8166-R5 
(light blue) and differently induced Affinofile cells. The surface expression levels of CD4, CCR5 
and CXCR4 were monitored by bulk quantitative FACS measurement at the time point of 
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transduction, as well as at the time point of GFP read-out and were shown to be similar for both 
time points and in the expected range for all cell lines (compare Fig. 3.25).  
Fig. 3.35: Bulk entry efficiencies of the selected variants into different cell types. C8166 and C8166-R5 
cells (left axis; orange and light blue bars, respectively) and Affinofile cells (right axis) not induced (white 
bars) or induced with 10 ng/ml Tet to express CD4 alone (red bars) or with a combination of 10 ng/ml Tet 
and 1 µM PonA to express CD4 and CCR5 (blue bars) were incubated with 25 ng (T-cell) and 5 ng p24 
equivalent (Affinofile) of isogenic GFP-coding viruses carrying different Env proteins harboring the 
selected V3-loop sequences, respectively. Cells were tested for GFP fluorescence 48 h after transduction by 
flow cytometry. Mean percentage of GFP-positive cells of triplicate measurements and standard deviation 
are depicted for the different clones. Note the different scaling due to higher overall entry efficiencies on 
Affinofile cells.  
Regarding entry efficiency, both T-cell lines showed GFP-expression of the reporter gene 
to a significantly lower level than Affinofile cells (note different scales of left (T-cells) and right 
(Affinofile) y-axes). As a control, viruses lacking any Env protein on their surface (Env(-)), were 
also tested and did not enter into any of the tested cell lines. Only clearly X4-predicted clones 
(marked in red on the x-axis) showed detectable entry into C8166 cells, with only clone X4_C3 
failing in this regard. On the other hand, entry efficiency of these X4-tropic variants was 
decreased in the related cell line, C8166-R5, which expresses a lower concentration of CD4 than 
the parental clone (compare Fig. 3.25 B). In contrast to that, all clearly R5-predicted clones 
showed detectable entry only on the CCR5-expressing T-cell line, C8166-R5. In this regard, the 
standard clone NL4-3 R5 showed the highest entry levels, followed by one ambiguous variant, 
X4_36b, and the two clearly R5-predicted clones, R5_C29 and R5_C30. In addition, also another 
ambiguous variant, X4_25a showed very low but detectable entry efficiency on C8166-R5 cells. 
Affinofile cells not induced for CD4 or CCR5 (white) showed low levels of entry efficiency for 
some variants, most prominent in case of the standard X4-tropic variant NL4-3 and to a lesser 
degree for X4_7b, X4_36b and NL4-3 R5. Those low levels of entry efficiency could be increased 
in Affinofile cells expressing high CD4 levels for clones X4_7b, X4_25a, R5_C29 and X4_36b 
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and reached over 10 % GFP-positive cells for clones R5_C30, NL4-3 and NL4-3 R5. After 
additional induction of high levels of CCR5 (red), all clones except for the ambiguously predicted 
clone X4_C15, that showed no entry in either cell line, were shown to exhibit GFP-positive cells 
of up to nearly 70 % (R5_C30 and NL4-3 R5). All clearly R5-predicted clones displayed 
markedly increased entry efficiencies in comparison to Affinofile cells only induced for CD4, 
whereas the clearly X4-predicted clones X4_7b and NL4-3, showed no further increase of entry 
efficiency. In contrast to that, the also clearly X4-predicted clone X4_C3 was only able to enter 
Affinofile cells with high CD4 and CCR5 levels, hinting at a CCR5-dependence of this clone 
which was unexpected with the clear prediction outcome. The ambiguously predicted clones 
X4_25a and X4_36b showed matching increase in entry efficiency in presence of CCR5 surface 
expression on C8166-R5 and dually induced Affinofile cells, with the latter yielding overall 
higher entry efficiencies than the former. Of note, the standard X4-tropic clone NL4-3 showed, in 
comparison to all other clones, relatively much higher entry efficiencies on both T-cell lines than 
on the adherent Affinofile cells, which can be explained by its need for high CXCR4 expression 
levels, only present on the T-cell lines tested (compare Fig. 3.25 B).  
In conclusion, the overall entry pattern of both standard clones and most of the clones 
tested proved to be in line with their predicted tropism, with some unexpected patterns in co-
receptor usage for one clearly predicted clone (e.g. X4_C3) and as expected for the ambiguously 
predicted clones X4_25a, X4_36b. One ambiguous clone, X4_C15, did not gain entry in any of 
the cell lines tested at the chosen experimental settings.  
Next, a deeper differential analysis was performed with 16 different induction levels of 
CD4 and CCR5 on Affinofile cells. To achieve this, the cells were induced with all possible 
combinations of the two induction agents at the concentrations of 0, 2.5, 3.75 and 10 ng/ml Tet 
and 0, 0.25, 0.5 and 1 µM PonA, respectively. Cells were again transduced with GFP-coding 
viruses harboring the individual Env sequences selected and entry efficiency was quantified with 
the help of the microscopic single-cell read-out. First, a bulk analysis of these data was performed 
to describe the overall CD4/CCR5-dependencies of entry efficiency of the different clones in a 
comprehensive way. Hence, the mean percentages of GFP-positive cells for each condition were 
analyzed and patterns were mathematically transformed into 3D surface plots with the web- 
based tool V.E.R.S.A. (Viral Entry Receptor Sensitivity Analysis; [105]; 
http://versa.biomath.ucla.edu). For CD4 and CCR5 expression levels, the mean fluorescence 
intensities of the respective immunostain were taken into account.  
 
 
 
Results – Patient- and drug-specific models of HIV-1 entry 
87 
Fig. 3.36 shows the 3D surface plots drawn from the polynomial functions of the web-tool 
output. NL4-3 (Fig. 3.36 A) displayed a clear dependence on CD4 levels, whereas variation of 
CCR5 levels did not affect entry. In contrast to this, NL4-3 R5 (Fig. 3.36 B) was dependant on 
the presence of high expression levels of both CD4 and CCR5. In uninfected cells (no virus; Fig. 
3.36 C), GFP-positive cells were found only at background levels and no dependence on either of 
the receptors could be detected. All patient derived variants tested showed distinct patterns of 
CD4 and CCR5 dependency, with R5_C29, R5_C30 and X4_36b (Fig. 3.36 I-K) most closely 
mimicking NL4-3 R5, whereas no variant showed an exclusive CD4 dependence comparable to 
NL4-3. In contrast, all clearly X4-predicted clones showed a mixed dependency on both receptors 
tested, with highest entry efficiencies in the presence of high surface expression levels of both 
CD4 and CCR5. This entry efficiency pattern was also displayed by the ambiguous clone 
X4_25a. Clones X4_C3 and X4_C26 both showed a very clear dependence from CCR5, although 
they both were clearly predicted to be X4-tropic. The ambiguous clone X4_C15 again showed 
entry levels not significantly above background (not exceeding 0.8 % GFP-positive cells under 
any condition, resulting in a smoothed 3D plot function not exceeding 0.5 % entry efficiency). 
The saddle-shaped surface pattern was considered to be an artifact of low entry efficiencies and 
therefore neglected in further analyses.  
Note that X4-classified variants (red) again showed overall lower entry efficiencies than 
R5-tropic variants (blue). In this regard, the ambiguous clones (black), except the above 
mentioned clone X4_C15, behaved more like R5-tropic variants, displaying medium to high entry 
efficiencies.  
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Fig. 3.36: Viral Entry Receptor Sensitivity Analysis (V.E.R.S.A.) of all clones selected. See page 89. 
Another way to interpret the data obtained from the VERSA analysis web-tool is depicted 
in Fig. 3.37. Here, the sensitivity vector angle θ, a measure to describe the gross feature of the 3D 
surface plots (for details see [105]), is plotted for the different clones. The closer this angle is to 
90°, the more CCR5-dependent is the respective virus clone, whereas angles close to 0° represent 
almost exclusive sensitivity to CD4 levels. To correlate this sensitivity vector with the overall 
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entry efficiency, the length of the arrows was drawn with respect to the vector magnitude, which 
is a direct measure for entry efficiency. The longer an arrow, the higher the overall entry 
efficiency, with R5_C30 showing the highest vector magnitude (86.3) and X4_C15 showing the 
lowest vector magnitude (0.2) in the same range as the mock-infected control (0.29). X4_C15 will 
therefore be ignored for further interpretation and is thus neglected in the plot. The length 
differences of the arrows again stresses the overall difference in entry efficiency of the clearly X4-
predicted clones (labelled in red), which all showed low vector magnitudes, and the clearly R5-
predicted as well as two of the ambiguously predicted clones (labelled in blue and black, 
respectively), which showed much higher vector magnitudes.  
Fig. 3.37: Sensitivity Vector Angles for the 
different clones. Additional analysis output 
from VERSA of the data from Fig. 3.36. 
Length of arrow reflects sensitivity vector 
magnitude. A sensitivity vector angle θ close 
to 0° represents high CD4-dependency of a 
clone whereas an angle of close to 90° high 
CCR5-dependency. Grey dotted line 
indicates an angle of 45°. 
 
In regard to the actual sensitivity vector angle, only the standard X4-tropic clone NL4-3 
showed an exclusive CD4-dependence, whereas all other clones exhibited mixed dependencies. 
Surprisingly, two clearly X4-predicted clones, X4_C3 and X4_C26, displayed sensitivity vector 
angles above 45°, hinting of a strong CCR5-dependency. An angle close to 45° could otherwise 
only be reached by the ambiguous clone X4_25a (41.28°), whereas all clearly R5-tropic variants 
as well as the third ambiguous clone X4_36b showed angles below 25°.  
 
 
 
 
Fig. 3.36 (page 88): Viral Entry Receptor Sensitivity Analysis (V.E.R.S.A.) of all clones selected. 
Affinofile cells were induced with 16 different combinations of Tet and PonA concentrations for 18 h, and 
then infected with isogenic viruses carrying the 10 selected Env-proteins. 48 h later, cells were fixed, stained 
for CCR5 and CD4 surface expression, nuclei were counterstained with Hoechst, fluorescence microscopy 
performed, images were segmented and percentage of GFP-positive cells determined. Entry efficiency 
expressed in % GFP-positive cells for the different viral strains and CD4 and CCR5 levels expressed as 
mean fluorescence values were uploaded to the VERSA analysis web-tool ([105], 
http://versa.biomath.ucla.edu) and fitting polynomials were plotted with R ([190], http://www.R-
project.org). The graphs, showing the respective clone number on top, show entry efficiency in % GFP-
positive cells (z-axis) plotted against normalized surface expression levels of CD4 (x-axis) and CCR5 (y-
axis). Functions of viruses predicted to be X4-tropic are plotted in red, those of viruses predicted to be R5-
tropic in blue, those of ambiguous clones in black and a control without virus (C, no virus) is depicted in 
grey as a background control.  
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3.2.6 Quantifying the effect of entry inhibitors 
In addition to the direct correlation of entry efficiency and the presence of receptor 
and/or co-receptor on the surface of target cells, sensitivity to entry inhibitors also provides 
valuable information about the behaviour of the different isogenic viruses. To include this 
component into our multivariable study, the complete virus panel was tested for entry efficiency 
at the fully inhibitory concentrations of three prototype entry inhibitors. C46 [93], a derivative of 
T-20/Enfuvirtide ([66, 116]; trade name Fuzeon (Roche Pharmaceuticals, Basel, Switzerland)), is 
a peptidic fusion inhibitor of HIV-1 that blocks six-helix bundle formation of gp41 during the 
fusion process of viral and cellular membrane. It should therefore inhibit entry of all HIV-1 
variants selected in this study, independent of their respective co-receptor tropism [68]. In 
addition to this broadly acting fusion inhibitor I also utilized two prototype co-receptor 
antagonists. AMD-3100 (AMD) is a bicyclam that has been shown to potently inhibit HIV-1 
entry by antagonizing the CXCR4 co-receptor molecule [47, 210]. It is nevertheless not used in 
HIV-1 therapy due to massive adverse effects observed in humans [91]. On the other hand, the 
CCR5 co-receptor can easily be blocked by the small compound Maraviroc (MVC) [9], which 
was approved for antiretroviral treatment in Europe in 2007 ([63]; trade name Celsentri (ViiV 
Healthcare, Brentford, UK)).  
Fig. 3.38: Sensitivity towards prototype entry inhibitors. GFP-coding viruses with the different Env 
proteins (x-axis) where used to transduce Affinofile cells induced for low expression levels of CD4 and 
CCR5 in the presence of the indicated concentrations of three prototype entry inhibitors. After 48 h, 
infection rate (ratio of GFP-positive cells) was determined by microscopic read-out. Mean values of 
triplicate measurements (6 measurements for no drug) and standard deviations are shown.  
Results – Patient- and drug-specific models of HIV-1 entry 
91 
To investigate the sensitivity of all selected V3-loop variants, Affinofile cells induced for a 
low bulk expression level of CD4 and CCR5 (2.5 ng/ml Tet and 0.25 µM PonA) were transduced 
with GFP-coding isogenic vectors in the absence (no drug – white bars) or presence of fully 
inhibitory concentrations of C46 (black bars), AMD-3100 (blue bars) and MVC (red bars). Fig. 
3.38 summarizes the bulk results of the microscopic read-out of this experiment after 48 h. As 
expected, all vectors were sensitive to the addition of 100 nM C46. Clones showing a higher 
initial infection rate (R5-tropic variants labelled in blue on the x-axis and two of the ambiguous 
clones, labelled in black on the x-axis) retained a higher background infection rate in the presence 
of C46, demonstrating a virus specific effect of the decrease in the number of GFP-positive cells. 
In contrast to those very clear results, both co-receptor antagonists showed less definite inhibition 
patterns. A clear match of expectations and tested sensitivity could be observed with the control 
viruses NL4-3, which was inhibited by AMD, but not MVC, and NL4-3 R5, which in turn was 
inhibited only by MVC and not by AMD. This clear phenotype was only mimicked by both 
clones clearly predicted to be R5-tropic as well as one of the clearly X4-predicted clones (labelled 
in red on the x-axis), namely X4_7b. The two remaining clearly X4-predicted clones showed an 
“inverted” phenotype: they were both inhibited by MVC but not AMD. The ambiguous clones 
all (except for X4_C15 which again showed insignificant overall entry levels) displayed a clear 
sensitivity towards MVC, but their entry efficiency was not affected by the presence of AMD.  
In order to obtain a more detailed picture of the sensitivity of the different virus variants 
to the presence of entry inhibitors, titration experiments were performed. For this purpose, 
SupT1-R5 (Fig. 3.39) or Affinofile cells (Fig. 3.40) were incubated with the isogenic virus variants 
in the presence of different concentrations of MVC.  
On SupT1-R5 cells, the BlaM assay was used as a read-out. Fig. 3.39 displays dose-
response curves for the different variants labelled on top of each plot. The fits were calculated 
with the software GraphPad Prism and IC50 values for curves reaching the non-inhibited plateau 
and a correlation of the fit over R2 = 0.8 are shown. Variants X4_7b (Fig. 3.39 B), X4_C15 (Fig. 
3.39 C), X4_C26 (Fig. 3.39 E) as well as the standard X4-tropic clone NL4-3 (Fig. 3.39 I) did not 
show any response to increasing amounts of the CCR5-antagonist MVC. The remaining variants 
displayed strong inhibition with IC50 values in the low- to mid-nanomolar range. The control 
variant for R5-tropic viruses, NL4-3 R5 (Fig. 3.39 J) displayed the highest IC50 of 62.3 nM, 
followed by one ambiguous variant (X4_36b, IC50 = 40.1 nM, Fig. 3.39 H), the two clearly R5-
predicted variants (R5_C30 and R5_C29, IC50 = 30.4 nM and 16.5 nM, respectively, Fig. 3.39 G 
and F) and the second ambiguous variant, X4_25, with the lowest calculated IC50 value of 
3.9 nM (Fig. 3.39 D). The clearly X4-predicted variant X4_C3 (Fig. 3.39 A) showed a very steep 
MVC-response curve not allowing to calculate a reliable IC50 value as the plateau was not 
reached with the administered concentrations of drug. To properly illustrate the strong inhibition, 
an additional display of this data set was chosen on a linear scale (Fig. 3.39 K).  
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Fig. 3.39: Sensitivity of different virus variants towards MVC on SupT1-R5 cells. Entry efficiency of 
isogenic viruses into SupT1-R5 cells was investigated using the BlaM assay in the presence of different 
concentrations of MVC. Data of two independent experiments are shown (mean value of overlapping data 
points with standard deviation). Dose response curves were fitted with the GraphPad Prism software. The 
Env variant is indicated above the respective plot. IC50 values in nM are depicted for reliable curves. Note 
the non-logarithmic x-axis in (K) to display the data point without MVC.  
A similar analysis was conducted on the Affinofile cell line to compare the two model 
systems. Affinofile cells were induced with 2.5 ng/ml Tet and 0.25 µM PonA for this purpose and 
transduced with 10 ng GFP-coding isogenic vector variants carrying the different Env proteins. 
Entry efficiency was analyzed using the microscopic read-out 48 h post transduction. The results 
of this experiment are depicted in Fig. 3.40.  
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Fig. 3.40: Sensitivity of different virus variants towards MVC on Affinofile cells. Entry efficiency of 
isogenic viruses into Affinofile cells induced for a low expression of CD4 and CCR5 was investigated with 
the microscopic GFP-transduction assay in the presence of different concentrations of MVC. Data of two 
triplicate measurements and standard deviations are shown. The Env variant is indicated above the 
respective plot. Logarithmic curves fitted with dose response functions using the GraphPad Prism software 
are shown.  
Only two X4-tropic variants were insensitive to MVC inhibition (Fig. 3.40 A and Fig. 
3.40 F). All other clones were inhibited in a dose-dependent manner. Dose-response curves were 
fitted to the data sets showing clear phenotypes, although the lowest MVC concentration did not 
allow the detection of the upper plateau for any of the variants. Thus, the IC50 values calculated 
are not considered reliable and have not been displayed, here. The standard R5-tropic clone, 
NL4-3 R5 (Fig. 3.40 G), as well as the two clearly R5-predicted variants (Fig. 3.40 C-D) and one 
ambiguously predicted clone, X4_36b (Fig. 3.40 E), showed a clear MVC sensitivity in the same 
range as observed on SupT1-R5 cells (compare Fig. 3.39).  
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Fig. 3.41: Sensitivity of different virus variants towards MVC on Affinofile cells. Linear display of a 
subset of Env variants depicted above the respective plots. Details see Fig. 3.40.  
For clarity, the response curves of some variants are depicted in a linear display in Fig. 
3.41 to highlight the strong drop in entry efficiency from the first data point (0 nM MVC) to the 
second (0.015625 nM MVC). Those graphs are restricted to 100 nM MVC input to easily 
visualize the low drug concentrations. However, note the extended scale in Fig. 3.41 H to 
illustrate the resistance of the standard X4-tropic clone NL4-3 to CCR5-antagonist inhibition 
even in presence of high drug concentrations. A very steep decrease in entry efficiencies can 
nevertheless be seen in the subnanomolar range for the variants X4_C3 (Fig. 3.41 B), X4_25a 
(Fig. 3.41 C) and X4_C26 (Fig. 3.41 D). Two of those, X4_C3 and X4_C26, display entry 
efficiencies of below 10 % already at the baseline (no MVC) and the steepness of the curve could 
therefore result from the overall low entry efficiency with this virus input. In contrast to this, 
X4_25a is inhibited from an initial entry efficiency of over 50 %, laying further stress on the 
strong R5-dependence of this variant. The ambiguous variant X4_C15 (Fig. 3.41 B) seemed to 
show a slight sensitivity towards MVC despite very low overall entry efficiencies. 
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For easier comparison, Tab. 3.2 summarizes the sensitivities of entry efficiency into the 
two different cell lines for the individual clones.  
 
Tab. 3.2: Summary of MVC sensitivity on 
different cell lines. The sensitivity of 
individual clones is expressed as ++ for very 
strong inhibition, + for inhibition, (+) for 
minor reduction and - for lacking inhibition. 
IC50 values in nM on SupT1-R5 cells are 
indicated if determined. n.d. = not determined.  
 
 
 
In order to test whether variants that were inhibited by the CCR5-antagonist MVC could 
further be influenced by the presence of a CXCR4-antagonist by blocking the second available 
major co-receptor, an experiment was conducted where the two drugs MVC and AMD were 
titrated against each other. For this purpose, Affinofile cells were again induced for medium 
levels of CD4 and CCR5 (2.5 ng/ml Tet and 0.25 µM PonA) and transduced with the panel of 
isogenic GFP-vectors for 48 h. Concentrations which did not lead to full inhibition of the 
standard clones NL4-3 and NL4-3 R5, respectively, were used, leading to a 4x4 inhibition grid 
with AMD concentrations of 0, 0.4, 2 and 10 ng/ml AMD and 0, 8, 40 and 200 nM MVC, in 
each combination.  
Fig. 3.42 depicts the 16 data points of the individual data sets for each virus variant in a 
3D plot with bulk entry efficiencies from two merged independent experiments displayed on the 
z-axis in dependence of increasing AMD (x-axis) and MVC (y-axis) concentrations towards the 
right front of the plot. The overall sensitivities to the drugs could be confirmed as tested before by 
these results: The X4-tropic standard NL4-3 (Fig. 3.42 A) and the clearly X4-predicted variant 
X4_7b (Fig. 3.42 D) were shown to display a clear sensitivity to increasing AMD concentrations, 
but they were not inhibited by the addition of MVC. In contrast to this, the two remaining clearly 
X4-predicted variants, X4_C3 (Fig. 3.42 C) and X4_C26 (Fig. 3.42 F), respectively, as well as 
two of the ambiguously predicted clones, X4_25a (Fig. 3.42 E) and X4_36b (Fig. 3.42 I), and the 
clearly R5-predicted variants and standard, R5_C29 (Fig. 3.42 G), R5_C30 (Fig. 3.42 H) and 
NL4-3 R5 (Fig. 3.42 B), respectively, were shown to be sensitive to MVC but not AMD. 
However, no additive effect of the two drugs could be observed in this experiment.  
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Fig. 3.42: Dependence of entry efficiency on the combination of two co-receptor antagonists. Affinofile 
cells were induced for low level expression of both CD4 and CCR5 for 18 h, incubated for 48 h with GFP-
expressing virus with different Env proteins as indicated above the plots and subjected to microscopic read-
out. Ratio of GFP-positive cells per total cells is depicted in dependence of increasing amounts of AMD 
and MVC towards the frontal corner.  
The single-cell analysis method developed in this study was able to reveal a much more 
detailed picture of those experimental results. The dependency of entry efficiency on CD4- and 
CCR5 levels in the presence of increasing drug amounts is depicted exemplary for three virus 
variants in Fig. 3.43 and Fig. 3.44. Reflecting the overall results of the bulk analysis, AMD-
sensitivity could only be detected for NL4-3 (Fig. 3.43 B), whereas X4_C3 (Fig. 3.43 A) and 
NL4-3 R5 (Fig. 3.43 C) showed no sensitivity towards this drug. Accordingly, a clear dependence 
on CCR5-levels can be observed for X4_C3 with a steep gradient of high entry efficiency towards 
high surface concentrations of this co-receptor, which is not changed dramatically in the presence 
of increasing amounts of AMD. In contrast to this, for NL4-3 the flat plateau of entry positive 
cells distributed more equally over the range of CCR5-expression levels is vanishing evenly with 
increasing AMD concentrations. The very high entry efficiencies of NL4-3 R5 impede the correct 
interpretation of receptor- and co-receptor-dependence in this case as the high entry efficiency-
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pattern is not changed dramatically in the presence of AMD.  
Fig. 3.43: Single cell analysis of entry dependency on CD4 and CCR5 expression levels with increasing 
amounts of AMD. Affinofile cells were induced with 2.5 ng/ml Tet and 0.25 µM PonA and entry 
efficiency of isogenic vector variants in presence of increasing amounts of AMD assessed with the 
microscopic assay. 3D-plots of relative entry efficiency (z-axis) in dependence on CD4- (x-axis) and CCR5- 
(y-axis) surface expression levels are shown as determined by the single cell analysis method developed in 
3.2.3 for clone X4_C3 (A) as well as the two standard clones NL4-3 (B) and NL4-3 R5 (C). AMD 
concentrations from left to right: 0, 0.4, 2 and 10 ng/ml. 
In contrast to this, the sensitivity towards MVC on the single cell level is shown in Fig. 
3.44. Both variants that did not react to AMD, X4_C3 (Fig. 3.44 A) and NL4-3 R5 (Fig. 3.44 C) 
showed a clear sensitivity towards MVC. With respect to receptor dependence of this reduction in 
entry efficiency, a peculiar phenotype could be observed: in presence of MVC, viruses seemed to 
enter cells that expressed low CD4-levels to a higher degree than in the absence of drug. This 
could be observed for both variants, although more obvious for NL4-3 R5 due to higher overall 
entry efficiencies, where it could best be seen at 0.04 and 0.2 µM MVC. The same phenotype was 
observed for all virus variants that were sensitive to MVC. Surprisingly, NL4-3 (Fig. 3.44 B) also 
showed a similar phenotype, although only in the presence of the highest MVC concentration 
and not as pronounced as for the R5-tropic variants. 
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Fig. 3.44: Single cell analysis of entry dependency on CD4 and CCR5 expression levels with increasing 
amounts of MVC. Affinofile cells were induced with 2.5 ng/ml Tet and 0.25 µM PonA and entry 
efficiency of isogenic vector variants in presence of increasing amounts of MVC assessed with the 
microscopic assay. 3D-plots of relative entry efficiency (z-axis) in dependence on CD4- (x-axis) and CCR5- 
(y-axis) surface expression levels are shown as determined by the single cell analysis method developed in 
3.2.3 for clone X4_C3 (A) as well as the two standard clones NL4-3 (B) and NL4-3 R5 (C). MVC 
concentrations from left to right: 0, 8, 40 and 200 nM. 
3.2.7 Comparison of different analysis methods 
The subtle differences described above were invisible in the bulk analysis of the same 
data, proving an advantage of the single-cell analysis of entry efficiencies developed here. To 
compare the different analysis methods side by side, all data obtained with the differential 
induction experiment (compare 3.2.5) was analyzed in three different ways. To compare the 
results of those analyses, three representative graphs are shown for each method in Fig. 3.45.  
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Fig. 3.45: Comparison of different analyses of the same data set. Affinofile cells were induced with 16 
different combinations of Tet and PonA concentrations for 18 h, and then infected with viruses coding for 
GFP. 48 h later, cells were fixed, stained for CCR5 and CD4 surface expression, nuclei were 
counterstained with Hoechst, fluorescence microscopy performed, images were segmented and percentage 
of GFP-positive cells determined as described above. Entry efficiency expressed in % GFP-positive cells (z-
axis) were either plotted as a function of the concentration of both induction agents Tetracycline (Tet) and 
PonasteroneA (PonA) in A, D and G or as a function of CD4 (x-axis) and CCR5 (y-axis) levels expressed 
as mean fluorescence values. Values were either uploaded to the VERSA analysis web-tool ([105], 
http://versa.biomath.ucla.edu) and fitting polynomials were plotted with R ([190], www.R-project.org) (B, 
E and H) or single-cell analysis performed as described above (C, F and I). Analyses for viruses carrying 
three different Env-proteins are shown: NL4-3 (A-C), NL4-3 R5 (D-F) and X4_C3 (G-I).  
The roughest analysis is represented by plotting the mean entry efficiency for each single 
of the 16 induction conditions (first column; Fig. 3.45 A, D, G). No information on the actual 
expression level of both receptors CD4 and CCR5 after induction with different concentrations of 
the two inducing agents, Tet and PonA, respectively, was included here. The graphs give a coarse 
impression of the dependence of entry efficiency on the presence of different concentrations of 
both inducing agents. The second column (Fig. 3.45 B, E, H) represents the graphic output of the 
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VERSA analysis. Those graphs have been discussed in detail above (compare page 86). Finally, 
the third column (Fig. 3.45 C, F, I) depicts single-cell analysis of the same data sets. In contrast to 
the other two methods, those graphs reveal subtle differences in entry efficiencies with minor 
changes in receptor concentrations. While all three methods of analysis revealed the same trend 
in entry dependency on induction intensity of the Affinofile cell line, an increase in analysis depth 
could clearly be seen from left to right in every row of Fig. 3.45.  
Fig. 3.46: Distinct CD4/CCR5 surface expression levels at different induction conditions. Affinofile 
cells were induced with different combinations of Tet and PonA. Surface expression of CD4 and CCR5 
was measured by immunofluorescence after 66 h. 3D plots show number (#) of cells in the respective 
CD4/CCR5 bin for different induction conditions indicated in Tet and PonA concentration in the upper 
right corner of each plot.  
The much more detailed pattern of the dependence of entry efficiency on the levels of 
CD4 and CCR5 in the single cell analysis can be explained by the broad distribution of different 
expression levels of both receptors at the individual induction conditions. This is visualized in 
Fig. 3.46, where the frequency of distinct CD4/CCR5 expression levels (i.e. number of cells in a 
given bin) is shown for several induction conditions. Although the overall expression level is 
clearly dependent on the concentration of the respective inducing agent (compare also Fig. 3.24), 
the picture is different on the level of single cells. Even in the presence of only low amounts of an 
inducing agent resulting in low bulk levels of receptor expression, some individual cells expressed 
high amounts of the induced receptor molecule. This is neglected in the VERSA analysis, where 
mean values of expression levels were taken into account for the individual induction condition. 
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In contrast to this, the single cell analysis established here assigns the entry efficiency to the actual 
expression level of every single cell and thus integrates outliers within one induction condition in 
the right way.  
In conclusion, single cell analysis established in this study represents a superior method 
for the generation of detailed quantitative data as a basis for mathematical modeling of the entry 
process.  
3.2.8 Summary of phenotypes determined for the individual clones 
For easier discussion of the differences between the selected V3-loop variants, a summary 
of characteristics of every individual clone is helpful and is hence described in the following 
paragraphs.  
3.2.8.1 The standard clones, NL4-3 and NL4-3 R5 
The two clones chosen as standard variants proved to behave as expected in most of the 
tests performed. A very clear CXCR4-dependence of NL4-3 could be shown by comparison of 
entry efficiencies on T-cell lines expressing high amounts of this co-receptor in contrast to the 
Affinofile cell line that displays only very low surface levels of CXCR4. In addition, NL4-3 
showed a very clear and exclusive CD4-dependence on Affinofile cells, establishing the 
independence of this clone from any surface concentration of CCR5. Furthermore, a strong 
sensitivity towards the CXCR4-antagonist AMD-3100 could be established. NL4-3 showed no 
sensitivity towards MVC, although a minor decrease in entry efficiency could be observed in 
some experiments.  
This is in contrast to the second control virus, NL4-3 R5. This variant showed a very 
strong sensitivity to CCR5-expression on the T-cell line pair C8166 and C8166-R5. Low 
background entry efficiency was observed on Affinofile cells not induced for CCR5-expression, 
which could be increased markedly upon induction of this co-receptor. On both cell lines tested, 
NL4-3 R5 could easily be inhibited by the addition of MVC, with an estimated IC50 in the 
nanomolar range on SupT1-R5 cells.  
3.2.8.2 The clearly X4-predicted clone X4_C3 
All selection parameters used clearly predicted that this clone was an X4-tropic variant. 
All genotyping algorithms used, including the 11/25 charge rule were in agreement, as well as the 
phenotypic analysis which stated a SI-phenotype. Surprisingly, the viruses produced to 
incorporate the Env protein with this particular V3-loop did not behave X4-tropic at all. Entry 
into both C8166 cell lines was at background levels. However, entry into SupT1-R5 cells 
demonstrated the viability of this variant. A clear CCR5-dependence could furthermore be shown 
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on Affinofile cells, where induction of both CD4 and CCR5 was needed for entry. Overall low 
entry efficiencies of this variant hampered the calculation of IC50 values in response to MVC 
treatment. However, a clear sensitivity towards the CCR5-antagonist could be established, while 
the virus did not respond to the CXCR4-antagonist.  
3.2.8.3 The clearly X4-predicted clone X4_7b 
The likewise very clearly X4-predicted clone X4_7b reacted as expected in all tests and in 
line with its predicted X4-tropism. It entered into all cell lines tested, independent of the 
expression level of CCR5. A slight decrease in entry efficiency was observed in the cell line 
C8166-R5 in comparison to its parental cell line, C8166. On Affinofile cells, a dependence on 
CD4-levels was visible, although not as exclusive as for the standard X4-tropic variant NL4-3. In 
regard to drug sensitivity, X4_7b behaved as expected as well: inhibition was achieved only by 
AMD, whereas even high concentrations of MVC did not inhibit entry of this variant.  
3.2.8.4 The ambiguous-predicted clone X4_C15 
X4_C15 did not show significant entry into any of the systems tested. Even very high 
virus input levels did not rescue entry efficiency.  
3.2.8.5 The ambiguous-predicted clone X4_25a 
This clone lacking any clear tropism prediction behaved clearly as a R5-tropic virus in all 
cellular assays. It only entered cells when CCR5 was present and was inhibited by MVC but not 
AMD. The R5-tropism had been predicted by webPSSM and the lack of a charged amino acid at 
position 11 or 25 equally hinted at this phenotype. However, the SI-classification of the original 
patient’s sample was in favour for the wrong X4-prediction.  
3.2.8.6 The clearly X4-predicted clone X4_C26 
This variant showed an ambiguous behaviour opposed to the very clear tropism 
prediction by all different methods tested. On T-cell lines, the virus was readily able to enter into 
cells lacking the CCR5-co-receptor. However, it was not shown to be sensitive to AMD and 
slightly sensitive to MVC. This hint towards a dual-tropic behaviour was strengthened on 
Affinofile cells. In these cells, X4_C26 only entered when they had been induced for CCR5-
expression. In addition, a strong sensitivity towards MVC was observed on this cell line.  
3.2.8.7 The clearly R5-predicted clone R5_C29 and R5_C30 
Both clearly R5-predicted clones that we chose to take into the initial selection were 
found to behave as expected. No entry was observable on cell lines without CCR5-expression and 
a clear inhibition was detected in the presence of increasing amounts of MVC but not AMD.  
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3.2.8.8 The ambiguous-predicted clone X4_36b 
The last ambiguous clone in this panel was found to be clearly R5-tropic in all assays 
including drug sensitivity.  
In conclusion, the whole spectrum of outcomes was observed, ranging from confirmation 
of the predicted phenotype (two standard clones as well as one X4-variant and both R5-variants), 
over the clear characterization of ambiguously predicted variants, to the revelation of opposing 
phenotype (one clearly X4-predicted variant proved to be R5-tropic) and the discovery of one 
dual-tropic variant. The overall bias in the selection towards X4-prediction (6/8) was therefore 
turned upside down with the majority of clones proving clearly R5-tropic after careful 
examination (5/8).  
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4 Discussion 
4.1 Fluorescently labelled viruses to study virus cell interactions 
In the first part of the thesis, an alternative labelling approach was developed which offers 
new possibilities to study virus entry and egress. Furthermore, the system of fluorescently labelled 
HIV-1 derivatives has, for the first time, successfully been implemented for HCVpp. In addition, 
new single-particle techniques making use of theses fluorescently labelled viruses could be 
established and were utilized also to study the binding of HIV-1 derivatives to individual cells in 
dependence of different factors.  
4.1.1 SNAP-tag as a tool to study virus release 
The insertion of the SNAP-tag into the ORF of HIV-1 gag proved to be a promising 
expansion of the already existing palette of fluorescence labelling tools for viruses. The effects of 
this modification on particle release, entry efficiency and infectivity were minor and completely 
restorable by the equimolar addition of wt Gag. The most promising part of this full 
characterization of HIVSNAP is the non-detrimental effect on replication capacity without the need 
for mixing with wt HIV. In contrast to similar constructs with a fusion of MA to eGFP (B. 
Müller, personal communication), the spreading in culture was observed to similar final levels as 
wt, although with a lower initial speed, and the inserted tag proved to be expressed stably over 
several replication rounds. This offers the possibility to use the constructed HIVSNAP variants in 
infected T-cells and to easily label particles produced from those.  
The introduction of an additional HIV-1 protease cleavage site before the MA-SNAP-tag 
junction did not improve the impaired replication speed any further. This is in contrast to the 
eGFP label, which could be shown to replicate to significantly higher degrees if the second 
cleavage site was present (data not shown and [98]). In the case of HIVSNAP the second cleavage 
site may even represent a drawback rather than an improvement: The original MA.SNAP fusion 
should allow studying of tagged and labelled MA even after entry into newly infected cells, 
whereas this possibility would be lost with the full cleavage of SNAP-tag from the viral 
components.  
Labelling of HIVSNAP particles and of the tagged Gag precursor within transfected cells 
was easily applicable and initial pulse-chase experiments have been conducted. The quite rapid 
labelling of newly synthesized GagSNAP after 5 min of chase period seemed surprising. However, 
under closer examination this result may in part be influenced by the design of the experiment. 
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First, the synthesis of new protein had not been inhibited, e.g. with cycloheximide [172]. Thus, 
already translated proteins which had not been folded properly at the time of blocking with non-
labelled SNAP-substrate, could finish folding within this short time period and then be ready for 
labelling. Second, the staining protocol itself harbours the possibility of underestimation of the 
time needed to produce new fusion protein: The fluorescently labelled substrate was offered for 
staining according to manufacturer’s suggestions for 15 min at 37°C, thereby prolonging the 
chase period to 20 min instead of the assumed 5 min. Besides reduction of staining time, which 
might come at the expense of lower signals, another strategy could be possible to circumvent this 
issue. It has been shown that the SNAP-tag retains its self-labelling activity even after fixation 
(manufacturer’s information and personal communication with J. Chojnacki). This could be used 
by fixing cells directly after the chase period and only subject them to labelling afterwards in 
order to minimize the overlap of chase period and staining time.  
This method would also render HIVSNAP amenable to labelling with e.g. Atto or Dyomics 
dyes. These organic dyes display a higher quantum yield, enhanced photostability and an 
improved spectrum of available excitation and emission wavelengths. With this method, new 
imaging techniques, such as simulated emission depletion (STED) microscopy [90] or stochastic 
optical reconstruction microscopy (STORM) [202] could also be applied to study trafficking of 
HIV-1 Gag. These methods allow the detailed investigation of protein interactions with a 
resolution below the diffraction limit [96]. For example, interactions of HIV-1 Gag with the 
cellular components of the ESCRT complex at individual budding sites would be of major 
interest and those studies are pursued in our department as well as in collaboration with others 
(W. Muranyi, S. Ivanchenko, personal communication). However, available Atto or Dyomics 
dyes have the disadvantage of often being cell impermeable. Therefore, one challenge to make 
use of the SNAP-tag also in live cell experiments is the development of a wider variety of cell-
permeable organic dyes. Several methods aiming at this have been developed and are currently 
under investigation [142].  
4.1.2 Fluorescently labelled HCV pseudoparticles to dissect the steps of virus entry 
The combination of fluorescently labelled HIV-1 derivatives and HCVpp was successfully 
established in this study, creating fluorescently labelled HCVpp which were used to investigate 
binding and endocytosis. Until very recently, binding of HCV particles has been studied by 
indirect measurements exclusively. For example, a soluble version of E2 (sE2) was used to mimic 
cell binding of HCV [11]. In addition, HCV binding to cells was studied with insect cell-derived 
HCV-like particles [14] and by quantification of the amount of bound viral RNA [159]. In 
contrast, the virus binding assay established in this thesis provides information on the single 
particle level by direct visualization of particles bound to host cells. Inhibition of HCVpp binding 
to cells by competition with heparin proved the functionality of this assay, as this phenotype had 
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been shown already by other techniques [11, 122]. The observed independence of HCVpp 
binding to Lunet cells from HDL is also in line with previous findings on a different cell line [55].  
Single-cell analysis comes at the expense of high cell to cell variations. The differences of 
e.g. surface expression of proteins during the replication cycle of each individual cell are levelled 
out in bulk analyses. Each individual cell will add to the overall population, resulting in a 
Gaussian shaped distribution of cellular marker proteins as well as other parameters that might be 
dependent on the stage of the cell cycle. The width of variation is not shrinking with increasing 
sample sizes, although differences may statistically become more significant. In bulk assays, the 
width of these single-cell variations is the same, but basically never surfaces, as it is included in 
the mean values that are measured. In single-cell analyses, these variations often handicap easy 
interpretation of data and only very strong phenotypes can easily be observed. On the other hand, 
this technique provides a much more detailed picture of the individual steps during virus entry.  
The advantage in resolution that is obtained with single particle analysis is unfortunately 
accompanied by another drawback. The very low specific infectivity of HCVcc (on average, app. 
only every 1000th - 10000th particle is infectious [137]) leads to a very high number of 
“background” events which is counter-productive for single-particle methods. The low number of 
infectious particles per total amount of particles is most likely even further decreased in the 
HCVpp system. Although this model system has very successfully been used in the past to study 
various aspects of the early steps of the HCV replication cycle, many limitations have been 
discussed repeatedly. First, the incorporation of HCV E1E2 into retroviral particles occurs 
randomly. Due to an ER retention signal, E1E2 are normally forced to stay at the predicted site 
of HCV particle assembly [57]. However, this localization is undesired for incorporation into 
retroviral particles, as budding of HIV-1 occurs predominantly at the plasma membrane [167, 
241]. In addition, the amount of Env protein incorporated per virion is most likely different for 
HCV and HIV-1. HIV-1 has been shown to incorporate a very low number of Env proteins into 
its lipid envelope, probably as few as 10 to 20 Env trimers [254]. In contrast to this, the closest 
relatives of HCV that has been studied in this regard, i.e. Dengue virus, showed a dense packing 
of Env proteins (~180 per virion) covering the entire viral particle surface [125]. The amount of 
E1E2 incorporated into wild type HCV particles is not known yet, but similar high levels could be 
assumed. The unspecific binding to as well as uptake into cells observed with fluorescently 
labelled HCVpp in this study could result from this hurdle. Minor differences in binding and 
endocytosis which are dependent on the presence of E1E2 would be missed if they are obscured 
by the presence of particles carrying too few glycoproteins on their surface.  
In addition, another issue of HCVpp has to be taken into account. HCV produced in cell 
culture or isolated from patients has been found to possess a variety of buoyant densities, which 
results from the close association of virus particles with different lipoproteins, i.e. LDL and 
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VLDL [7, 71]. Infectivity of different particle fractions has closely been linked with this 
association: Particles of low density show much higher infectivity than the majority of the 
preparation. This fact, as well as the involvement of cellular molecules which interact with 
lipoproteins in their original function, i.e. the attachment factor LDLr and one of the receptor 
molecules of HCV, SR-BI, imply an important contribution of lipoproteins to the entry process of 
HCV. Due to their production from non-hepatic cells as well as the changed budding location 
and mechanism driven by their retroviral core, HCVpp do not associate with lipoproteins per se, 
therefore lacking this important facet of the entry process. The presence of HDL during infection 
with HCVpp can mimic the association with lipoproteins and enhance entry efficiency [56], 
although the clear mechanism of this association has not yet been elucidated.  
Nevertheless, the fact that HCVpp can be produced easily and handled under lower safety 
conditions than fully infectious HCVcc makes them a valuable tool for many fields of study. The 
dissection of HCV entry into several clearly defined parts has been the goal of this part of my 
thesis. Binding and cellular uptake of particles were studied with the above described 
fluorescently labelled HCVpp, whereas the next step in early replication, fusion of viral and 
cellular membranes, was approached with another technique.  
The β-Lactamase virion fusion assay has long been established for quantification of HIV-1 
cytosolic entry. It measures the steps up to cytosolic entry uncoupled from any subsequent steps 
in the replication cycle by incorporation of the enzyme β-Lactamase into virions which can upon 
cytosolic delivery cleave a substrate loaded to cells. Several optimization steps accomplished in 
this thesis led to the successful implementation of this assay for HCVpp entry into susceptible 
cells. With this, the dependence of HCVpp cytosolic entry on several factors could be proven: 
enhancement of cytosolic entry by HDL, opposed to its inhibition by oxLDL, αCD81 antibody, 
inhibition of endosomal acidification and the presence of heparin.  
While this assay is completely uncoupled from later steps in the replication cycle, it is still 
tightly associated with the steps preceding fusion. Therefore, no clear conclusion can be drawn 
whether these factors influence only fusion itself or the attachment and specific binding before. 
For heparin, a clear implication in binding has been shown by the virus binding assay, as 
described above. In contrast to this, HDL was dispensable for binding and uptake but clearly 
enhanced cytocolic entry of HCVpp. In the same line, CD81 expression on the target cell surface 
and the presence of E1E2 on the particle surface could not been shown to be involved in particle 
binding and uptake, but were clearly shown to be necessary for cytosolic entry in Lunet cells. 
This implies an involvement in a step between endocytic uptake and cytosolic delivery of the 
virus core. The clear temporal confinement of CD81 action is in agreement with a current model 
of HCV entry, in which HCV glycoprotein binding to CD81 is thought to trigger the transport of 
bound virus towards tight junctions in an actin-dependent way [27]. The model proposes that 
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only there, it can then engage the two subsequent receptors CLDN and OCLN, which both are 
tight junction proteins. A similar mode of entry has been shown for coxsackievirus group B, 
where primary binding to a receptor triggers actin-dependent transport to the tight junction 
localized receptor that promotes particle internalization [43].  
 
The shortcomings of HCVpp as discussed above also apply for the BlaM assay established 
here. Incorporation of β-Lactamase into HCVcc could therefore be a desired goal. HCV reporter 
viruses used so far contain a reporter gene coding for luciferase or a FP inserted into the viral 
genome (e.g. [122, 228]). This requires the expression of the reporter inside the infected cell and 
thus is a less direct measure for virus entry than provided by the BlaM assay. Incorporation of 
viral fusion proteins provided in trans comparable to the method applied with HIV-1 and Vpr 
fusion proteins, has not been adopted, yet. Recently, a reporter system based on the cleavage of a 
cellular expressed FP fusion protein by the viral protease has been established with two different 
readouts: secretion of the FP [100] and change of subcellular localization of a FP fusion protein 
[108]. Other than that, fluorescence labelling techniques of HCV mostly comprise the fusion of 
single viral proteins to FPs to study their subcellular localization and interaction with several 
cellular proteins (e.g. [212]). The use of fluorescently labelled HCV in real-time single particle 
imaging would have been an implication of the fluorescently labelled HCVpp described in this 
thesis. The above mentioned hurdles however hampered this plan, so far. Although the authors 
using the change of subcellular localization as a marker of infection claim real-time imaging of 
HCV entry with this technique [108], another recent report fulfils this task using live cell 
microscopy [41]. There, Coller and colleagues describe the labelling of HCVcc with the lipophilic 
dyes DiD and DiI, analogue to studies with other viruses, including Dengue virus [230, 231]. The 
use of HCVcc offers the advantage of production of particles in relevant hepatic cells, which leads 
to the association with lipoproteins and the possibility of isolation of highly infectious fractions of 
virus associated with a certain buoyant density thus circumventing the problems arising from the 
use of HCVpp.  
4.1.3 Fluorescently labelled HIV-1 derivatives 
In contrast to the findings with HCV pseudoparticles, HIV-1 attachment to T-cell lines 
was found to be dependent on the presence of Env in viral particles. This finding is in line with a 
report showing the CD4-dependency of HIV-1 cell binding by inhibition with soluble CD4 and 
blocking antibodies [17]. The amount of particles bound per single cell was cell-type specific, with 
more particles binding to C8166 than SupT1-R5 cells. The unspecific binding of Env(-) particles 
was also increased on C8166 cells, hinting at an at least partial contribution of non-CD4-specific 
interactions. T-cell lines have been shown to harbour differing levels of HSPGs whereas primary 
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T-cells display only low levels on their surface [173]. C8166 cells display high surface levels of 
HSPGs (M. Lampe, personal communication), which probably contribute to this enhanced 
binding. In addition, several other attachment factors could play a role. The most prominent 
attachment factor known for HIV-1 is DC-SIGN, which is expressed on dentritic cells and helps 
them to capture virus to facilitate spread to T-cells [131]. In addition, the incorporation of the 
cellular protein ICAM-1 (intercellular adhesion molecule-1) into viral particles has been shown to 
facilitate virus binding to host cells expressing the ligand LFA1 (leucocyte function associated 
antigen 1) [94]. In conclusion, the high level of unspecific binding of HIV-1 to C8166 cells has 
implications on studies of the early events of HIV-1 replication: To enhance the chance of 
observing meaningful interactions of the virus with its host cell, cells with a low amount of 
unspecific binding should be chosen. The SupT1-R5 cell line therefore represents a good tool to 
study HIV-1 attachment and binding in greater detail and on the single-cell level.  
The observed time-dependent increase in Env-dependent binding to cells over 4 h is most 
likely explained by a “scanning” mechanism of viral particles along the cell surface for CD4-
molecules. Time-course studies of HIV-1 infectivity showed that the majority of entry occurs 
during the first two hours after virus addition at 37°C (B. Glass, personal communication). The 
virus binding assay has been carried out at room temperature, thus possibly prolonging this 
increase in specific binding over a period of four hours.  
 
HIV-1 binding to cells was shown to be independent from the surface concentration of the 
cellular restriction factor CD317. It has recently been shown that CD317 acts as the physical 
tether between newly budded viruses to the membrane of infected cells [85]. The observed 
phenotype seems to be counter-intuitive for this proposed mechanism. Since incorporation of 
CD317 into virus particles is not changed in the presence or absence of the viral countermeasure 
Vpu [82], the tethering activity in dependence of Vpu should be explained by the cellular part in 
some way. This could then also lead to a positive effect in cell-free virus infection of neighbouring 
cells by enhanced attachment. However, an artificial system had to be used to study this aspect: 
fluorescently labelled particles were produced by transfection of cells and then purified and 
concentrated by ultra centrifugation. After this step, the particles were resuspended in FCS-
containing buffer to prevent aggregation in the following freezing step. One possible explanation 
is that this freeze-thaw circle harmed the tethering activity of Tetherin in some way. Another 
possibility would be the shielding of interaction sites by the high protein amounts in the added 
FCS. In addition, the unspecific attachment of virus particles to cells could also play a role. To 
prevent this, HSPGs were removed from cells by heparinase I treatment before the addition of 
virus. The effect of significantly lowered virus binding to cells in comparison to untreated control 
cells could be shown, although the decrease of cellular heparan sulphate could not be proven by 
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flow cytometry. This argues that residual amounts of HSPGs could still mask specific differences 
in particle binding. Assessment of virus binding on more relevant cells such as primary T-cells 
could shed more light in this question.  
Another explanation is the time point of establishment of the intermolecular interaction. 
The tethering phenotype has been observed in cells producing virus progeny. The interactions 
between adjacent CD317 molecules will therefore most likely be established during this budding 
process. An interference with the interaction at this stage could block the tethering phenotype, 
not only by depletion of the molecule from the cell surface. The incorporation of one of its 
membrane anchors in either of the tethered membranes, viral and cellular, could be a possibility 
for this. This model of tethering is in line with results from Perez-Caballero and colleagues who 
favour the integration of parallel homodimers of CD317 in a fashion that either the C- or the N-
terminus of both molecules are anchored in one and the other terminus is anchored in the 
opposing membrane [181]. Another very recent report implied the existence of long connections 
between tethered particles or cells, hinting at the involvement of several dimers of CD317 [85]. 
This establishment of multimers of CD317 would also point in the direction that tethering of 
particles can only occur during budding and not be established retrospectively after this process is 
finished.  
4.2 Patient- and drug-specific models of HIV-1 entry 
In this part of the thesis, new techniques to study the entry efficiency of HIV-1 in 
dependence on multiple parameters have been established. All of these have been designed to 
provide a very detailed insight on the interdependencies of viral and host cellular factors during 
entry and were hence developed on single cell basis. These multidimensional data are currently 
being used to develop and compute mathematical models of HIV-1 entry and should lead to a 
better understanding of this process and the impact of entry inhibitors.  
4.2.1 Experimental systems to create multidimensional data 
In order to create a system in which reliable and quantitative data on the entry efficiency 
of HIV-1 derivatives could be gathered, several decisions had to be made. On the one hand, the 
system had to be variable enough to provide a wide span of data. On the other hand, these 
variables had to be controlled tightly so that quantitative data could be obtained. In addition, all 
variables should be well defined to provide a solid basis for mathematical modelling.  
To do so, we chose the following parameters to be varied: Surface concentration of CD4 
receptor molecules on the target cell, surface concentration of CCR5 co-receptor molecules on the 
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target cell, V3-loop sequence of HIV-1 Env protein and presence of different concentrations of 
prototype entry inhibitors.  
4.2.1.1 Cell systems with variable receptor and co-receptor levels 
For the purpose of variation of receptor and co-receptor molecules on the cell surface, 
several options were considered. The HeLa-derived cell line collection described by the Kabat 
laboratory [110] is composed of a panel of cell lines that express differential amounts of CD4 and 
got later on extended by cells with different CCR5-expression levels [186]. These cells 
nevertheless possess the drawback of the possibility of subtle differences between the different cell 
clones as also discussed below. A B-cell line inducible for CD4 expression [124] had also been 
discussed, but was dismissed due to the availability of a more versatile option. The recently 
established dual inducible cell line Affinofile [105] proved as a useful tool. Levels of both surface 
markers were found to be readily inducible in a wide range, although to a moderately lower bulk 
level as described in the literature. These differences can easily be explained by differing culturing 
conditions, e.g. the permanent selective pressure with all four antibiotics in contrast to the 
minimized setup of only one in the Lee lab. The expression range reached in this study however 
provided a wide variability of CD4 and CCR5 levels which can be resolved by single-cell 
analysis. Single-cell analysis of surface expression revealed a broad distribution of different 
expression levels of both receptors at the individual induction conditions (compare Fig. 3.46). 
Although the overall expression level was clearly dependent on the concentration of the 
respective inducing agent (compare also Fig. 3.25), the picture was different on the level of single 
cells. This becomes obvious if the Gaussian shape of receptor level distribution is taken into 
account, whereas only the mean value of the whole distribution is used in bulk analysis, which 
was also the case in the VERSA analysis. In contrast to this, the single cell analysis established in 
this thesis assigns the entry efficiency to the actual expression level of every single cell and thus 
appropriately integrates outliers within one induction condition. The much more detailed pattern 
of the dependence of entry efficiency on the levels of CD4 and CCR5 in single cell analysis can 
easily be explained by this.  
The fact that CCR5-levels on Affinofile cells were found to be at the background of 
unstained cells does not exclude residual “leaky” CCR5-expression even in the non-induced 
control. Under some experimental conditions, CCR5-detection was hard to achieve in flow 
cytometry measurements. Interestingly, the entry of clearly R5-tropic viruses turned out to be 
much more sensitive than the CCR5-staining. A titration of a clearly R5-tropic strain down to 
very low CCR5-induction levels in direct comparison to co-receptor detection in flow cytometry 
could add to the answer of sensitivity.  
Application of the Affinofile cell line is limited by the low expression level of the second 
major co-receptor, CXCR4. This resulted in low overall entry efficiencies of X4-dependent virus 
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variants, decreasing the effective range of observation. Therefore, the dependencies of those 
clones need to be evaluated further with higher virus inputs. In addition, the low expression level 
of CXCR4 also abolished the evaluation of its expression on the single cell level. Both read-out 
methods used, flow cytometry as well as the microscopic assay, rely on antibody recognition of 
the respective cellular surface molecules. Specific CXCR4-antibody binding to cells was below 
the detection limit in the microscopic assay and hence no direct evaluation of CXCR4 levels can 
be extracted from these single-cell data. To compensate for this, the Affinofile cells will be 
assigned a mean CXCR4-expression level based on the quantitative bulk FACS-measurements. 
Another possibility would be to establish a high-throughput FACS-based assay for the adherent 
Affinofile cell line, preferentially using a 96-well device.  
Another way to circumvent the low CXCR4-expression on Affinofile cells is the use of 
another cell line. In this regard, the T-cell lines used in this study represent a valuable addition to 
the spectrum of data generated. The major cause why we initially decided to use the inducible 
Affinofile cell line system was the lack of a comparable variable system in T-cell lines. To be able 
to distinguish viruses with different tropisms, we used T-cell line pairs originally negative for 
CCR5 and only rendered CCR5+ upon stable transfection. Although this strategy allowed 
comparing virus entry in presence and absence of CCR5, an identical cellular background is not 
given in this system. Upon transfection of the CCR5-expression plasmid, the parental cell line 
had to be put under selective pressure to select for clones stably expressing the desired co-
receptor. This procedure, as well as individual adaptations of the individual cell lines could lead 
to small but significant effects on the evaluation of entry efficiency. This becomes evident when 
comparing the different CD4 expression level of C8166-R5 cells in comparison to the parental cell 
line, C8166 (compare Fig. 3.25). The advantage of the Affinofile cell line becomes obvious in this 
regard: the same pool of cells is seeded and will only be induced to express different levels of the 
desired receptor and co-receptor. However, the presence of inducing agents could also influence 
the cell’s behaviour, as can be seen by the slightly altered CXCR4 levels under different induction 
conditions. Effects of these agents on the expression of the marker protein, GFP, have not been 
studied, but could also pose a possible interference. In addition, the presence of the inducing 
agent could in theory also interfere with the entry efficiency of viruses per se. This could be 
investigated by monitoring entry efficiency of a CD4- and CCR5-independent virus, such as 
VSVpp. This could rule out possible general effects of the inducing agents, although a final 
conclusion concerning HIV-1 entry cannot be drawn from this.  
In this regard, the T-cell lines used again have an advantage over the Affinofile system. 
These cells, although being cell lines as well, are closer to the physiological target cells of HIV-1, 
primary T-cells. The cell culture system mimicking a physiological infection even better are 
freshly isolated human primary blood mononuclear cells (PBMC). These cells have already been 
used in initial experiments. However, the degrees of freedom increase with such a variable 
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system. Thus, the inclusion of PBMCs, which always pose a mixture of subpopulations of cells, 
will only be considered at a later stage of this project. To circumvent donor variations in CD4+ 
percentages, CD4+ enriched cell populations could also be used. 
4.2.1.2 Systems to monitor entry efficiency 
I made use of two different systems to monitor entry efficiencies of the diverse viral 
variants in this study. The BlaM assay proved to be a very useful tool in this, since it exclusively 
measures cytosolic entry of viruses [35]. If analysed by flow cytometry, it allows for single-cell 
data and the parallel surface staining of several cellular molecules. This strategy therefore allows 
extracting several parameters at once from every single cell: cell entry, CD4-, CCR5-, and 
CXCR4-levels. Furthermore, by combination of the raw fluorescence read-out and quantitative 
measurements of bulk receptor levels, the calculation of approximate numbers of receptor 
molecules on the single cell level is possible.  
Due to very high background levels, the BlaM assay was not applicable for the Affinofile 
cell line. This high cellular background signal most likely stems from the stable transfection of 
four plasmids into those cells. β-Lactamase is a bacterial protein that confers resistance to 
antibiotics by cleaving the β-lactam ring of e.g. ampicillin. It is thus encoded in every plasmid 
harbouring the ampr gene for bacterial selection. Although the gene is usually inserted in antisense 
orientation in relation to the gene of interest on eukaryotic expression vectors and is driven from 
a prokaryotic promoter, there could be leaky expression as described in early studies of 
bacteriophage expression in mammalian cells [149]. Also, random integration of the plasmid 
DNA could lead to the positioning of the bacterial gene downstream of a mammalian promoter 
and hence lead to gene expression of the β-Lactamase gene. I tried to deactivate the intrinsic β-
Lactamase in Affinofile cells by incubation at elevated temperatures. This markedly decreased the 
intrinsic BlaM signal in these cells and allowed the detection of a virus-delivered heat-stable β-
Lactamase [88]. However, the heat-treatment interfered with the controlled detection of fusion-
dependent signals, as also Env(-) particles were able to deliver the heat-stable β-Lactamase. 
Therefore, this system cannot be used.  
Due to this, another technique was sought to easily monitor entry efficiencies. The GFP-
transduction system proved as a very useful tool in this regard. Although this assay does not 
exclusively measure cytosolic entry of the virus but relies on the expression of a marker protein, it 
has widely been used to study the entry of different viruses into their host cells. Results obtained 
with this method showed higher entry efficiencies in Affinofile cells than on the two tested T-cell 
lines. This might reflect the entry efficiency, but could also be an artefact of higher expression 
from the gfp reporter gene in Affinofile cells. Comparing the entry efficiency of similar virus input 
on the T-cell line in the BlaM assay versus GFP-transduction would strengthen this point, but a 
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clear correlation is hard to be made due to different virus preps used. A combination of both 
systems by incorporation of Vpr.BlaM into the GFP-transducing vector particles would allow a 
direct correlation of this issue, though.  
The microscopic assay established in this study allows the quantitative investigation of the 
relationship between entry efficiency and the expression of receptor and co-receptor molecules on 
the single cell level. The key step in this assay possibly is the segmentation of single cell bodies. 
This step has been shown to be possible for example on actin staining of cells (K. Börner & Ch. 
Sommer, personal communication). This additional staining step however would slow down the 
complete procedure of this method by requiring more processing time of the sample, 
accompanied by the possible loss of cells due to additional washing steps, and the recording of 
additional images which also implies the usage of additional filter sets not interfering with the 
original microscopy. To circumvent this, the segmentation process was adapted to the already 
existent cell surface stainings for receptor and co-receptor. In a setup with different induction 
conditions, the lack of expression of either of those receptors poses a hurdle for proper 
segmentation in this channel. Thus, a maximum projection of both channels was used as the 
segmentation input. With this, the lack of a strong signal in one of the two channels could be 
compensated.  
 
In this study, only entry efficiency of cell-free virus was taken into account. Viruses of 
several families, including HIV-1, have been shown to use direct transmission routes from cell to 
cell [206]. For HIV-1, the most prominent way to do so is via the formation of a so-called 
virological synapse (VS). This area of cell-cell contact between an infected cell and an uninfected 
target cell is enriched in receptor and co-receptor molecules on the target cell side as well as Env 
protein at the surface of the infected cell. Cells are held in close contact by interactions of cellular 
surface molecules as well as Env-receptor interactions [106, 107]. This method of spread is much 
more efficient than cell-free virus infection; reports range from 1 to 4 orders of magnitude [38, 
217] and is thought to play a crucial role in in vivo infection. The possibility to inhibit this cell-to-
cell spread by entry inhibitors has been discussed controversially. However, a recent report 
showed the accessibility of even preformed VS to a broad range of entry inhibitors, including T20 
and two co-receptor antagonists [146]. A minor preference of cell-free virus entry inhibition was 
found with the CCR5-antagonist TAK 779 resulting in a slightly shifted dose-response curve, 
while no significant difference in IC50 values was observed. The fact that in this study, free virions 
were found within the gap between both cells engaged in the VS argues in favour of similar 
overall entry mechanisms for both transmission routes, cell-free versus cell-to-cell spread.  
Another issue that has been discussed in regard to sensitivity towards entry inhibitors is 
the involvement of endocytic entry for HIV-1, which has recently been proposed to be the 
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predominant route of entry [152]. Regardless of the route of entry, many years of research have 
clearly validated the necessity of the HIV-1 Env protein in the entry process. It has been 
speculated that entry via the endocytic route may prevent the accessibility of entry inhibitors to 
the site of entry. In vivo, the drug will however be present before encounter of virus and 
uninfected cell – no matter if the transmission will occur via cell-free virus or cell-to-cell spread. 
To mimic this scenario, we preincubated cells with the respective drug before the addition of 
virus. With this, the simultaneous uptake of drug and virus into endosomes which may lead to 
productive infection is enabled. The influence of endocytosis on virus entry should nevertheless 
be considered. Unspecific uptake of virus may end in an unproductive dead-end. The amount of 
unspecific binding and uptake is a cell-type dependent feature (compare 3.1.3.1), thus introducing 
possible differences between the systems used here and the in vivo situation. In SupT1-R5 cells, 
the CD4- and Env-dependence of viral endocytosis suggests a specific entry mechanism via this 
route (N. Herold, personal communication), whereas other cell lines have been shown to display 
massive unspecific particle uptake. The thereby created difference of virus available for specific 
interactions could lead to a difference in entry efficiency and should be included if data of 
different cell types are compared.  
4.2.2 Evaluation of the selected V3-loop variants 
The V3-loop is, as its name implies, a highly variable sequence within the HIV-1 Env 
protein. During the course of an infection, the virus evolves very quickly to escape immune 
recognition and potential antiviral treatment. Variations in nucleotide sequences are mostly 
acquired by random errors of the viral reverse transcriptase lacking a proof-reading function 
[196]. However, exogenous sequences originating from the host cell genome can be incorporated 
into the viral genome, as described by a recent study where a 15 bp insertion from the gene of a 
transcription factor into the V3-loop sequence resulted in a co-receptor switch of the respective 
virus variant [245]. Even smaller changes in the V3-loop can change the tropism of the virus 
carrying it, which makes this short sequence an optimal target for variation when studying virus 
tropism.  
In this work, the selection process of the V3-loop variants was conducted based on the 
comparison of the outcome of several prediction tools in combination with the reported SI/NSI-
phenotype of the original patient’s sample the sequences were obtained from. The selection from 
this pool of samples could be viewed as biased per se. All samples were sequenced from frozen 
stocks of virus supernatant of the co-culturing of primary isolates from patients with uninfected 
PBMCs. It has been reported that X4-tropic viruses can be expanded in vitro more easily than R5-
variants, leading to a bias towards more X4-tropic clones. Samples from patients with exclusively 
R5-tropic variants may not have spread in the cell culture in the first place. An additional factor 
would be the outgrowth of minority X4-tropic populations under those uncontrolled conditions. 
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No means to prevent this have been available at the time of collection (1986 until 1989). If 
samples would be collected today, the viral sequences could be obtained directly from patient’s 
plasma without any intermediate in vitro expansion step. This bias in X4-selectivity was also 
clearly reflected in the fact that the majority of primary samples showed an SI phenotype (63/94).  
 
The set of V3-loops used for this analysis nevertheless lead to an interesting panel of 
results. Tab. 4.1 summarizes the initial prediction as well as the experimental outcome for all 
individual clones. Taken together, these results led to the conclusion regarding the true tropism 
shown at the end of the table.  
Tab. 4.1: Summary of selected variants. Prediction outcome, entry efficiency, sensitivity to MVC and 
conclusion of tropism drawn from all data are depicted for the individual clones. g2p = 
geno2pheno[coreceptor], FPR = false positive rate at which prediction would switch to X4 in g2p, PSSM = 
webPSSM, 11/25 = charge rule, SI/NSI = phenotype. Entry efficiencies are indicated by symbols with 
different margins for the different cell lines. C8166 and C8166-R5: -<0.2 %, (+)<0.5 %, +>0.5 %, ++>5 %; 
SupT1-R5: -<2 %, +<10 %, ++>10 %; Affinofile: -<1 %, (+)<5 %, +<20 %, ++<50 %, +++>50 %. n.d. = 
not determined.  
In summary, all clearly R5-predicted clones were shown to behave as predicted, whereas 
the X4-prediction was much less accurate. Only the standard clone NL4-3 as well as one selected 
variant, X4_7b displayed a clear X4-phenotype after careful investigation.  
One of the clearly X4-predicted clones (X4_C3) was shown to be wrongly predicted and 
displayed a clear R5-tropism instead. Evaluation of the factors that led to the wrong classification 
of this clone with all available prediction programs despite the very clear in vitro phenotype will 
be very interesting. The counter-intuitive SI-phenotype could easily be explained by the existence 
of X4-tropic variants within the patient’s quasispecies [200]. Deep-sequencing of this patient’s 
sample and retesting several clonal V3-loop sequences in our assay system could therefore be 
interesting.  
The case of variant X4_C26 is particularly interesting, as the viruses harbouring this V3-
loop showed an ambiguous behaviour in all experimental setups opposed to the very clear X4-
tropism prediction by all different methods tested. The most possible explanation for the 
displayed phenotype in concordance with the seemingly wrong X4-prediction by the various 
algorithms is the following scenario: The V3-loop present in this variant is capable of utilizing 
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CXCR4 as a co-receptor for entry, hence the prediction algorithms were right with their 
prediction. All of the web-tools available have been trained to distinguish if a sequence would 
hint at the possibility of CXCR4-usage or not. If this possibility exists, the output will be X4-
tropic, while only purely R5-tropic variants will be assigned as such (see also below). Syncitium-
formation with T-cell lines is therefore also an expected phenotype, as the utilized reporter cells 
express this receptor and therefore infected cells will be able to form syncitia with neighbouring 
uninfected cells. If CXCR4 is not present or blocked, this particular V3-loop sequence allows the 
utilization of CCR5 as a co-receptor, as well. Obviously, Affinofile cells express too low CXCR4-
levels on the cell surface to be able to act as a co-recetor for X4_C26. Hence, on these cells the 
entry efficiency is CCR5-dependent. This also explains the lack of sensitivity to AMD-treatment 
on these cells as well as on SupT1-R5 cells (data not shown). MVC on the other hand can 
efficiently block the only remaining alternative for X4_C26 to enter into Affinofile cells, whereas 
the virus will still utilize CXCR4 on MVC-treated T-cell lines. For this clone, it would be of 
particular interest to establish the dependence towards combinations of both drugs on T-cell lines 
expressing both co-receptors.  
Whereas two variants that had been ambiguously predicted turned out to be clearly R5-
tropic (X4_25a and X4_36b), X4_C15 did not show significant entry in any of the systems tested. 
Therefore, a problem of this variant seems to be very likely. In the light of the way that all 
sequences were obtained, this is nevertheless not easily understood. The V3-loop sequence of this 
variant, as well as all other sequences used in this study, was amplified from a coculture of 
patient’s sample with PBMCs. Hence, this particular V3-loop sequence must have existed in the 
patient’s sample and most likely also to a high extend, given the clonal sequence obtained from 
this amplification. Sequencing of the whole env gene of this variant could maybe give a clue 
whether just the combination of this particular V3-loop with the gp120 backbone of NL4-3 is 
defective.  
4.2.2.1 Overrepresentation of R5-tropism 
The fact that the majority of sequences were found to display an R5-tropic phenotype 
after careful examination is in the range of expectations. R5-tropic variants have been shown to 
be transmitted between infected individuals in the majority of cases [16]. This is in line with 
current tropism-testing, where 85 % of all viral sequences in patients that are treatment-naïve 
were R5-tropic [39]. Even in treatment-experienced individuals, this number only went down to 
56 %. However, if cultured in vitro, X4-tropic variants have an advantage over R5-tropic strains. 
This fact most likely explains the overrepresentation of SI-phenotypes in the pool of sequences in 
the first place. However, some of these variants with SI-phenotype were shown to harbour an R5-
tropism.  
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4.2.2.2 Overrepresentation of X4-prediction 
A discrepancy between more sequences in our selection being predicted to be X4-tropic 
and more of those variants displaying a clear R5-tropic phenotype in the experimental systems 
was observed in this study. All available co-receptor prediction algorithms have been developed 
in respect to the introduction of CCR5-co-receptor antagonists into the market. Due to the 
concurrence of disease progression and the emergence of X4-tropic variants [143], one goal 
during therapy with this new drug has been to avoid a shift of R5- to X4-tropism of the patient’s 
virus population. Resistance development has been shown to mainly occur through the 
outgrowth of pre-existing minor populations of X4-tropic variants [134], and hence an emphasis 
has been made on avoiding the administration of the R5-antagonist in the presence of X4-tropic 
viruses within the patient. A positive treatment outcome has also been linked to the exclusive 
existence of R5-tropic viruses in the patient’s quasispecies at baseline [86, 89]. Thus, prediction 
programs have been designed to detect X4-tropic variants with a high accuracy, therefore taking 
the risk of misinterpretation of possible R5-tropic variants. This tendency is reflected in the quite 
stringent recommendations to use the co-receptor tropism prediction program 
geno2pheno[coreceptor]. The German recommendations that are currently in effect [235] suggest a 
false positive rate (FPR) of 20 % for patient’s with other treatment options. This translates into 
20 % of R5-tropic sequences to be falsely predicted as X4-tropic. For patients with strongly 
limited treatment options they recommend a FPR of 12.5 % and an additional phenotypic assay 
is advised. However, the web-tool also displays the FPR at which a switch from X4- to R5-tropic 
prediction would occur as a measure of accuracy of the prediction. This actual FPR was given as 
1.7 % for the wrongly predicted clone X4_C3, which would be interpreted as a very good 
prediction of X4-tropism. Nevertheless, the FPR for the two clones that proved to be X4-tropic in 
all experimental systems, X4_7b and the standard NL4-3, had FPRs below 1 % (0.2 and 0.7 %, 
respectively). No clone that had been predicted to be R5-tropic proved to be X4-tropic in the end. 
This displays the high emphasis on safety of theses algorithms, while it clearly shows that there 
might be more room for specificity. The overrepresentation of X4-prediction in this study is in 
contrast to another report, where the overrepresentation of R5-prediction of clinical isolates was 
described [141]. Low and colleagues reported the tropism misinterpretation of primary clinical 
isolates by genotypic methods in contrast to phenotypic assays. The major difference to this study 
is the used of bulk sequencing data, whereas we applied the prediction algorithms on single clonal 
data.  
In regard to the SI/NSI phenotype of the variants selected, some inconsistencies have 
been unravelled as well. The two clones X4_C3 and X4_25a have been reported to show an SI 
phenotype. Nevertheless, they clearly proved to be dependent on CCR5 as a co-receptor, hence a 
NSI phenotype would rather be expected. The weakness of this early phenotyping scheme clearly 
is the biased read-out. The judgement is based solely on visual inspection of T-cell lines 
Discussion 
119 
cocultured with cells infected with the patient’s virus sample. The inherent possibility of 
misjudgement is obvious, as the phenotype itself is not restricted to virus infected cells alone. The 
spontaneous formation of syncytia has also been reported. In addition, if cocultured with 
PBMCs, cells from this latter population could be able to form syncytia when infected with R5-
tropic strains, as those primary cells harbour both major co-receptors – at least parts of the 
population. Nevertheless, the expectation would have been to over-interpret the actual number of 
NSI-samples, as the formation of syncytia can sometimes hard to be seen. The read-out is 
therefore highly dependent on the person interpreting it, which introduces a wide error margin. 
These data were recorded at the time of sample collection, so a re-evaluation under today’s 
standards would maybe shed more light on this aspect.  
 
Due to the fact that disease progression has been linked to the emergence of X4-tropic 
variants during the course of HIV-1 infection [143], the prediction of their development is a major 
goal. Mild and colleagues have described the several factors in gp120 that could hint towards the 
development of an X4-shift, including V2-loop length, glycosylation density of gp120 and V3-
loop net charge [150]. By observing longitudinal data, they found that those values can be 
predictive of a R5 population of patient’s isolate to shift to X4 or not. The reduction of net charge 
of the amino acids of the V3-loop was significantly higher in virus of patients that did not display 
an X4-shift over the course of the study (up to 12 years). In our study, the variants shown to be 
able to utilize CXCR4, including the dual tropic variant, all showed net charges of 7 or higher, 
whereas the clearly R5-dependent variants had a mean net charge of 3.3 (scores: arginine and 
lysine = +1, aspartic acid and glutamic acid = -1), which is in line with previous findings [87]. In 
this analysis, clone X4_C3, which acted R5-tropic in our assays shows a relatively high value of 
5, which could hint at a development towards X4-usage and probably explains the wrong initial 
prediction by all genotyping tools.  
 
One of the ambiguously predicted clones that was proven to be R5-tropic in this study 
(X4_36b) could offer some deeper insight into the prediction process. While both web-based tools 
failed to predict the clear R5-tropism, the 11/25 rule as well as the NSI phenotype hinted in this 
direction. Nevertheless, it has been found to be quite far from other R5-sequences in sequence 
space (compare also location in Splitstree analysis, Fig. 3.26), which does not fit to the clear R5-
tropism. A closely related sequence to clone X4_36b was included in the primary sequence pool, 
differing in only one single amino acid. This sequence was predicted R5-tropic by all methods 
used, so a direct comparison of both sequences could be of interest to elucidate why the two web-
based prediction tools failed to correctly classify this sequence. In regard to the distance in 
sequence space, Bozek and colleagues have demonstrated that 98 % of all R5-sequences cluster 
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together [24]. This leads to a very low probability (2 %) that a clone with a V3-loop sequence as 
far in sequence space as X4_36b is truly R5-tropic. Exceptions of this are however observed, 
which can also be appreciated in the Splitstree analysis (Fig. 3.26), where a single blue dot 
(representing a random R5-tropic sequence from the Los Alamos Database) is found spread 
between the far separated red dots (X4-tropic sequences). The authors of the above mentioned 
study also report that sequences which were misclassified by all different genotypic methods were 
found to behave discordant in the sequence space and hence only a very slight improvement of 
prediction outcome could be observed when this analysis was integrated into existing 
classification methods.  
 
4.2.3 Outlook and perspective 
The data presented in this study represent a comprehensive quantitative analysis of the 
dependence of entry efficiency on several factors. The detailed characterization of several 
prototype sequences has been carried out successfully, although some further tests will be needed. 
These comprise mainly the evaluation of drug sensitivity of the individual clones to a greater 
extent. As mentioned above, the evaluation whether the two co-receptor antagonists show 
additive or even cooperative effects on the entry efficiency of the dual-tropic variant X4_C26 will 
be of great interest. Furthermore, the results describing the variants with low overall entry 
efficiencies will be repeated with higher virus input to increase the dynamic range of the 
experiments. On the other hand, transduction of Affinofile cells with R5-tropic variants resulted 
in very high numbers of positive cells. To exclude a masking effect of multiple integration events 
of the reporter virus which could lead to an underestimation of entry efficiency, these 
experiments should be repeated with lower virus input.  
In addition, the correlation of results obtained with the newly established single-cell 
methods with already existing analyses will be crucial. The easiest way to do so will be the 
correlation with the VERSA analysis provided by the Lee lab and already applied to data from 
this study [105]. Comparable sensitivity vectors calculated on the single-cell data could serve as a 
control in reference to the VERSA analysis using bulk data.  
4.2.3.1 Modelling 
The huge amount of data obtained during this study will now be used to calculate 
mathematical models describing the complex relations between the different varied parameters 
and virus entry efficiency. To this end, preliminary models have already been calculated by our 
collaboration partners (K. Bozek, MPI for Computer Sciences, Saarbrücken, Germany). 
Multivariate regression models were used to describe and compare the entry efficiency 
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dependencies of the analyzed clones on the measured parameters. Regression analysis allows 
describing the entry efficiency as a function of the input parameters. Models have been trained on 
two variants with a clear R5- or X4-tropism outcome in all experimental systems. For this 
purpose, R5_C29 and R5_C30 were chosen as clearly R5-tropic, while the standard X4-variant 
NL4-3 and clone X4_7b were chosen as clearly X4-tropic. Vectors of parameter coefficients that 
depict each parameter effect on the cell entry efficiency of the respective model were extracted 
from the trained models. The normalized vectors of these multidimensional models were then 
compared to the normalized coefficient vectors of models trained on the data of all individual 
variants. A clone characteristic is quantified as the correlation between a vector of the given clone 
and vectors of the R5/X4-models. In these initial experimental models, data obtained on SupT1-
R5 cells with the BlaM assay were used and experiments with two MVC-titrations and one 
AMD-titration were taken into account. The dependence of entry efficiency on all three 
monitored cellular molecules, CD4, CXCR4 and CCR5 as well as the drug response was 
included. 
 
 
Fig. 4.1: Correlation of vectors describing 
mathematical models for the individual variants. 
X4 (red) model is trained on variants NL4-3 and 
X4_7b, whereas R5 (blue) is trained on variants 
R5_C29 and R5_C30. Correlation with both standard 
models is shown for distinct models trained on the 
individual variants. The overall correlation of both 
standard models is depicted in the lower left corner.  
 
 
 
Fig. 4.1 depicts the correlation of these normalized vectors to the vectors of the R5- and 
X4- models. The blue and red dots symbolize the R5- and X4-tropic test-models, respectively, 
while all variants are labelled accordingly. A high correlation of a clone vector to a vector of 
either R5- or X4-model indicates similar entry efficiency dependencies. The overall correlation of 
the standard X4- and R5-models was 0.48 in this experiment, which reflects the 
interdependencies of the tropism of clearly defined variants. For example, all of the variants 
tested showed a clear CD4-dependency, which will increase the overall correlation of both 
phenotypes. The inclusion of CD4-independent viral variants could be of interest in this regard. 
Entry efficiency of the simian immunodeficiency virus clone 316 for example has been described 
to be strongly dependent on CCR5 but independent from CD4 [58]. This comparison of models 
for the different variants can help to distinguish between the impact of different factors if they are 
included in the process or not. An observed correlation of CXCR4- and CCR5-staining on cells 
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will have to be evaluated further and the impact of including only one of the co-receptors on the 
modelling outcome will have to be closely examined.  
4.2.3.2 Inclusion of larger parts of Env 
When modelling biological processes by mathematical methods, a lot of presumptions 
have to be made. For exact modelling outcome, all variables of the system have to be defined as 
exactly as possible. This is mostly hampered by the complexity of biological systems, where most 
of the interdependencies are not known, yet, and are therefore hard to take into account. Due to 
this, mathematical models of biological processes are always restricted to the conditions the 
model has been trained on.  
Based on this thought, we decided to keep the variables of our system as small as possible, 
thereby aiming at the most precise mathematical model. On the viral side, we therefore started 
with the variation of a very small proportion of the Env protein, the V3-loop. Although this part 
of Env has been shown to play an essential role in co-receptor tropism [40], other regions of 
gp120 have also been implicated in this regard [176, 195]. Inclusion of the V2-loop for example 
has been reported not to increase the predictive value of co-receptor-tropism, however [24]. The 
probable importance of other Env regions is stressed by a study describing an env sequence with a 
partial V3-loop deletion that retains entry competence by adaptive mutations in both gp120 and 
gp41 [3]. Concerns that the Env backbone used in this study, namely the one of the X4-tropic 
standard clone NL4-3, could lead to a misinterpretation of the effect of the respective V3-loops 
inserted on entry efficiency could be raised. It has been reported that the insertion of an R5 V3-
loop led to an incomplete shift in tropism [97] and the authors reported a role of sequences in 
gp41 to contribute to this phenotype. However, in the present study this does not seem to be very 
likely since most of the variants tested showed an R5-phenotype. If anything, an increase in X4-
tropism would have been assumed. The complete env sequence could nevertheless shed more 
light on the involvement of other regions within the Env protein.  
In this regard, another point from this study could also be important. It was shown here, 
that the amount of Env protein incorporated into viral particles correlated with the entry 
efficiency of the respective virus preparation, although the correlation was found to be associated 
with a high error rate. The importance of Env incorporation is stressed by another report, where 
differential incorporation of Env proteins from different virus isolates into pseudoparticles was 
observed and a correlation with entry efficiency was reported [189]. In conclusion, even if the 
amount of Env/virus is monitored closely and integrated into the calculations, an error will still 
result from pseudotyping. The inclusion of the varying V3-loop sequences into an env-containing 
proviral plasmid would pose a marked increase in reliability of Env-incorporation levels and rule 
out this source of error completely.  
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4.2.3.3 Longitudinal data from patients under MVC treatment and deep-sequencing of patient’s 
samples 
Although the course of HIV-1 infection can efficiently slowed down by the administration 
of HAART, escape of virus populations by resistance mutations is a major issue for successful 
treatment. Those mechanisms cannot easily be predicted, as for example a very unexpected 
resistance pathway has been described for protease inhibitors, where the virus escapes by 
mutation of the protease target sequence (Gag) rather than classical mutations within the active 
site of the enzyme [170]. The analysis of resistance development against the newly introduced co-
receptor antagonist will be of major interest. The cooperation with the Department of Virology in 
Cologne offers the possibility to include longitudinal data from patients under MVC treatment, 
which will provide a useful data set for the quantitative analysis of these processes. Concerning 
this strategy, the possibility of ultra-deep sequencing of patient’s samples will be of major interest. 
With this, the tracking of virus evolution under selective pressure is possible and could add to the 
understanding of resistance development. In particular, sequence variants that display an 
interesting genotype would be selected and tested quantitatively in the systems established here. 
Initial models developed from the data obtained so far will be helpful to decide on features of the 
sequences that could lead to the most insightful results.  
 
The newly emerged field of systems biology is built on the premise that complex 
biological systems consist of several interdependent factors that interact in a non-linear, non-
additive way [128]. This implies the need to look at the whole picture of biological events, rather 
than the separated small parts of them. Complex diseases like cancer are widely being studied by 
systems biology approaches [123]. Viruses are relatively simple organism which makes them 
amenable for the development of mathematical models. Although this study focused on one 
aspect of virus replication and thereby impeded with the non-reductive strategy, we still served 
the idea of systems biology by recording data including simultaneous information on several 
factors on the single cell level. 
References 
124 
5 References 
1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. 
Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus 
in human and nonhuman cells transfected with an infectious molecular clone. J Virol 
59(2):284-91. 
2. Agnello, V., G. Abel, M. Elfahal, G. B. Knight, and Q. X. Zhang. 1999. Hepatitis C 
virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc 
Natl Acad Sci U S A 96(22):12766-71. 
3. Agrawal-Gamse, C., F. H. Lee, B. Haggarty, A. P. Jordan, Y. Yi, B. Lee, R. G. 
Collman, J. A. Hoxie, R. W. Doms, and M. M. Laakso. 2009. Adaptive mutations in a 
human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore 
function by improving interactions with CD4. J Virol 83(21):11005-15. 
4. Albanese, A., D. Arosio, M. Terreni, and A. Cereseto. 2008. HIV-1 pre-integration 
complexes selectively target decondensed chromatin in the nuclear periphery. PLoS One 
3(6):e2413. 
5. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, 
and E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a 
fusion cofactor for macrophage-tropic HIV-1. Science 272(5270):1955-8. 
6. Alter, M. J. 2007. Epidemiology of hepatitis C virus infection. World J Gastroenterol 
13(17):2436-41. 
7. Andre, P., F. Komurian-Pradel, S. Deforges, M. Perret, J. L. Berland, M. Sodoyer, S. 
Pol, C. Brechot, G. Paranhos-Baccala, and V. Lotteau. 2002. Characterization of low- 
and very-low-density hepatitis C virus RNA-containing particles. J Virol 76(14):6919-28. 
8. Arhel, N., A. Genovesio, K. A. Kim, S. Miko, E. Perret, J. C. Olivo-Marin, S. 
Shorte, and P. Charneau. 2006. Quantitative four-dimensional tracking of cytoplasmic 
and nuclear HIV-1 complexes. Nat Methods 3(10):817-24. 
9. Baba, M., O. Nishimura, N. Kanzaki, M. Okamoto, H. Sawada, Y. Iizawa, M. 
Shiraishi, Y. Aramaki, K. Okonogi, Y. Ogawa, K. Meguro, and M. Fujino. 1999. A 
small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 
activity. Proc Natl Acad Sci U S A 96(10):5698-703. 
10. Barre-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, 
C. Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum, and L. 
Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for 
acquired immune deficiency syndrome (AIDS). Science 220(4599):868-71. 
11. Barth, H., C. Schafer, M. I. Adah, F. Zhang, R. J. Linhardt, H. Toyoda, A. 
Kinoshita-Toyoda, T. Toida, T. H. Van Kuppevelt, E. Depla, F. Von Weizsacker, H. 
E. Blum, and T. F. Baumert. 2003. Cellular binding of hepatitis C virus envelope 
glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278(42):41003-12. 
12. Bartosch, B., J. Dubuisson, and F. L. Cosset. 2003. Infectious hepatitis C virus pseudo-
particles containing functional E1-E2 envelope protein complexes. J Exp Med 197(5):633-
42. 
13. Basu, A., T. Kanda, A. Beyene, K. Saito, K. Meyer, and R. Ray. 2007. Sulfated 
homologues of heparin inhibit hepatitis C virus entry into mammalian cells. J Virol 
81(8):3933-41. 
14. Baumert, T. F., S. Ito, D. T. Wong, and T. J. Liang. 1998. Hepatitis C virus structural 
proteins assemble into viruslike particles in insect cells. J Virol 72(5):3827-36. 
15. Berger, E. A., R. W. Doms, E. M. Fenyo, B. T. Korber, D. R. Littman, J. P. Moore, 
Q. J. Sattentau, H. Schuitemaker, J. Sodroski, and R. A. Weiss. 1998. A new 
classification for HIV-1. Nature 391(6664):240. 
16. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 
coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17657-700. 
References 
125 
17. Berlinger, L., P. Rusert, and A. Trkola. 2009. P04-40. Dissecting pre- and post-
attachment activity of HIV-1 entry inhibitors and neutralizing antibodies. Retrovirology 
6(Suppl 3):P68. 
18. Biebricher, C. K., and M. Eigen. 2005. The error threshold. Virus Res 107(2):117-27. 
19. Bieniasz, P. D. 2009. The cell biology of HIV-1 virion genesis. Cell Host Microbe 
5(6):550-8. 
20. Biswas, P., G. Tambussi, and A. Lazzarin. 2007. Access denied? The status of co-
receptor inhibition to counter HIV entry. Expert Opin Pharmacother 8(7):923-33. 
21. Blanchard, E., S. Belouzard, L. Goueslain, T. Wakita, J. Dubuisson, C. Wychowski, 
and Y. Rouille. 2006. Hepatitis C virus entry depends on clathrin-mediated endocytosis. 
J Virol 80(14):6964-72. 
22. Borner, K., J. Hermle, C. Sommer, N. P. Brown, B. Knapp, B. Glass, J. Kunkel, G. 
Torralba, J. Reymann, N. Beil, J. Beneke, R. Pepperkok, R. Schneider, T. Ludwig, 
M. Hausmann, F. Hamprecht, H. Erfle, L. Kaderali, H. G. Krausslich, and M. J. 
Lehmann. 2009. From experimental setup to bioinformatics: An RNAi screening 
platform to identify host factors involved in HIV-1 replication. Biotechnol J. 
23. Bour, S., R. Geleziunas, and M. A. Wainberg. 1995. The human immunodeficiency 
virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. 
Microbiol Rev 59(1):63-93. 
24. Bozek, K., A. Thielen, S. Sierra, R. Kaiser, and T. Lengauer. 2009. V3 loop sequence 
space analysis suggests different evolutionary patterns of CCR5- and CXCR4-tropic HIV. 
PLoS One 4(10):e7387. 
25. Brandenburg, B., L. Y. Lee, M. Lakadamyali, M. J. Rust, X. Zhuang, and J. M. 
Hogle. 2007. Imaging poliovirus entry in live cells. PLoS Biol 5(7):e183. 
26. Brandenburg, B., and X. Zhuang. 2007. Virus trafficking - learning from single-virus 
tracking. Nat Rev Microbiol 5(3):197-208. 
27. Brazzoli, M., A. Bianchi, S. Filippini, A. Weiner, Q. Zhu, M. Pizza, and S. Crotta. 
2008. CD81 is a central regulator of cellular events required for hepatitis C virus infection 
of human hepatocytes. J Virol 82(17):8316-29. 
28. Briggs, J. A., T. Wilk, R. Welker, H. G. Krausslich, and S. D. Fuller. 2003. Structural 
organization of authentic, mature HIV-1 virions and cores. EMBO J 22(7):1707-15. 
29. Brumme, Z. L., J. Goodrich, H. B. Mayer, C. J. Brumme, B. M. Henrick, B. 
Wynhoven, J. J. Asselin, P. K. Cheung, R. S. Hogg, J. S. Montaner, and P. R. 
Harrigan. 2005. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large 
population of antiretroviral-naive individuals. J Infect Dis 192(3):466-74. 
30. Bukrinsky, M. 2004. A hard way to the nucleus. Mol Med 10(1-6):1-5. 
31. Bullough, P. A., F. M. Hughson, J. J. Skehel, and D. C. Wiley. 1994. Structure of 
influenza haemagglutinin at the pH of membrane fusion. Nature 371(6492):37-43. 
32. Burniston, M. T., A. Cimarelli, J. Colgan, S. P. Curtis, and J. Luban. 1999. Human 
immunodeficiency virus type 1 Gag polyprotein multimerization requires the 
nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the 
basic region of matrix protein. J Virol 73(10):8527-40. 
33. Caffrey, M., M. Cai, J. Kaufman, S. J. Stahl, P. T. Wingfield, D. G. Covell, A. M. 
Gronenborn, and G. M. Clore. 1998. Three-dimensional solution structure of the 44 
kDa ectodomain of SIV gp41. EMBO J 17(16):4572-84. 
34. Campbell, E. M., O. Perez, M. Melar, and T. J. Hope. 2007. Labeling HIV-1 virions 
with two fluorescent proteins allows identification of virions that have productively 
entered the target cell. Virology 360(2):286-93. 
35. Cavrois, M., C. De Noronha, and W. C. Greene. 2002. A sensitive and specific 
enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat 
Biotechnol 20(11):1151-4. 
36. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93(5):681-4. 
References 
126 
37. Charneau, P., M. Alizon, and F. Clavel. 1992. A second origin of DNA plus-strand 
synthesis is required for optimal human immunodeficiency virus replication. J Virol 
66(5):2814-20. 
38. Chen, P., W. Hubner, M. A. Spinelli, and B. K. Chen. 2007. Predominant mode of 
human immunodeficiency virus transfer between T cells is mediated by sustained Env-
dependent neutralization-resistant virological synapses. J Virol 81(22):12582-95. 
39. Coakley, E., J. Benhamida, C. Chappey, J. Whitcomb, and colleagues. 2006. An 
evaluation of tropism profiles and other characteristics among 3988 individuals screened 
from A4001026, A4001027 (MOTIVATE 1) and A4001028 (MOTIVATE 2) studies for 
maraviroc. Second International Workshop on Targeting HIV Entry. Boston, MA, USA. 
Oct 20–21 2006. Abstract 8.  
40. Cocchi, F., A. L. DeVico, A. Garzino-Demo, A. Cara, R. C. Gallo, and P. Lusso. 
1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-
mediated blockade of infection. Nat Med 2(11):1244-7. 
41. Coller, K. E., K. L. Berger, N. S. Heaton, J. D. Cooper, R. Yoon, and G. Randall. 
2009. RNA interference and single particle tracking analysis of hepatitis C virus 
endocytosis. PLoS Pathog 5(12):e1000702. 
42. Collman, R., N. F. Hassan, R. Walker, B. Godfrey, J. Cutilli, J. C. Hastings, H. 
Friedman, S. D. Douglas, and N. Nathanson. 1989. Infection of monocyte-derived 
macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and 
lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of 
cell types. J Exp Med 170(4):1149-63. 
43. Coyne, C. B., and J. M. Bergelson. 2006. Virus-induced Abl and Fyn kinase signals 
permit coxsackievirus entry through epithelial tight junctions. Cell 124(1):119-31. 
44. Crabb, C. 2006. GlaxoSmithKline ends aplaviroc trials. AIDS 20(5):641. 
45. Daecke, J., O. T. Fackler, M. T. Dittmar, and H. G. Krausslich. 2005. Involvement of 
clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry. J Virol 
79(3):1581-94. 
46. Day, R. N., and M. W. Davidson. 2009. The fluorescent protein palette: tools for 
cellular imaging. Chem Soc Rev 38(10):2887-921. 
47. De Clercq, E., N. Yamamoto, R. Pauwels, M. Baba, D. Schols, H. Nakashima, J. 
Balzarini, Z. Debyser, B. A. Murrer, D. Schwartz, and et al. 1992. Potent and selective 
inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of 
bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci U S A 
89(12):5286-90. 
48. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. 
Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. 
Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary 
isolates of HIV-1. Nature 381(6584):661-6. 
49. Di Primio, C., D. Arosio, D. Gallo, D. Dylla, G. Cianci, T. J. Hope, and A. 
Cereseto. 2009. Nuclear Trafficking of HIV-1 pre-Integration Complexes in Living Cells. 
34th annual meeting on Retroviruses. Cold Spring Harbor, NY, USA. May 18 - 23 2009.  
50. Dimitrov, A. 2007. Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection. Curr 
Opin Investig Drugs 8(8):653-61. 
51. Doms, R. W., and J. P. Moore. 1997. HIV-1 Coreceptor Use: A Molecular Window 
into Viral Tropism, p. IV-25-36. In B. Korber, C. Brander, B. Haynes, R. Koup, J. Moore, 
and B. Walker (ed.), HIV Molecular Immunology Database 1997. Theoretical Biology 
and Biophysics Group, Los Alamos, NM. 
52. Dong, X., H. Li, A. Derdowski, L. Ding, A. Burnett, X. Chen, T. R. Peters, T. S. 
Dermody, E. Woodruff, J. J. Wang, and P. Spearman. 2005. AP-3 directs the 
intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. Cell 
120(5):663-74. 
 
References 
127 
53. Dorr, P., M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. 
Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. 
Stammen, A. Wood, and M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally 
bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with 
broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents 
Chemother 49(11):4721-32. 
54. Douek, D. C., L. J. Picker, and R. A. Koup. 2003. T cell dynamics in HIV-1 infection. 
Annu Rev Immunol 21265-304. 
55. Dreux, M., B. Boson, S. Ricard-Blum, J. Molle, D. Lavillette, B. Bartosch, E. I. 
Pecheur, and F. L. Cosset. 2007. The exchangeable apolipoprotein ApoC-I promotes 
membrane fusion of hepatitis C virus. J Biol Chem 282(44):32357-69. 
56. Dreux, M., T. Pietschmann, C. Granier, C. Voisset, S. Ricard-Blum, P. E. Mangeot, 
Z. Keck, S. Foung, N. Vu-Dac, J. Dubuisson, R. Bartenschlager, D. Lavillette, and F. 
L. Cosset. 2006. High density lipoprotein inhibits hepatitis C virus-neutralizing 
antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol 
Chem 281(27):18285-95. 
57. Duvet, S., L. Cocquerel, A. Pillez, R. Cacan, A. Verbert, D. Moradpour, C. 
Wychowski, and J. Dubuisson. 1998. Hepatitis C virus glycoprotein complex 
localization in the endoplasmic reticulum involves a determinant for retention and not 
retrieval. J Biol Chem 273(48):32088-95. 
58. Edinger, A. L., J. L. Mankowski, B. J. Doranz, B. J. Margulies, B. Lee, J. Rucker, 
M. Sharron, T. L. Hoffman, J. F. Berson, M. C. Zink, V. M. Hirsch, J. E. Clements, 
and R. W. Doms. 1997. CD4-independent, CCR5-dependent infection of brain capillary 
endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl 
Acad Sci U S A 94(26):14742-7. 
59. Eigen, M., and P. Schuster. 1977. The hypercycle. A principle of natural self-
organization. Part A: Emergence of the hypercycle. Naturwissenschaften 64(11):541-65. 
60. Este, J. A., and A. Telenti. 2007. HIV entry inhibitors. Lancet 370(9581):81-8. 
61. Evans, M. J., T. von Hahn, D. M. Tscherne, A. J. Syder, M. Panis, B. Wolk, T. 
Hatziioannou, J. A. McKeating, P. D. Bieniasz, and C. M. Rice. 2007. Claudin-1 is a 
hepatitis C virus co-receptor required for a late step in entry. Nature 446(7137):801-5. 
62. Fatkenheuer, G., M. Nelson, A. Lazzarin, I. Konourina, A. I. Hoepelman, H. 
Lampiris, B. Hirschel, P. Tebas, F. Raffi, B. Trottier, N. Bellos, M. Saag, D. A. 
Cooper, M. Westby, M. Tawadrous, J. F. Sullivan, C. Ridgway, M. W. Dunne, S. 
Felstead, H. Mayer, and E. van der Ryst. 2008. Subgroup analyses of maraviroc in 
previously treated R5 HIV-1 infection. N Engl J Med 359(14):1442-55. 
63. Fatkenheuer, G., A. L. Pozniak, M. A. Johnson, A. Plettenberg, S. Staszewski, A. I. 
Hoepelman, M. S. Saag, F. D. Goebel, J. K. Rockstroh, B. J. Dezube, T. M. Jenkins, 
C. Medhurst, J. F. Sullivan, C. Ridgway, S. Abel, I. T. James, M. Youle, and E. van 
der Ryst. 2005. Efficacy of short-term monotherapy with maraviroc, a new CCR5 
antagonist, in patients infected with HIV-1. Nat Med 11(11):1170-2. 
64. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: 
functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 
272(5263):872-7. 
65. Fenyo, E. M., L. Morfeldt-Manson, F. Chiodi, B. Lind, A. von Gegerfelt, J. Albert, 
E. Olausson, and B. Asjo. 1988. Distinct replicative and cytopathic characteristics of 
human immunodeficiency virus isolates. J Virol 62(11):4414-9. 
66. Fletcher, C. V. 2003. Enfuvirtide, a new drug for HIV infection. Lancet 361(9369):1577-
8. 
67. Fouchier, R. A., M. Brouwer, S. M. Broersen, and H. Schuitemaker. 1995. Simple 
determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype 
by PCR. J Clin Microbiol 33(4):906-11. 
68. Furuta, R. A., C. T. Wild, Y. Weng, and C. D. Weiss. 1998. Capture of an early 
fusion-active conformation of HIV-1 gp41. Nat Struct Biol 5(4):276-9. 
References 
128 
69. Gaddis, N. C., E. Chertova, A. M. Sheehy, L. E. Henderson, and M. H. Malim. 
2003. Comprehensive investigation of the molecular defect in vif-deficient human 
immunodeficiency virus type 1 virions. J Virol 77(10):5810-20. 
70. Gallo, R. C., S. Z. Salahuddin, M. Popovic, G. M. Shearer, M. Kaplan, B. F. 
Haynes, T. J. Palker, R. Redfield, J. Oleske, B. Safai, and et al. 1984. Frequent 
detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS 
and at risk for AIDS. Science 224(4648):500-3. 
71. Gastaminza, P., S. B. Kapadia, and F. V. Chisari. 2006. Differential biophysical 
properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 
80(22):11074-81. 
72. Gheysen, D., E. Jacobs, F. de Foresta, C. Thiriart, M. Francotte, D. Thines, and M. 
De Wilde. 1989. Assembly and release of HIV-1 precursor Pr55gag virus-like particles 
from recombinant baculovirus-infected insect cells. Cell 59(1):103-12. 
73. Glynn, E. F. 2006. FCSExtract Utility. Stowers Institute for Medical Research. 
http://research.stowers-
institute.org/efg/ScientificSoftware/Utility/FCSExtract/index.htm 
74. Goff, S. P. 2007. Host factors exploited by retroviruses. Nat Rev Microbiol 5(4):253-63. 
75. Goffard, A., N. Callens, B. Bartosch, C. Wychowski, F. L. Cosset, C. Montpellier, 
and J. Dubuisson. 2005. Role of N-linked glycans in the functions of hepatitis C virus 
envelope glycoproteins. J Virol 79(13):8400-9. 
76. Gosert, R., D. Egger, V. Lohmann, R. Bartenschlager, H. E. Blum, K. Bienz, and D. 
Moradpour. 2003. Identification of the hepatitis C virus RNA replication complex in 
Huh-7 cells harboring subgenomic replicons. J Virol 77(9):5487-92. 
77. Gottwein, J. M., T. K. Scheel, T. B. Jensen, J. B. Lademann, J. C. Prentoe, M. L. 
Knudsen, A. M. Hoegh, and J. Bukh. 2009. Development and characterization of 
hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor 
class B type I and effect of antiviral drugs. Hepatology 49(2):364-77. 
78. Gould, S. J., A. M. Booth, and J. E. Hildreth. 2003. The Trojan exosome hypothesis. 
Proc Natl Acad Sci U S A 100(19):10592-7. 
79. Gousset, K., S. D. Ablan, L. V. Coren, A. Ono, F. Soheilian, K. Nagashima, D. E. 
Ott, and E. O. Freed. 2008. Real-time visualization of HIV-1 GAG trafficking in 
infected macrophages. PLoS Pathog 4(3):e1000015. 
80. Grewe, C., A. Beck, and H. R. Gelderblom. 1990. HIV: early virus-cell interactions. J 
Acquir Immune Defic Syndr 3(10):965-74. 
81. Gu, M., J. Rappaport, and S. H. Leppla. 1995. Furin is important but not essential for 
the proteolytic maturation of gp160 of HIV-1. FEBS Lett 365(1):95-7. 
82. Habermann, A., J. Krijnse Locker, H. Oberwinkler, M. Eckhardt, S. Homann, A. 
Andrew, K. Strebel, and H. G. Krausslich. 2010. CD317/Tetherin is Enriched in the 
HIV-1 Envelope and Downregulated from the Plasma Membrane upon Virus Infection. J 
Virol[Epub ahead of print: 2010/02/12]. 
83. Hallenberger, S., M. Moulard, M. Sordel, H. D. Klenk, and W. Garten. 1997. The 
role of eukaryotic subtilisin-like endoproteases for the activation of human 
immunodeficiency virus glycoproteins in natural host cells. J Virol 71(2):1036-45. 
84. Haller, C., S. Rauch, N. Michel, S. Hannemann, M. J. Lehmann, O. T. Keppler, and 
O. T. Fackler. 2006. The HIV-1 pathogenicity factor Nef interferes with maturation of 
stimulatory T-lymphocyte contacts by modulation of N-Wasp activity. J Biol Chem 
281(28):19618-30. 
85. Hammonds, J., J. J. Wang, H. Yi, and P. Spearman. 2010. Immunoelectron 
microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions 
and the plasma membrane. PLoS Pathog 6(2):e1000749. 
 
 
References 
129 
86. Hardy, D., J. Reynes, I. Konourina, D. wheeler, S. Moreno, E. van der Ryst, W. 
Towner, A. Horban, H. Mayer, and J. Goodrich. 2008. Efficacy and Safety of 
Maraviroc plus Optimized Background Therapy in Treatment-experienced Patients 
Infected with CCR5-Tropic HIV-1: 48-Week Combined Analysis of the MOTIVATE 
Studies. 15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, 
MA, USA. February 3-6 2008. Abstract 792.  
87. Hartley, O., P. J. Klasse, Q. J. Sattentau, and J. P. Moore. 2005. V3: HIV's switch-
hitter. AIDS Res Hum Retroviruses 21(2):171-89. 
88. Hecky, J., and K. M. Muller. 2005. Structural perturbation and compensation by 
directed evolution at physiological temperature leads to thermostabilization of beta-
lactamase. Biochemistry 44(38):12640-54. 
89. Heera, J., M. Saag, P. Ive, J. Whitcomb, M. Lewis, L. McFadyen, J. Goodrich, H. 
Mayer, E. van der Ryst, and M. Westby. 2008. Virological Correlates Associated with 
Treatment Failure at Week 48 in the Phase 3 Study of Maraviroc in Treatment-Naive 
Patients. 15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, 
MA, USA. February 3–6 2008. Abstract 40LB.  
90. Hell, S. W., and J. Wichmann. 1994. Breaking the diffraction resolution limit by 
stimulated emission: stimulated-emission-depletion fluorescence microscopy. Opt Lett 
19(11):780-2. 
91. Hendrix, C. W., A. C. Collier, M. M. Lederman, D. Schols, R. B. Pollard, S. Brown, 
J. B. Jackson, R. W. Coombs, M. J. Glesby, C. W. Flexner, G. J. Bridger, K. Badel, 
R. T. MacFarland, G. W. Henson, and G. Calandra. 2004. Safety, pharmacokinetics, 
and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 
infection. J Acquir Immune Defic Syndr 37(2):1253-62. 
92. Hermida-Matsumoto, L., and M. D. Resh. 2000. Localization of human 
immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal 
imaging. J Virol 74(18):8670-9. 
93. Hildinger, M., M. T. Dittmar, P. Schult-Dietrich, B. Fehse, B. S. Schnierle, S. 
Thaler, G. Stiegler, R. Welker, and D. von Laer. 2001. Membrane-anchored peptide 
inhibits human immunodeficiency virus entry. J Virol 75(6):3038-42. 
94. Hildreth, J. E., and R. J. Orentas. 1989. Involvement of a leukocyte adhesion receptor 
(LFA-1) in HIV-induced syncytium formation. Science 244(4908):1075-8. 
95. Hoxie, J. A., C. C. LaBranche, M. J. Endres, J. D. Turner, J. F. Berson, R. W. 
Doms, and T. J. Matthews. 1998. CD4-independent utilization of the CXCR4 
chemokine receptor by HIV-1 and HIV-2. J Reprod Immunol 41(1-2):197-211. 
96. Huang, B., M. Bates, and X. Zhuang. 2009. Super-resolution fluorescence microscopy. 
Annu Rev Biochem 78993-1016. 
97. Huang, W., J. Toma, S. Fransen, E. Stawiski, J. D. Reeves, J. M. Whitcomb, N. 
Parkin, and C. J. Petropoulos. 2008. Coreceptor tropism can be influenced by amino 
acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus 
type 1 envelope protein. J Virol 82(11):5584-93. 
98. Hubner, W., P. Chen, A. Del Portillo, Y. Liu, R. E. Gordon, and B. K. Chen. 2007. 
Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and 
oligomerization monitored with live confocal imaging of a replication-competent, 
fluorescently tagged HIV-1. J Virol 81(22):12596-607. 
99. Huson, D. H. 1998. SplitsTree: analyzing and visualizing evolutionary data. 
Bioinformatics 14(1):68-73. 
100. Iro, M., J. Witteveldt, A. G. Angus, I. Woerz, A. Kaul, R. Bartenschlager, and A. H. 
Patel. 2009. A reporter cell line for rapid and sensitive evaluation of hepatitis C virus 
infectivity and replication. Antiviral Res 83(2):148-55. 
101. Ivanchenko, S., W. J. Godinez, M. Lampe, H. G. Krausslich, R. Eils, K. Rohr, C. 
Brauchle, B. Muller, and D. C. Lamb. 2009. Dynamics of HIV-1 assembly and release. 
PLoS Pathog 5(11):e1000652. 
References 
130 
102. Jacobson, J. M., D. R. Kuritzkes, E. Godofsky, E. DeJesus, J. A. Larson, S. P. 
Weinheimer, and S. T. Lewis. 2009. Safety, pharmacokinetics, and antiretroviral 
activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal 
antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents 
Chemother 53(2):450-7. 
103. Jäger, S. 2008. HIV-1 Gag Ubiquitination and the Role of ESCRT Factors in Retroviral 
Release. PhD Thesis. University of Heidelberg, Heidelberg, Germany. 
104. Jensen, M. A., F. S. Li, A. B. van 't Wout, D. C. Nickle, D. Shriner, H. X. He, S. 
McLaughlin, R. Shankarappa, J. B. Margolick, and J. I. Mullins. 2003. Improved 
coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif 
analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 
77(24):13376-88. 
105. Johnston, S. H., M. A. Lobritz, S. Nguyen, K. Lassen, S. Delair, F. Posta, Y. J. 
Bryson, E. J. Arts, T. Chou, and B. Lee. 2009. A quantitative affinity-profiling system 
that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus 
type 1 and simian immunodeficiency virus strains. J Virol 83(21):11016-26. 
106. Jolly, C., K. Kashefi, M. Hollinshead, and Q. J. Sattentau. 2004. HIV-1 cell to cell 
transfer across an Env-induced, actin-dependent synapse. J Exp Med 199(2):283-93. 
107. Jolly, C., I. Mitar, and Q. J. Sattentau. 2007. Adhesion molecule interactions facilitate 
human immunodeficiency virus type 1-induced virological synapse formation between T 
cells. J Virol 81(24):13916-21. 
108. Jones, C. T., M. T. Catanese, L. M. Law, S. R. Khetani, A. J. Syder, A. Ploss, T. S. 
Oh, J. W. Schoggins, M. R. MacDonald, S. N. Bhatia, and C. M. Rice. 2010. Real-
time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. 
Nat Biotechnol 28(2):167-71. 
109. Jouvenet, N., P. D. Bieniasz, and S. M. Simon. 2008. Imaging the biogenesis of 
individual HIV-1 virions in live cells. Nature 454(7201):236-40. 
110. Kabat, D., S. L. Kozak, K. Wehrly, and B. Chesebro. 1994. Differences in CD4 
dependence for infectivity of laboratory-adapted and primary patient isolates of human 
immunodeficiency virus type 1. J Virol 68(4):2570-7. 
111. Kamradt, T., D. Niese, K. E. Schneweis, H. H. Brackmann, B. Kamps, B. van Loo, 
and U. Hammerstein. 1989. Natural history of HIV-infection in hemophiliacs: clinical, 
immunological, and virological findings. Klin Wochenschr 67(20):1033-41. 
112. Karlsson Hedestam, G. B., R. A. Fouchier, S. Phogat, D. R. Burton, J. Sodroski, and 
R. T. Wyatt. 2008. The challenges of eliciting neutralizing antibodies to HIV-1 and to 
influenza virus. Nat Rev Microbiol 6(2):143-55. 
113. Keppler, A., S. Gendreizig, T. Gronemeyer, H. Pick, H. Vogel, and K. Johnsson. 
2003. A general method for the covalent labeling of fusion proteins with small molecules 
in vivo. Nat Biotechnol 21(1):86-9. 
114. Keppler, A., M. Kindermann, S. Gendreizig, H. Pick, H. Vogel, and K. Johnsson. 
2004. Labeling of fusion proteins of O6-alkylguanine-DNA alkyltransferase with small 
molecules in vivo and in vitro. Methods 32(4):437-44. 
115. Keppler, A., H. Pick, C. Arrivoli, H. Vogel, and K. Johnsson. 2004. Labeling of fusion 
proteins with synthetic fluorophores in live cells. Proc Natl Acad Sci U S A 101(27):9955-
9. 
116. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. 
Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. 
A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication 
in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 
4(11):1302-7. 
117. Koch, P., M. Lampe, W. J. Godinez, B. Muller, K. Rohr, H. G. Krausslich, and M. 
J. Lehmann. 2009. Visualizing fusion of pseudotyped HIV-1 particles in real time by live 
cell microscopy. Retrovirology 684. 
References 
131 
118. Koch, P., M. J. Lehmann, and H. G. Krausslich. 2010. Triple labelled pseudotyped 
HIV-1 particles to visualize fusion by live cell microscopy. Department of Infectious 
Diseases, Virology, Heidelberg, Germany. Unpublished work.  
119. Koot, M., I. P. Keet, A. H. Vos, R. E. de Goede, M. T. Roos, R. A. Coutinho, F. 
Miedema, P. T. Schellekens, and M. Tersmette. 1993. Prognostic value of HIV-1 
syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. 
Ann Intern Med 118(9):681-8. 
120. Koot, M., A. H. Vos, R. P. Keet, R. E. de Goede, M. W. Dercksen, F. G. Terpstra, 
R. A. Coutinho, F. Miedema, and M. Tersmette. 1992. HIV-1 biological phenotype in 
long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 6(1):49-
54. 
121. Koutsoudakis, G., E. Herrmann, S. Kallis, R. Bartenschlager, and T. Pietschmann. 
2007. The level of CD81 cell surface expression is a key determinant for productive entry 
of hepatitis C virus into host cells. J Virol 81(2):588-98. 
122. Koutsoudakis, G., A. Kaul, E. Steinmann, S. Kallis, V. Lohmann, T. Pietschmann, 
and R. Bartenschlager. 2006. Characterization of the early steps of hepatitis C virus 
infection by using luciferase reporter viruses. J Virol 80(11):5308-20. 
123. Kreeger, P. K., and D. A. Lauffenburger. 2010. Cancer systems biology: a network 
modeling perspective. Carcinogenesis 31(1):2-8. 
124. Kruger, U., T. Pfeiffer, and V. Bosch. 1996. Generation of lymphocyte cell lines 
coexpressing CD4 and wild-type or mutant HIV type 1 glycoproteins: implications for 
HIV type 1 Env-induced cell lysis. AIDS Res Hum Retroviruses 12(9):783-92. 
125. Kuhn, R. J., W. Zhang, M. G. Rossmann, S. V. Pletnev, J. Corver, E. Lenches, C. T. 
Jones, S. Mukhopadhyay, P. R. Chipman, E. G. Strauss, T. S. Baker, and J. H. 
Strauss. 2002. Structure of dengue virus: implications for flavivirus organization, 
maturation, and fusion. Cell 108(5):717-25. 
126. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. 
Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with 
the CD4 receptor and a neutralizing human antibody. Nature 393(6686):648-59. 
127. Lampe, M., J. A. Briggs, T. Endress, B. Glass, S. Riegelsberger, H. G. Krausslich, D. 
C. Lamb, C. Brauchle, and B. Muller. 2007. Double-labelled HIV-1 particles for study 
of virus-cell interaction. Virology 360(1):92-104. 
128. Laubenbacher, R., V. Hower, A. Jarrah, S. V. Torti, V. Shulaev, P. Mendes, F. M. 
Torti, and S. Akman. 2009. A systems biology view of cancer. Biochim Biophys Acta 
1796(2):129-39. 
129. Lehmann, M. J., N. M. Sherer, C. B. Marks, M. Pypaert, and W. Mothes. 2005. 
Actin- and myosin-driven movement of viruses along filopodia precedes their entry into 
cells. J Cell Biol 170(2):317-25. 
130. Leitner, T., B. Foley, B. Hahn, P. Marx, F. McCutchan, J. Mellors, S. Wolinsky, and 
B. Korber (ed.). 2005. HIV Sequence Compendium 2005. Theoretical Biology and 
Biophysics Group, Los Alamos National Laboratory. 
131. Lekkerkerker, A. N., Y. van Kooyk, and T. B. Geijtenbeek. 2006. Viral piracy: HIV-1 
targets dendritic cells for transmission. Curr HIV Res 4(2):169-76. 
132. Lengauer, T., O. Sander, S. Sierra, A. Thielen, and R. Kaiser. 2007. Bioinformatics 
prediction of HIV coreceptor usage. Nat Biotechnol 25(12):1407-10. 
133. Leonard, C. K., M. W. Spellman, L. Riddle, R. J. Harris, J. N. Thomas, and T. J. 
Gregory. 1990. Assignment of intrachain disulfide bonds and characterization of 
potential glycosylation sites of the type 1 recombinant human immunodeficiency virus 
envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 
265(18):10373-82. 
 
 
References 
132 
134. Lewis, M., P. Simpson, S. Fransen, W. Huang, J. Whitcomb, M. Mosley, D. L. 
Robertson, R. Mansfield, G. Ciaramella, and M. Westby. 2007. CXCR4-using virus 
detected in patients receiving maraviroc in the Phase III studies MOTIVATE 1 and 2 
originates from a pre-existing minority of CXCR4-using virus. XVI International HIV 
Drug Resistance Workshop. Barbados, West Indies. 12-16 June 2007. Abstract 10.  
135. Liesnard, C., M. L. Delforge, M. Tchetcheroff, V. De Maertelaer, C. M. Farber, and 
J. P. Van Vooren. 1997. Importance of method in the determination of syncytium-
inducing phenotype of human immunodeficiency virus type 1 clinical isolates. J Virol 
Methods 64(2):137-45. 
136. Lifson, J. D., G. R. Reyes, M. S. McGrath, B. S. Stein, and E. G. Engleman. 1986. 
AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 
antigen. Science 232(4754):1123-7. 
137. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. 
Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 
2005. Complete replication of hepatitis C virus in cell culture. Science 309(5734):623-6. 
138. Lippincott-Schwartz, J., and G. H. Patterson. 2003. Development and use of 
fluorescent protein markers in living cells. Science 300(5616):87-91. 
139. Littman, D. R. 1998. Chemokine receptors: keys to AIDS pathogenesis? Cell 93(5):677-
80. 
140. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. 
MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect 
in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-
1 infection. Cell 86(3):367-77. 
141. Low, A. J., W. Dong, D. Chan, T. Sing, R. Swanstrom, M. Jensen, S. Pillai, B. 
Good, and P. R. Harrigan. 2007. Current V3 genotyping algorithms are inadequate for 
predicting X4 co-receptor usage in clinical isolates. AIDS 21(14):F17-24. 
142. Lymperopoulos, K., A. Kiel, A. Seefeld, K. Stohr, and D. P. Herten. 2010. 
Fluorescent probes and delivery methods for single-molecule experiments. 
Chemphyschem 11(1):43-53. 
143. Maas, J. J., S. J. Gange, H. Schuitemaker, R. A. Coutinho, R. van Leeuwen, and J. 
B. Margolick. 2000. Strong association between failure of T cell homeostasis and the 
syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort 
Study. AIDS 14(9):1155-61. 
144. Maddon, P. J., A. G. Dalgleish, J. S. McDougal, P. R. Clapham, R. A. Weiss, and 
R. Axel. 1986. The T4 gene encodes the AIDS virus receptor and is expressed in the 
immune system and the brain. Cell 47(3):333-48. 
145. Marsh, M., and A. Helenius. 2006. Virus entry: open sesame. Cell 124(4):729-40. 
146. Martin, N., S. Welsch, C. Jolly, J. A. Briggs, D. Vaux, and Q. J. Sattentau. 2010. 
Virological synapse-mediated spread of human immunodeficiency virus type 1 between T 
cells is sensitive to entry inhibition. J Virol 84(7):3516-27. 
147. McDonald, D., M. A. Vodicka, G. Lucero, T. M. Svitkina, G. G. Borisy, M. 
Emerman, and T. J. Hope. 2002. Visualization of the intracellular behavior of HIV in 
living cells. J Cell Biol 159(3):441-52. 
148. Meertens, L., C. Bertaux, and T. Dragic. 2006. Hepatitis C virus entry requires a 
critical postinternalization step and delivery to early endosomes via clathrin-coated 
vesicles. J Virol 80(23):11571-8. 
149. Merril, C. R., M. R. Geier, and J. C. Petricciani. 1971. Bacterial virus gene expression 
in human cells. Nature 233(5319):398-400. 
150. Mild, M., A. Kvist, J. Esbjornsson, I. Karlsson, E. M. Fenyo, and P. Medstrand. 
2010. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and 
non-switch (R5-tropic only) HIV-1 populations during infection. Infect Genet Evol 
10(3):356-364. 
References 
133 
151. Miyagi, E., A. J. Andrew, S. Kao, and K. Strebel. 2009. Vpu enhances HIV-1 virus 
release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. 
Proc Natl Acad Sci U S A 106(8):2868-73. 
152. Miyauchi, K., Y. Kim, O. Latinovic, V. Morozov, and G. B. Melikyan. 2009. HIV 
enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 
137(3):433-44. 
153. Miyoshi, I., H. Taguchi, M. Fujishita, K. Niiya, T. Kitagawa, Y. Ohtsuki, and T. 
Akagi. 1982. Asymptomatic type C virus carriers in the family of an adult T-cell leukemia 
patient. Gann 73(2):339-40. 
154. Mondor, I., S. Ugolini, and Q. J. Sattentau. 1998. Human immunodeficiency virus 
type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and 
requires cell surface heparans. J Virol 72(5):3623-34. 
155. Moore, J. P., J. A. McKeating, R. A. Weiss, and Q. J. Sattentau. 1990. Dissociation 
of gp120 from HIV-1 virions induced by soluble CD4. Science 250(4984):1139-42. 
156. Moradpour, D., F. Penin, and C. M. Rice. 2007. Replication of hepatitis C virus. Nat 
Rev Microbiol 5(6):453-63. 
157. Mori, J., M. Lewis, P. Simpson, and colleagues. 2008. Characterization of maraviroc 
resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and 
MOTIVATE2 (24 week analysis). European HIV Drug Resistance Workshop. Budapest, 
Hungary. March 26-28 2008. Abstract 51.  
158. Mori, J., M. Mosley, M. Lewis, P. Simpson, J. Toma, W. Huang, J. Whitcomb, G. 
Ciaramella, and M. Westby. 2007. Characterization of maraviroc resistance in patients 
failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE2. XVI 
International HIV Drug Resistance Workshop: Basic Principles & Clinical Implications. 
Barbados, West Indies. June 12-16 2007. Abstract 10.  
159. Morikawa, K., Z. Zhao, T. Date, M. Miyamoto, A. Murayama, D. Akazawa, J. 
Tanabe, S. Sone, and T. Wakita. 2007. The roles of CD81 and glycosaminoglycans in 
the adsorption and uptake of infectious HCV particles. J Med Virol 79(6):714-23. 
160. Moyle, G. J., E. DeJesus, and M. Boffito. 2007. Presented at the 14th Conference on 
Retroviruses and Opportunistic Infection, Los Angeles, CA, USA, Feb 25–28 2007. 
161. Moyle, G. J., A. Wildfire, S. Mandalia, H. Mayer, J. Goodrich, J. Whitcomb, and B. 
G. Gazzard. 2005. Epidemiology and predictive factors for chemokine receptor use in 
HIV-1 infection. J Infect Dis 191(6):866-72. 
162. Muller, B., J. Daecke, O. T. Fackler, M. T. Dittmar, H. Zentgraf, and H. G. 
Krausslich. 2004. Construction and characterization of a fluorescently labeled infectious 
human immunodeficiency virus type 1 derivative. J Virol 78(19):10803-13. 
163. Murakami, T., and E. O. Freed. 2000. Genetic evidence for an interaction between 
human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic 
tail. J Virol 74(8):3548-54. 
164. Neil, S. J., S. W. Eastman, N. Jouvenet, and P. D. Bieniasz. 2006. HIV-1 Vpu 
promotes release and prevents endocytosis of nascent retrovirus particles from the plasma 
membrane. PLoS Pathog 2(5):e39. 
165. Neil, S. J., T. Zang, and P. D. Bieniasz. 2008. Tetherin inhibits retrovirus release and is 
antagonized by HIV-1 Vpu. Nature 451(7177):425-30. 
166. Nguyen, D. G., A. Booth, S. J. Gould, and J. E. Hildreth. 2003. Evidence that HIV 
budding in primary macrophages occurs through the exosome release pathway. J Biol 
Chem 278(52):52347-54. 
167. Nguyen, D. H., and J. E. Hildreth. 2000. Evidence for budding of human 
immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. 
J Virol 74(7):3264-72. 
168. Nicholson, J. K., S. W. Browning, R. L. Hengel, E. Lew, L. E. Gallagher, D. 
Rimland, and J. S. McDougal. 2001. CCR5 and CXCR4 expression on memory and 
naive T cells in HIV-1 infection and response to highly active antiretroviral therapy. J 
Acquir Immune Defic Syndr 27(2):105-15. 
References 
134 
169. NIH 2010. Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized 
Background Regimen in Patients With HIV-1 (TMB-202). 
http://clinicaltrials.gov/ct2/show/NCT00784147. [Online.] 
170. Nijhuis, M., N. M. van Maarseveen, S. Lastere, P. Schipper, E. Coakley, B. Glass, 
M. Rovenska, D. de Jong, C. Chappey, I. W. Goedegebuure, G. Heilek-Snyder, D. 
Dulude, N. Cammack, L. Brakier-Gingras, J. Konvalinka, N. Parkin, H. G. 
Krausslich, F. Brun-Vezinet, and C. A. Boucher. 2007. A novel substrate-based HIV-1 
protease inhibitor drug resistance mechanism. PLoS Med 4(1):e36. 
171. Oberlin, E., A. Amara, F. Bachelerie, C. Bessia, J. L. Virelizier, F. Arenzana-
Seisdedos, O. Schwartz, J. M. Heard, I. Clark-Lewis, D. F. Legler, M. Loetscher, M. 
Baggiolini, and B. Moser. 1996. The CXC chemokine SDF-1 is the ligand for 
LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382(6594):833-
5. 
172. Obrig, T. G., W. J. Culp, W. L. McKeehan, and B. Hardesty. 1971. The mechanism 
by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on 
reticulocyte ribosomes. J Biol Chem 246(1):174-81. 
173. Ohshiro, Y., T. Murakami, K. Matsuda, K. Nishioka, K. Yoshida, and N. 
Yamamoto. 1996. Role of cell surface glycosaminoglycans of human T cells in human 
immunodeficiency virus type-1 (HIV-1) infection. Microbiol Immunol 40(11):827-35. 
174. Ono, A., S. D. Ablan, S. J. Lockett, K. Nagashima, and E. O. Freed. 2004. 
Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma 
membrane. Proc Natl Acad Sci U S A 101(41):14889-94. 
175. Op De Beeck, A., R. Montserret, S. Duvet, L. Cocquerel, R. Cacan, B. Barberot, M. 
Le Maire, F. Penin, and J. Dubuisson. 2000. The transmembrane domains of hepatitis 
C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization. J Biol 
Chem 275(40):31428-37. 
176. Pastore, C., R. Nedellec, A. Ramos, S. Pontow, L. Ratner, and D. E. Mosier. 2006. 
Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness 
mutations compensate for V3 loss-of-fitness mutations. J Virol 80(2):750-8. 
177. Pegg, A. E. 2000. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 462(2-
3):83-100. 
178. Pelchen-Matthews, A., B. Kramer, and M. Marsh. 2003. Infectious HIV-1 assembles in 
late endosomes in primary macrophages. J Cell Biol 162(3):443-55. 
179. Pelkmans, L., J. Kartenbeck, and A. Helenius. 2001. Caveolar endocytosis of simian 
virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 
3(5):473-83. 
180. Perez-Caballero, D., T. Hatziioannou, J. Martin-Serrano, and P. D. Bieniasz. 2004. 
Human immunodeficiency virus type 1 matrix inhibits and confers cooperativity on gag 
precursor-membrane interactions. J Virol 78(17):9560-3. 
181. Perez-Caballero, D., T. Zang, A. Ebrahimi, M. W. McNatt, D. A. Gregory, M. C. 
Johnson, and P. D. Bieniasz. 2009. Tetherin inhibits HIV-1 release by directly tethering 
virions to cells. Cell 139(3):499-511. 
182. Perlman, M., and M. D. Resh. 2006. Identification of an intracellular trafficking and 
assembly pathway for HIV-1 gag. Traffic 7(6):731-45. 
183. Pierson, R. 2010. Merck HIV drug from Schering merger fails trials, 21.01.2010 ed. 
www.reuters.com. 
184. Pileri, P., Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, A. J. 
Weiner, M. Houghton, D. Rosa, G. Grandi, and S. Abrignani. 1998. Binding of 
hepatitis C virus to CD81. Science 282(5390):938-41. 
185. Pillai, S., B. Good, D. Richman, and J. Corbeil. 2003. A new perspective on V3 
phenotype prediction. AIDS Res Hum Retroviruses 19(2):145-9. 
186. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of 
CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of 
human immunodeficiency virus type 1. J Virol 72(4):2855-64. 
References 
135 
187. Ploss, A., M. J. Evans, V. A. Gaysinskaya, M. Panis, H. You, Y. P. de Jong, and C. 
M. Rice. 2009. Human occludin is a hepatitis C virus entry factor required for infection 
of mouse cells. Nature 457(7231):882-6. 
188. Prasher, D. C., V. K. Eckenrode, W. W. Ward, F. G. Prendergast, and M. J. 
Cormier. 1992. Primary structure of the Aequorea victoria green-fluorescent protein. 
Gene 111(2):229-33. 
189. Provine, N. M., W. B. Puryear, X. Wu, J. Overbaugh, and N. L. Haigwood. 2009. 
The infectious molecular clone and pseudotyped virus models of human 
immunodeficiency virus type 1 exhibit significant differences in virion composition with 
only moderate differences in infectivity and inhibition sensitivity. J Virol 83(17):9002-7. 
190. R_Development_Core_Team. 2009. R: A Language and Environment for Statistical 
Computing. R Foundation for Statistical Computing. http://www.R-project.org 
191. Regoes, R. R., and S. Bonhoeffer. 2005. The HIV coreceptor switch: a population 
dynamical perspective. Trends Microbiol 13(6):269-77. 
192. Resh, M. D. 2005. Intracellular trafficking of HIV-1 Gag: how Gag interacts with cell 
membranes and makes viral particles. AIDS Rev 7(2):84-91. 
193. Resh, M. D. 2004. A myristoyl switch regulates membrane binding of HIV-1 Gag. Proc 
Natl Acad Sci U S A 101(2):417-8. 
194. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998. Determinants of human 
immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 
72(2):986-93. 
195. Rizzuto, C. D., R. Wyatt, N. Hernandez-Ramos, Y. Sun, P. D. Kwong, W. A. 
Hendrickson, and J. Sodroski. 1998. A conserved HIV gp120 glycoprotein structure 
involved in chemokine receptor binding. Science 280(5371):1949-53. 
196. Roberts, J. D., K. Bebenek, and T. A. Kunkel. 1988. The accuracy of reverse 
transcriptase from HIV-1. Science 242(4882):1171-3. 
197. Ronaghi, M., M. Uhlen, and P. Nyren. 1998. A sequencing method based on real-time 
pyrophosphate. Science 281(5375):363, 365. 
198. Roos, M. T., J. M. Lange, R. E. de Goede, R. A. Coutinho, P. T. Schellekens, F. 
Miedema, and M. Tersmette. 1992. Viral phenotype and immune response in primary 
human immunodeficiency virus type 1 infection. J Infect Dis 165(3):427-32. 
199. Rowell, J. F., P. E. Stanhope, and R. F. Siliciano. 1995. Endocytosis of endogenously 
synthesized HIV-1 envelope protein. Mechanism and role in processing for association 
with class II MHC. J Immunol 155(1):473-88. 
200. Rozera, G., I. Abbate, A. Bruselles, C. Vlassi, G. D'Offizi, P. Narciso, G. Chillemi, 
M. Prosperi, G. Ippolito, and M. R. Capobianchi. 2009. Massively parallel 
pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from 
lymphomonocyte sub-populations. Retrovirology 615. 
201. Rudner, L., S. Nydegger, L. V. Coren, K. Nagashima, M. Thali, and D. E. Ott. 2005. 
Dynamic fluorescent imaging of human immunodeficiency virus type 1 gag in live cells 
by biarsenical labeling. J Virol 79(7):4055-65. 
202. Rust, M. J., M. Bates, and X. Zhuang. 2006. Sub-diffraction-limit imaging by stochastic 
optical reconstruction microscopy (STORM). Nat Methods 3(10):793-5. 
203. Rust, M. J., M. Lakadamyali, F. Zhang, and X. Zhuang. 2004. Assembly of endocytic 
machinery around individual influenza viruses during viral entry. Nat Struct Mol Biol 
11(6):567-73. 
204. Salahuddin, S. Z., P. D. Markham, F. Wong-Staal, G. Franchini, V. S. 
Kalyanaraman, and R. C. Gallo. 1983. Restricted expression of human T-cell leukemia--
lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. 
Virology 129(1):51-64. 
205. Samson, M., O. Labbe, C. Mollereau, G. Vassart, and M. Parmentier. 1996. 
Molecular cloning and functional expression of a new human CC-chemokine receptor 
gene. Biochemistry 35(11):3362-7. 
References 
136 
206. Sattentau, Q. 2008. Avoiding the void: cell-to-cell spread of human viruses. Nat Rev 
Microbiol 6(11):815-26. 
207. Scarselli, E., H. Ansuini, R. Cerino, R. M. Roccasecca, S. Acali, G. Filocamo, C. 
Traboni, A. Nicosia, R. Cortese, and A. Vitelli. 2002. The human scavenger receptor 
class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21(19):5017-
25. 
208. Schaller, T., N. Appel, G. Koutsoudakis, S. Kallis, V. Lohmann, T. Pietschmann, 
and R. Bartenschlager. 2007. Analysis of hepatitis C virus superinfection exclusion by 
using novel fluorochrome gene-tagged viral genomes. J Virol 81(9):4591-603. 
209. Scherer, W. F., J. T. Syverton, and G. O. Gey. 1953. Studies on the propagation in 
vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human 
malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the 
cervix. J Exp Med 97(5):695-710. 
210. Schols, D., S. Struyf, J. Van Damme, J. A. Este, G. Henson, and E. De Clercq. 1997. 
Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor 
CXCR4. J Exp Med 186(8):1383-8. 
211. Sena-Esteves, M., Y. Saeki, S. M. Camp, E. A. Chiocca, and X. O. Breakefield. 1999. 
Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-
Epstein-Barr virus hybrid amplicons. J Virol 73(12):10426-39. 
212. Shavinskaya, A., S. Boulant, F. Penin, J. McLauchlan, and R. Bartenschlager. 2007. 
The lipid droplet binding domain of hepatitis C virus core protein is a major determinant 
for efficient virus assembly. J Biol Chem 282(51):37158-69. 
213. Shugars, D. C., C. T. Wild, T. K. Greenwell, and T. J. Matthews. 1996. Biophysical 
characterization of recombinant proteins expressing the leucine zipper-like domain of the 
human immunodeficiency virus type 1 transmembrane protein gp41. J Virol 70(5):2982-
91. 
214. Sierra, S., R. Kaiser, A. Thielen, and T. Lengauer. 2007. Genotypic coreceptor 
analysis. Eur J Med Res 12(9):453-62. 
215. Simmonds, P. 1995. Variability of hepatitis C virus. Hepatology 21(2):570-83. 
216. Sing, T., A. J. Low, N. Beerenwinkel, O. Sander, P. K. Cheung, F. S. Domingues, J. 
Buch, M. Daumer, R. Kaiser, T. Lengauer, and P. R. Harrigan. 2007. Predicting HIV 
coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 12(7):1097-
106. 
217. Sourisseau, M., N. Sol-Foulon, F. Porrot, F. Blanchet, and O. Schwartz. 2007. 
Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol 
81(2):1000-12. 
218. Spearman, P., R. Horton, L. Ratner, and I. Kuli-Zade. 1997. Membrane binding of 
human immunodeficiency virus type 1 matrix protein in vivo supports a conformational 
myristyl switch mechanism. J Virol 71(9):6582-92. 
219. Starcich, B. R., B. H. Hahn, G. M. Shaw, P. D. McNeely, S. Modrow, H. Wolf, E. 
S. Parks, W. P. Parks, S. F. Josephs, R. C. Gallo, and et al. 1986. Identification and 
characterization of conserved and variable regions in the envelope gene of HTLV-
III/LAV, the retrovirus of AIDS. Cell 45(5):637-48. 
220. Tersmette, M., R. A. Gruters, F. de Wolf, R. E. de Goede, J. M. Lange, P. T. 
Schellekens, J. Goudsmit, H. G. Huisman, and F. Miedema. 1989. Evidence for a role 
of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired 
immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 63(5):2118-25. 
221. Tessmer, U., and H. G. Krausslich. 1998. Cleavage of human immunodeficiency virus 
type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag 
polyprotein processing and viral infectivity. J Virol 72(4):3459-63. 
222. Thomssen, R., S. Bonk, C. Propfe, K. H. Heermann, H. G. Kochel, and A. Uy. 1992. 
Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol 
Immunol 181(5):293-300. 
References 
137 
223. Tilton, J. C., and R. W. Doms. 2010. Entry inhibitors in the treatment of HIV-1 
infection. Antiviral Res 85(1):91-100. 
224. Tremblay, M. J., J. F. Fortin, and R. Cantin. 1998. The acquisition of host-encoded 
proteins by nascent HIV-1. Immunol Today 19(8):346-51. 
225. Trinh, L., D. Han, W. Huang, T. Wrin, J. A. Larson, L. D. Kiss, E. Coakley, C. J. 
Petropoulos, N. T. Parkin, J. Whitcomb, and J. D. Reeves. 2008. Technical Validation 
of an Enhanced Sensitivity Trofile HIV Co-receptor Tropism Assay for Selecting Patients 
for Therapy with Entry Inhibitors Targeting CCR5. XVII HIV Drug Resistance 
Workshop. Sitges, Spain. June 10-14 2008.  
226. Trkola, A., S. E. Kuhmann, J. M. Strizki, E. Maxwell, T. Ketas, T. Morgan, P. 
Pugach, S. Xu, L. Wojcik, J. Tagat, A. Palani, S. Shapiro, J. W. Clader, S. 
McCombie, G. R. Reyes, B. M. Baroudy, and J. P. Moore. 2002. HIV-1 escape from a 
small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl 
Acad Sci U S A 99(1):395-400. 
227. Trouplin, V., F. Salvatori, F. Cappello, V. Obry, A. Brelot, N. Heveker, M. Alizon, 
G. Scarlatti, F. Clavel, and F. Mammano. 2001. Determination of coreceptor usage of 
human immunodeficiency virus type 1 from patient plasma samples by using a 
recombinant phenotypic assay. J Virol 75(1):251-9. 
228. Tscherne, D. M., C. T. Jones, M. J. Evans, B. D. Lindenbach, J. A. McKeating, and 
C. M. Rice. 2006. Time- and temperature-dependent activation of hepatitis C virus for 
low-pH-triggered entry. J Virol 80(4):1734-41. 
229. UNAIDS. 2009. 2009 AIDS Epidemic update. UNAIDS. 
230. van der Schaar, H. M., M. J. Rust, C. Chen, H. van der Ende-Metselaar, J. Wilschut, 
X. Zhuang, and J. M. Smit. 2008. Dissecting the cell entry pathway of dengue virus by 
single-particle tracking in living cells. PLoS Pathog 4(12):e1000244. 
231. van der Schaar, H. M., M. J. Rust, B. L. Waarts, H. van der Ende-Metselaar, R. J. 
Kuhn, J. Wilschut, X. Zhuang, and J. M. Smit. 2007. Characterization of the early 
events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol 
81(21):12019-28. 
232. von Hahn, T., B. D. Lindenbach, A. Boullier, O. Quehenberger, M. Paulson, C. M. 
Rice, and J. A. McKeating. 2006. Oxidized low-density lipoprotein inhibits hepatitis C 
virus cell entry in human hepatoma cells. Hepatology 43(5):932-42. 
233. von Schwedler, U. K., M. Stuchell, B. Muller, D. M. Ward, H. Y. Chung, E. Morita, 
H. E. Wang, T. Davis, G. P. He, D. M. Cimbora, A. Scott, H. G. Krausslich, J. 
Kaplan, S. G. Morham, and W. I. Sundquist. 2003. The protein network of HIV 
budding. Cell 114(6):701-13. 
234. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, 
A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 
2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral 
genome. Nat Med 11(7):791-6. 
235. Walter, H., J. Eberle, H. Müller, C. Noah, E. Wolf, M. Stürmer, P. Braun, K. Korn, 
M. Däumer, T. Berg, M. Obermeier, A. Thielen, and R. Kaiser. 2009. Empfehlung zur 
Bestimmung des HIV-1-Korezeptor-Gebrauchs. National Reference Center for 
Retroviruses, University of Erlangen. 
236. Watson, C., S. Jenkinson, W. Kazmierski, and T. Kenakin. 2005. The CCR5 receptor-
based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry 
inhibitor. Mol Pharmacol 67(4):1268-82. 
237. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. 
Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human 
immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. 
Antimicrob Agents Chemother 46(6):1896-905. 
238. Weissenborn, K., A. B. Tryc, M. Heeren, H. Worthmann, H. Pflugrad, G. Berding, 
M. Bokemeyer, H. L. Tillmann, and A. Goldbecker. 2009. Hepatitis C virus infection 
and the brain. Metab Brain Dis 24(1):197-210. 
References 
138 
239. Weissenhorn, W., A. Dessen, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1997. 
Atomic structure of the ectodomain from HIV-1 gp41. Nature 387(6631):426-30. 
240. Welsch, S., A. Habermann, S. Jager, B. Muller, J. Krijnse-Locker, and H. G. 
Krausslich. 2006. Ultrastructural analysis of ESCRT proteins suggests a role for 
endosome-associated tubular-vesicular membranes in ESCRT function. Traffic 
7(11):1551-66. 
241. Welsch, S., O. T. Keppler, A. Habermann, I. Allespach, J. Krijnse-Locker, and H. G. 
Krausslich. 2007. HIV-1 buds predominantly at the plasma membrane of primary human 
macrophages. PLoS Pathog 3(3):e36. 
242. Westby, M., M. Lewis, J. Whitcomb, M. Youle, A. L. Pozniak, I. T. James, T. M. 
Jenkins, M. Perros, and E. van der Ryst. 2006. Emergence of CXCR4-using human 
immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients 
following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-
using virus reservoir. J Virol 80(10):4909-20. 
243. Westby, M., C. Smith-Burchnell, J. Mori, M. Lewis, M. Mosley, M. Stockdale, P. 
Dorr, G. Ciaramella, and M. Perros. 2007. Reduced maximal inhibition in phenotypic 
susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc 
utilize inhibitor-bound receptor for entry. J Virol 81(5):2359-71. 
244. Whitcomb, J. M., W. Huang, S. Fransen, K. Limoli, J. Toma, T. Wrin, C. Chappey, 
L. D. Kiss, E. E. Paxinos, and C. J. Petropoulos. 2007. Development and 
characterization of a novel single-cycle recombinant-virus assay to determine human 
immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 
51(2):566-75. 
245. White, E. J., B. McColgan, S. Kassaye, L. Zijenah, and D. Katzenstein. 2010. 
Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-
tropism (X4R5). AIDS. 
246. WHO. 2009. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and 
Adolescents. 
247. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 
1994. Peptides corresponding to a predictive alpha-helical domain of human 
immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl 
Acad Sci U S A 91(21):9770-4. 
248. Wilkin, T. J., Z. Su, D. R. Kuritzkes, M. Hughes, C. Flexner, R. Gross, E. Coakley, 
W. Greaves, C. Godfrey, P. R. Skolnik, J. Timpone, B. Rodriguez, and R. M. 
Gulick. 2007. HIV type 1 chemokine coreceptor use among antiretroviral-experienced 
patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group 
A5211. Clin Infect Dis 44(4):591-5. 
249. Wu, L., N. P. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, A. A. 
Cardoso, E. Desjardin, W. Newman, C. Gerard, and J. Sodroski. 1996. CD4-induced 
interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. 
Nature 384(6605):179-83. 
250. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. 
Hendrickson, and J. G. Sodroski. 1998. The antigenic structure of the HIV gp120 
envelope glycoprotein. Nature 393(6686):705-11. 
251. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, 
antigens, and immunogens. Science 280(5371):1884-8. 
252. Zanetti, G., J. A. Briggs, K. Grunewald, Q. J. Sattentau, and S. D. Fuller. 2006. 
Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in 
situ. PLoS Pathog 2(8):e83. 
253. Zheng, A., F. Yuan, Y. Li, F. Zhu, P. Hou, J. Li, X. Song, M. Ding, and H. Deng. 
2007. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J 
Virol 81(22):12465-71. 
 
References 
139 
254. Zhu, P., E. Chertova, J. Bess, Jr., J. D. Lifson, L. O. Arthur, J. Liu, K. A. Taylor, 
and K. H. Roux. 2003. Electron tomography analysis of envelope glycoprotein trimers 
on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 
100(26):15812-7. 
255. Zignego, A. L., C. Giannini, M. Monti, and L. Gragnani. 2007. Hepatitis C virus 
lymphotropism: lessons from a decade of studies. Dig Liver Dis 39 Suppl 1S38-45. 
256. Zimmerman, C., K. C. Klein, P. K. Kiser, A. R. Singh, B. L. Firestein, S. C. Riba, 
and J. R. Lingappa. 2002. Identification of a host protein essential for assembly of 
immature HIV-1 capsids. Nature 415(6867):88-92. 
257. Zufferey, R., T. Dull, R. J. Mandel, A. Bukovsky, D. Quiroz, L. Naldini, and D. 
Trono. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. 
J Virol 72(12):9873-80. 
 
Abbreviations 
140 
6 Abbreviations 
7AAD 7-Aminoactinomycin D 
a.u.  arbitrary units 
ABC antibodies bound per cell 
AMD AMD3100 – CXCR4 antagonist 
APC allophycocyanin 
APC-H7 APC-cyanine tandem conjugate 
app. approximately 
ASCII American Standard Code for Information Interchange (computer file format) 
BlaM β-Lactamase 
BSA bovine serum albumin 
BTP bromothenylpteridine 
CA HIV-1 capsid protein 
CCR5 CC chemokine receptor 5 – HIV-1 coreceptor 
conc. concentration 
CPE  cytopathic effect 
csv comma separated values (computer file format for tabular data) 
CXCR4 CXC chemokine receptor 4 – HIV-1 coreceptor 
DAPI 4’,6-diamidino-2-phenylindole 
DMEM Dulbecco’s modified Eagle medium 
DMSO dimethylsulfoxyd 
DNA desoxyribonucleic acid 
dNTP desoxy-nucleoside-triphosphate 
DTT dithiotreitol 
EDTA ethylenediaminetetraacetic acid 
EM electron micrsocopy 
Env envelope protein 
ER endoplasmic reticulum 
FACS fluorescence assisted cell sorting – also used for ‘flow cytometry’ in general 
FASTA text-based file format for nucleotide or amino acid sequences 
FCS fetal calf serum 
fcs flow cytometry standard (computer file format for FACS data) 
FDA Food and Drug Administration (US government) 
FFT fast Fourier transformation 
FP fluorescent protein 
GA glutaraldehyde 
Gag group specific antigen – HIV-1 structural precursor protein 
gp41 glycoprotein (number indicates size in kDa, e.g. gp41 – 41kDa) 
HIV Human Immunodeficiency Virus – also used to abbreviate HIV-1 
IN HIV-1 integrase protein 
kb kilo bases (unit for DNA and RNA – 1000 nucleotides) 
kDa kilo Daltons (unit for protein mass) 
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LA DB Los Alamos Database 
LTR long terminal repeat 
MA HIV-1 matrix protein 
MFI mean fluorescence intensity 
MIP-1 macrophage inflammatory protein 1 
MVC maraviroc – CCR5 antagonist 
NC HIV-1 nucleocapsid protein 
Nef negative factor – accessory protein of HIV-1 
NK cells natural killer cells (lymphocyte subset) 
o/n over night 
ORF open reading frame 
p6 protein (number indicates size in kDa, e.g. p6 – 6kDa) 
PBMC peripheral blood mononuclear cells 
PE phycoerythrin 
PEI polyethyleneimine 
PFA paraformaldehyde 
PI propidium iodide 
Pol polymerase – HIV-1 replication machinery precursor protein 
PonA Ponasterone A  
PR HIV-1 protease protein 
qWB quantitative Western Blot 
RANTES “regulated upon activation, normal T-cell expressed and secreted” –  
chemokine of the CXC group 
RNA ribonucleic acid 
rpm revolutions per minute 
RT HIV-1 reverse transcriptase protein 
or room temperature 
SDF-1 stromal cell-derived factor 1 
SDS sodium dodecyl sulfate 
SIN self-inactivating 
sp1  spacer peptide (number indicates size in kDa, e.g. sp1 – 1kDa) 
Tat transactivator – accessory protein of HIV-1 
TEM transmission electron microscope 
Tet Tetracycline 
V.E.R.S.A. or 
VERSA  
viral entry receptor sensitivity analysis 
Vpr HIV-1 viral protein R 
Vpu viral protein U – accessory protein of HIV-1 
VSV Vesicular Stomatitis Virus 
w/o without 
WB Western Blot 
wt wild-type 
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